WO2023212599A2 - Compounds and methods for targeted degradation of estrogen receptors - Google Patents
Compounds and methods for targeted degradation of estrogen receptors Download PDFInfo
- Publication number
- WO2023212599A2 WO2023212599A2 PCT/US2023/066243 US2023066243W WO2023212599A2 WO 2023212599 A2 WO2023212599 A2 WO 2023212599A2 US 2023066243 W US2023066243 W US 2023066243W WO 2023212599 A2 WO2023212599 A2 WO 2023212599A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- piperazin
- piperidin
- dioxopiperidin
- thiophen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 331
- 238000000034 method Methods 0.000 title claims abstract description 162
- 102000015694 estrogen receptors Human genes 0.000 title claims abstract description 91
- 108010038795 estrogen receptors Proteins 0.000 title claims abstract description 91
- 230000015556 catabolic process Effects 0.000 title abstract description 35
- 238000006731 degradation reaction Methods 0.000 title abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 66
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 63
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 201000010099 disease Diseases 0.000 claims abstract description 40
- -1 cycloalkynyl Chemical group 0.000 claims description 335
- 239000000203 mixture Substances 0.000 claims description 102
- 150000003839 salts Chemical class 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- 125000005647 linker group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000012453 solvate Substances 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 29
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 27
- 229910052805 deuterium Inorganic materials 0.000 claims description 27
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000005605 benzo group Chemical group 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 9
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims description 8
- 229910052796 boron Inorganic materials 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 208000030776 invasive breast carcinoma Diseases 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 15
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 78
- 238000011282 treatment Methods 0.000 abstract description 57
- 201000011510 cancer Diseases 0.000 abstract description 37
- 230000001588 bifunctional effect Effects 0.000 abstract description 18
- 230000002062 proliferating effect Effects 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 abstract description 11
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 abstract description 11
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 11
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 11
- 238000010798 ubiquitination Methods 0.000 abstract description 10
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 abstract description 6
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 102000015367 CRBN Human genes 0.000 abstract 2
- 239000001064 degrader Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 146
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 76
- 239000000543 intermediate Substances 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 70
- 230000002829 reductive effect Effects 0.000 description 55
- 239000007858 starting material Substances 0.000 description 52
- 239000007787 solid Substances 0.000 description 42
- 239000000243 solution Substances 0.000 description 40
- 239000002904 solvent Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 102100038595 Estrogen receptor Human genes 0.000 description 26
- 230000004083 survival effect Effects 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 231100000673 dose–response relationship Toxicity 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 229940011871 estrogen Drugs 0.000 description 16
- 239000000262 estrogen Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 230000000593 degrading effect Effects 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 230000001833 anti-estrogenic effect Effects 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229910052681 coesite Inorganic materials 0.000 description 12
- 229910052906 cristobalite Inorganic materials 0.000 description 12
- 229910052682 stishovite Inorganic materials 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 229910052905 tridymite Inorganic materials 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000002103 transcriptional effect Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 230000034512 ubiquitination Effects 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 238000003419 tautomerization reaction Methods 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 7
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 229940119564 Selective estrogen receptor downregulator Drugs 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 229940046836 anti-estrogen Drugs 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000009261 endocrine therapy Methods 0.000 description 6
- 239000000328 estrogen antagonist Substances 0.000 description 6
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- JRJGJUIMMUYSTQ-RSXGOPAZSA-N (5R,6S)-6-phenyl-5-(4-piperazin-1-ylphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(C=C1)N1CCNCC1 JRJGJUIMMUYSTQ-RSXGOPAZSA-N 0.000 description 5
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 102100032783 Protein cereblon Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 208000007641 Pinealoma Diseases 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YEYASRFTCLKCFD-UHFFFAOYSA-N (4-hydroxyphenyl)-[6-methoxy-2-(4-methoxyphenyl)-1-benzothiophen-3-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=C(C(=O)C=2C=CC(O)=CC=2)C2=CC=C(OC)C=C2S1 YEYASRFTCLKCFD-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LBMHPHUSGIEGHJ-UHFFFAOYSA-N 2-phenyl-1-benzothiophene Chemical class S1C2=CC=CC=C2C=C1C1=CC=CC=C1 LBMHPHUSGIEGHJ-UHFFFAOYSA-N 0.000 description 3
- VETYNAAAOVQSDR-UHFFFAOYSA-N 3-(3-oxo-6-piperidin-4-yl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=C1C=CC(=C2)C1CCNCC1)C1CCC(=O)NC1=O VETYNAAAOVQSDR-UHFFFAOYSA-N 0.000 description 3
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- 208000021309 Germ cell tumor Diseases 0.000 description 3
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
- RJXQLTLDEMZIFW-UHFFFAOYSA-N O=C1C(C2CCC(=O)NC2=O)C(=O)C2=CC(=CC=C12)N1CCNCC1 Chemical compound O=C1C(C2CCC(=O)NC2=O)C(=O)C2=CC(=CC=C12)N1CCNCC1 RJXQLTLDEMZIFW-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229960002258 fulvestrant Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- YWWDLQMMJPPTTP-UHFFFAOYSA-N tert-butyl 4-(4-formylpiperidin-1-yl)benzoate Chemical compound C(=O)C1CCN(CC1)C1=CC=C(C(=O)OC(C)(C)C)C=C1 YWWDLQMMJPPTTP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- YTKVMOBHMCOGHZ-UHFFFAOYSA-N 3-(3-oxo-6-piperazin-1-yl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=C1C=CC(=C2)N1CCNCC1)C1CCC(=O)NC1=O YTKVMOBHMCOGHZ-UHFFFAOYSA-N 0.000 description 2
- UMSZQHJDTPXYLU-UHFFFAOYSA-N 3-bromo-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene Chemical compound C1=CC(OC)=CC=C1C1=C(Br)C2=CC=C(OC)C=C2S1 UMSZQHJDTPXYLU-UHFFFAOYSA-N 0.000 description 2
- QEAYYPBCFUSRLI-UHFFFAOYSA-N 3-bromo-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene 1-oxide Chemical compound C1=CC(OC)=CC=C1C1=C(Br)C2=CC=C(OC)C=C2S1=O QEAYYPBCFUSRLI-UHFFFAOYSA-N 0.000 description 2
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- VUKNASHCUSHWPA-UHFFFAOYSA-N 4-[[6-methoxy-2-(4-methoxyphenyl)-1-benzothiophen-3-yl]oxy]phenol Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(O)=CC=2)C2=CC=C(OC)C=C2S1 VUKNASHCUSHWPA-UHFFFAOYSA-N 0.000 description 2
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 2
- NGGOMCQOHPHNOZ-UHFFFAOYSA-N 6-methoxy-2-(4-methoxyphenyl)-3-(4-phenylmethoxyphenoxy)-1-benzothiophene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C2=CC=C(OC)C=C2S1 NGGOMCQOHPHNOZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- RSYQLCWXJGDOJT-UHFFFAOYSA-N C(C)(=O)OC1=CC=C(C=C1)C(=O)C=1C2=C(SC=1C1=CC=C(C=C1)OC)C=C(C=C2)OC Chemical compound C(C)(=O)OC1=CC=C(C=C1)C(=O)C=1C2=C(SC=1C1=CC=C(C=C1)OC)C=C(C=C2)OC RSYQLCWXJGDOJT-UHFFFAOYSA-N 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010050487 Pinealoblastoma Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 229910020169 SiOa Inorganic materials 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- YFJYFIQSYHZRAJ-UHFFFAOYSA-N [4-[6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene-3-carbonyl]phenyl] trifluoromethanesulfonate Chemical compound C1=CC(OC)=CC=C1C1=C(C(=O)C=2C=CC(OS(=O)(=O)C(F)(F)F)=CC=2)C2=CC=C(OC)C=C2S1 YFJYFIQSYHZRAJ-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 201000003113 pineoblastoma Diseases 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000000239 visual pathway Anatomy 0.000 description 2
- 230000004400 visual pathway Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- CGEOYYBCLBIBLG-UHFFFAOYSA-N (4-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=C(C(Cl)=O)C=C1 CGEOYYBCLBIBLG-UHFFFAOYSA-N 0.000 description 1
- QRPUVEAHEMVOOG-UHFFFAOYSA-O (4-hydroxyphenyl)methanone Chemical compound OC1=CC=C([C+]=O)C=C1 QRPUVEAHEMVOOG-UHFFFAOYSA-O 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ABIPLJQFLRXYES-UHFFFAOYSA-N 1,2,3,3a-tetrahydropentalene Chemical compound C1=CC=C2CCCC21 ABIPLJQFLRXYES-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- QBQRRWPLTOBGST-UHFFFAOYSA-N 1-(4-bromophenyl)-1,3-diazinane-2,4-dione Chemical compound C1=CC(Br)=CC=C1N1C(=O)NC(=O)CC1 QBQRRWPLTOBGST-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical group CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- FLAYZKKEOIAALB-UHFFFAOYSA-N 2-bromo-1-(4-chlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C=C1 FLAYZKKEOIAALB-UHFFFAOYSA-N 0.000 description 1
- ZJFWCELATJMDNO-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CBr)C=C1 ZJFWCELATJMDNO-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- JRSAZEGGRXKTEY-UHFFFAOYSA-N 3-(5-fluoro-1,3-dioxoinden-2-yl)piperidine-2,6-dione Chemical compound FC1=CC=C2C(=O)C(C3CCC(=O)NC3=O)C(=O)C2=C1 JRSAZEGGRXKTEY-UHFFFAOYSA-N 0.000 description 1
- CMRQAKJTXKOGSF-UHFFFAOYSA-N 3-(6-bromo-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(Br)=CC=C2C(=O)N1C1CCC(=O)NC1=O CMRQAKJTXKOGSF-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- NTVCIOGUJHBVBO-UHFFFAOYSA-N 4,5-dihydro-3h-dioxepine Chemical compound C1COOC=CC1 NTVCIOGUJHBVBO-UHFFFAOYSA-N 0.000 description 1
- BAKUAUDFCNFLBX-UHFFFAOYSA-N 4,7-dihydro-1,3-dioxepine Chemical compound C1OCC=CCO1 BAKUAUDFCNFLBX-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 1
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KWBJYGNQDHVBQP-UHFFFAOYSA-N C1CC(CNC1)N2CC3=C(C2=O)C=CC(=C3)N4CCNCC4 Chemical compound C1CC(CNC1)N2CC3=C(C2=O)C=CC(=C3)N4CCNCC4 KWBJYGNQDHVBQP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 206010037127 Pseudolymphoma Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940125641 estrogen receptor degrader Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000010943 meningeal sarcoma Diseases 0.000 description 1
- 201000003776 meninges sarcoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- SGFACFBLUAWICV-UHFFFAOYSA-N methyl 4-bromo-2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1CBr SGFACFBLUAWICV-UHFFFAOYSA-N 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005648 named reaction Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000016802 peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- BIONLEZDCFVTBR-UHFFFAOYSA-N tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=CC1)C1=CC2=C(C=C1)C(=O)N(C2)C1CCC(=O)NC1=O BIONLEZDCFVTBR-UHFFFAOYSA-N 0.000 description 1
- DANIYVQIRXOIKI-UHFFFAOYSA-N tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)C1=CC2=C(C=C1)C(=O)N(C2)C1CCC(=O)NC1=O DANIYVQIRXOIKI-UHFFFAOYSA-N 0.000 description 1
- KOLFROKCTDISHC-UHFFFAOYSA-N tert-butyl 4-[4-(hydroxymethyl)piperidin-1-yl]benzoate Chemical compound OCC1CCN(CC1)C1=CC=C(C(=O)OC(C)(C)C)C=C1 KOLFROKCTDISHC-UHFFFAOYSA-N 0.000 description 1
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- Estrogen receptor is a member of the nuclear hormone receptor superfamily of transcription factors, and has a great pharmaceutical interest as a target for the treatment of breast cancer, osteoporosis and other endocrine female disorders. Binding of the natural ligand, 17-beta-estradiol, to the ER causes dimerization of the ER, which in turn binds to the estrogen response elements (ERE) in the promoters of the target gene or can interact with other transcription factor complexes like Fos/Jun (AP-1 -responsive elements), and influence transcription of genes.
- EAE estrogen response elements
- Fos/Jun AP-1 -responsive elements
- compositions and methods for modulating specific target proteins e.g., estrogen receptor (ER)
- ER estrogen receptor
- the present invention addresses this unmet need in the art.
- the present invention relates to novel bifunctional compounds and compositions useful for the degradation of a target protein by recruiting the target protein to an E3 ubiquitin ligase for degradation by the endogenous cellular ubiquitin proteasome system (UPS).
- the present invention furnishes ; bifunctional compounds, otherwise known as proteolysis targeting chimeric (PROTAC) compounds, which facilitates targeted ubiquitination of estrogen receptor (target protein), and then undergo degradation and/or exhibit inhibition of the target protein by the bifunctional compounds disclosed herein.
- PROTAC proteolysis targeting chimeric
- the present invention provides the methods of making such compounds and compositions; methods of using such compounds and compositions; pharmaceutical compositions comprising such compounds and compositions; and methods of using such pharmaceutical compositions, for the treatment or amelioration of a disease condition, such as cancer, especially breast cancer.
- the present invention provides a method of ubiquitinating followed by degrading a target protein by bifunctional compounds attached by a chemical linker; therapeutic compositions comprising an effective amount of a compound disclosed herein or salt/solvate form thereof, and its delivery using a pharmaceutically acceptable carrier.
- therapeutic compositions of a compound or multiple compounds that degrade and/or inhibit the target protein in a patient or subject, such as a human or animal can be used for treating or ameliorating disease conditions/states, e.g., breast cancer, through modulation of wild-type ER or mutant ER or other variants of ER.
- the present invention provides a compound having the structure of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof: rmula (I).
- R 1 is selected from hydrogen, deuterium, halogen, or hydroxyl.
- R1 is selected from hydrogen, deuterium, F, Cl, Br, or I.
- R 2 and R 3 are each independently selected from hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy, ” "O .
- each occurrence of R 4 , R 5 , and R G is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- each occurrence of Z is selected from Li, Na, or K
- each occurrence of m and n is independently an integer from 0 to 4.
- R 2 is selected from hydrogen, deuterium, F, Cl, Br, I, OH
- R 3 is selected from hydrogen, deuterium, F, Cl, Br, I, OH, OCH3,
- x and y are each independently an integer from 0 to 2. In some embodiments, x is an integer 0 or 1 . In some embodiments, y is an integer 1 or 2.
- the compound having the structure of Formula (I) is a compound having the structure selected from or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof; or or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the compound having the structure of Formula (II) is a compound having the structure of Formula (Ila)
- the compound having the structure of Formula (III) is a compound having the structure of Formula (Illa) or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30 alkyl, branched or linear amino-C 8 -Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C 8 -Cso alkyl, C5-C30 cycloalkyl, amino-C 8 -C 30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C 8 -Cso cycloalkyl, or any combination thereof.
- the linker is an optionally substituted linking moiety selected from the group consisting of a branched or linear C5-C24 alkyl, branched or linear amino-C 5 -C24 alkyl, branched or linear C5-C24 alkoxy, branched or linear thio-C 8 -C24 alkyl, C5-C24 cycloalkyl, amino-C 8 -C24 cycloalkyl, hydroxy-C 8 -C24 cycloalky, thio-C 5 -C24 cycloalkyl, or any combination thereof.
- 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from O, N, and S.
- the linker is selected from the group consisting of:
- the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30 alkyl, branched or linear amino-C 8 -C 30 alkyl, branched or linear C5-C3Q alkoxy, branched or linear thio-C 8 -C 30 alkyl, C5-C30 cycloalkyl, amino-C 8 -C 30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C 8 -C 30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C 8 -C 30 cycloalkyl, C5-C30 aryl-amino-C 8 -C 30 cycloalkyl, C5-C30 heteroaryl-C 8 -Cgo cycloalkyl, or C5-C30 heteroaryl-amin
- the E3 Ligand is selected from some embodiments, Y 1 is selected from
- Y 2 and Y 3 are each independently selected from C(R 4 ) or N.
- R 4 , R 5 , and R 6 are each independently selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- the E3 Ligand is selected from
- the present invention relates, in part, to a composition comprising at least one compound of the present invention.
- the composition is a pharmaceutical composition and/or a pharmaceutical formulation.
- the composition comprises at least one compound of the present invention and a pharmaceutically acceptable carrier.
- the composition is suitable for enteral administration, oral administration, and/or parenteral administration.
- the present invention relates, in part, to a method of preparing at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
- the present invention relates, in part, to a method of treating a disease or disorder in a subject in need thereof, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof to the subject.
- the disease or disorder is selected from a breast cancer, all stages of breast cancer, ER-positive breast cancer, invasive breast cancer, or any combination thereof.
- the present invention relates, in part, to a method for treating breast cancer in a subject in need thereof, the method comprising administering an effective amount of a compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof to the subject.
- the breast cancer is an ER-positive breast cancer and/or invasive breast cancer.
- the subject expresses a mutant ER-a protein.
- the present invention relates, in part, to a method of reducing the level or activity of a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
- the present invention relates, in part, to a method of inhibiting a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
- the target protein is an estrogen receptor.
- Figure 1 shows A) dose-dependent ERa degradation by exemplary compounds 8, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 8, of the present invention in T47D breast cancer cells.
- Figure 2 shows A) dose-dependent ERa degradation by exemplary compounds 10, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 10 of the present invention in T47D breast cancer cells.
- Figure 3 shows A) dose-dependent ERa degradation by exemplary compounds 74, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 74 of the present invention in T47D breast cancer cells.
- Figure 4 shows A) the dose-dependent ERa degradation by exemplary compound 94, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 94 of the present invention in T47D breast cancer cells.
- Figure 5 shows A) the dose-dependent ERa degradation by exemplary compound 106, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 106 of the present invention in T47D breast cancer cells.
- Figure 6 shows A) the dose-dependent ERa degradation by exemplary compound 107, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 107 of the present invention in T47D breast cancer cells.
- Figure 7 shows A) the dose-dependent ERa degradation by exemplary compound 115, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 115 of the present invention in T47D breast cancer cells.
- Figure 8 shows A) the dose-dependent ERa degradation by exemplary compound 131 , B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 131 of the present invention in T47D breast cancer cells.
- Figure 9 shows the dose-dependent ERa degradation by exemplary compound 10 in comparison with fulvestrant in MCF-7 breast cancer cells.
- Figure 10 shows the dose-dependent ERa degradation by exemplary compound 12, compound 160, and Compound 106 of the present invention in MCF-7 breast cancer cells.
- Figure 11 shows A) the dose-dependent ERa degradation by exemplary compound 103, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 103 of the present invention in T47D breast cancer cells.
- Figure 12 shows the dose-dependent ERa degradation by exemplary compounds 167, compound 173, and compound 180 of the present invention in MCF-7 breast cancer cells.
- Figure 13 shows the antiestrogenic effects of exemplary compound 167 on T47D-kb- luc cells.
- Figure 14 shows the antiestrogenic effects of exemplary compound 170 on T47D-kb- luc cells.
- Figure 15 shows the antiestrogenic effects of exemplary compound 173 on T47D-kb- luc cells.
- Figure 16 shows the antiestrogenic effects of exemplary compound 185 on T47D-kb- luc cells.
- Figure 17 shows the antiestrogenic effects of exemplary compound 186 on T47D-kb- luc cells.
- Figure 18 shows the effects of exemplary compound 167 on cell proliferation of CAMA- 1 breast cancer cells.
- Figure 19 shows the effects of exemplary compound 170 on cell proliferation of CAMA- 1 breast cancer cells.
- Figure 20 shows the effects of exemplary compound 173 on cell proliferation of CAMA-
- Figure 21 shows the effects of exemplary compound 186 on cell proliferation of MCF- 7 breast cancer cells.
- Figure 22 shows the single dose pharmacokinetic profile of compound 185 in Sprague Dawley rat.
- Figure 23 shows the single dose pharmacokinetic profile of compound 186 in Sprague Dawley rat.
- the present invention relates to compounds that bind competitively and/or non- competitively to the estrogen receptor alpha (ERa), and the E3 ubiquitin ligase, cereblon (CRBN) to effect ubiquitination and subsequent degradation of the ERa protein, thereby blocking the estrogen signaling pathways and inhibiting the growth of estrogen receptor (ER) dependent cells.
- the invention also relates to pharmaceutical compositions comprising these ER degrading compounds, and methods for using the same for treatment of diseases and conditions mediated by the estrogen receptor, including breast cancer.
- the disclosed bifunctional compounds can be applied for targeted degradation of ER, and be used to treat or prevent ER+ breast cancer.
- the following detailed description is furnished to assist those skilled in the art in joining the present invention.
- patient refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
- the patient, subject or individual is a human.
- a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate.
- a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.
- cancer refers to any of various types of malignant neoplasms, most of which invade surrounding tissues, may metastasize to several sites and are likely to recur after attempted removal and to cause death of the patient unless adequately treated.
- neoplasia comprises cancer.
- Representative cancers include, for example, squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias, including non-acute and acute leukemias, such as acute myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia (APL), acute T-cell lymphoblastic leukemia, T-lineage acute lymphoblastic leukemia (T-ALL), adult T-cell leukemia, basophilic leukemia, eosinophilic leukemia, granulocytic leukemia, hairy cell leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, megakaryoc
- a disease or disorder is “alleviated” if the severity of a sign or symptom of the disease or disorder, the frequency with which such a sign or symptom is experienced by a patient, or both, is reduced.
- minimize 1 ' or “reduce”, or derivatives thereof include a complete or partial degradation of a target protein (ER) and/or inhibition of a specified biological effect and/or reduction of ER expression at the transcript or protein level, (which is apparent from the context in which the terms "minimize” or “reduce” are used).
- inhibitor means to suppress or block an activity or function by at least about ten percent relative to a control value.
- the activity is suppressed or blocked by 50% compared to a control value, more preferably by 75%, and even more preferably by 95% or more.
- treatment is defined as the application or administration of a therapeutic agent, i.e., a compound of the invention (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell from a patient (e.g., for diagnosis or ex vivo applications), who has a disease or disorder contemplated herein, a sign or symptom of a disease or disorder contemplated herein or the potential to develop a disease or disorder contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a disease or disorder contemplated herein, the signs or symptoms of a disease or disorder contemplated herein or the potential to develop a disease or disorder contemplated herein.
- Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.
- To "treat” a disease as the term is used herein, means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.
- parenteral administration of a composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), or intrasternal injection, or infusion techniques.
- the compounds according to the disclosure are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as chromatography on a suitable support material.
- reverse phase preparative HPLC of compounds of the present invention which possess a sufficiently basic or acidic functionality may result in the formation of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example.
- Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. Additionally, the drying process during the isolation of compounds of the present invention may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognize which solvates or inclusion complexes are acceptable to be used in subsequent biological assays.
- One aspect of the invention is salts of the compounds according to the invention including all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
- salts include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, meglumine, ammonium, salts optionally derived from NH 3 or organic amines having from 1 to 16 C-atoms such as, e.g court ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, ethylendiamine, N-methylpiperindine, arginine, lysine, and guanidinium salts.
- the salts of the disclosed compounds include pharmaceutically acceptable water- insoluble and, particularly, water-soluble salts.
- the term "pharmaceutically acceptable” refers to a material, such as a earner or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing an undesirable biological effect or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- pharmaceutically acceptable salts refer to derivatives of the compounds disclosed herein wherein the parent compound is modified by making acid or base salts thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydra ba mic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic,
- salts include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1 -carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, and the like.
- the present invention also encompasses salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
- an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
- the ratio of the compound to the cation or anion of the salt may be 1:1, or any ratio other than 1:1 , e.g., 3:1 , 2:1, 1:2, or 1:3.
- Salts of the compounds of Formula (I) according to the invention can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethyl ketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
- a suitable solvent for example a ketone such as acetone, methylethyl ketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight alipha
- the acid or base can be employed in salt preparation, depending on whether a mono- or polybasic acid or base is concerned and depending on which salt is desired, in an equimolar quantitative ratio or one differing therefrom.
- the salts are obtained by filtering, reprecipitating, precipitating with a non-solvent for the salt or by evaporating the solvent. Salts obtained can be converted into the free compounds which, in turn, can be converted into salts. In this manner, pharmaceutically unacceptable salts, which can be obtained, for example, as process products in the manufacturing on an industrial scale, can be converted into pharmaceutically acceptable salts by processes known to the person skilled in the art.
- the compounds of Formula (I) according to this invention as well as their salts may contain, e.g., when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of Formula (I) according to this invention as well as all solvates and in particular all hydrates of the salts of the compounds of Formula (I) according to this invention.
- “Solvate” means solvent addition forms that contain either stoichiometric or non- stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate.
- the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
- tautomer refers to one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH conditions. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism.
- keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs.
- Ring-chain tautomerism arises as a result of the aldehyde group ( — CHO) in a sugar chain molecule reacting with one of the hydroxy groups ( — OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
- Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), imine-enamine and enamine-enamine.
- the compounds of the invention may, depending on their structure, exist in different stereoisomeric forms. These forms include configurational isomers or optically conformational isomers (enantiomers and/or diastereoisomers including those of atropisomers).
- the present invention therefore includes enantiomers, diastereoisomers as well as mixtures thereof. From those mixtures of enantiomers and/or disastereoisomers pure stereoisomeric forms can be isolated with methods known in the art, preferably methods of chromatography, especially high performance liquid chromatography (HPLC) using achiral or chiral phase.
- HPLC high performance liquid chromatography
- the invention further includes all mixtures of the stereoisomers mentioned above independent of the ratio, including the racemates.
- the compounds of the invention may, depending on their structure, exist in various stable isotopic forms. These forms include those in which one or more hydrogen atoms have been replaced with deuterium atoms, those in which one or more nitrogen atoms have been replaced with 15 N atoms, or those in which one or more atoms of carbon, fluorine, chlorine, bromine, sulfur, or oxygen have been replaced by the stable isotope of the respective, original atoms.
- the term “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier.
- the pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
- pharmacological composition,” “therapeutic composition,” “therapeutic formulation” or “pharmaceutically acceptable formulation” can mean, but is in no way limited to, a composition or formulation that allows for the effective distribution of an agent provided by the invention, which is in a form suitable for administration to the physical location most suitable for their desired activity, e.g., systemic administration.
- agents suitable for formulation with the, e.g., compounds provided by the instant invention include: cinnamoyl, PEG, phospholipids or lipophilic moieties, phosphorothioates, P-glycoprotein inhibitors (such as Pluronic P85) which can enhance entry of drugs into various tissues, for example the CNS (Jolliet-Riant and Tillement, 1999, Fundam. Clin. Pharmacol., 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after implantation (Emerich, D F et al, 1999, Cell Transplant, 8, 47-58) Alkermes, Inc.
- nanoparticles such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry, 23, 941-949, 1999).
- a “therapeutic” treatment is a treatment administered to a subject who exhibits signs or symptoms of pathology disease or disorder, for the purpose of diminishing or eliminating those signs or symptoms.
- the terms "effective amount,” “pharmaceutically effective amount” and “therapeutically effective amount” refer to a sufficient amount of an agent to provide the desired biological or physiologic result. That result may be reduction and/or alleviation of a sign, a symptom, or a cause of a disease or disorder, or any other desired alteration of a biological system. An appropriate effective amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
- a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
- Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient.
- materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butterand suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline
- pharmaceutically acceptable carrier also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions.
- the “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention.
- Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
- halo or halogen alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- alkyl by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e. Ci-s means one to six carbon atoms) and includes straight, branched chain, or cyclic substituent groups.
- alkyl examples include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl”, “haloalkyl” and “homoalkyl”.
- substituted alkyls include, but are not limited to, 2,2-difluoropropyl
- cycloalkyl refers to a mono cyclic or polycyclic non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom.
- the cycloalkyl group is saturated or partially unsaturated.
- the cycloalkyl group is fused with an aromatic ring.
- Cycloalkyl groups include groups having from 3 to 10 ring atoms.
- Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
- Monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Dicyclic cycloalkyls include, but are not limited to, tetrahydronaphthyl, indanyl, and tetrahydropentalene.
- Polycyclic cycloalkyls include adamantine and norbomane.
- cycloalkyl includes "unsaturated nonaromatic carbocyclyl” or “nonaromatic unsaturated carbocyclyl” groups, both of which refer to a nonaromatic carbocycle as defined herein, which contains at least one carbon double bond or one carbon triple bond.
- heteroalkyl by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quatemized.
- the heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group.
- heteroalkyl refers to “alkoxy,” “alkylamino” and “alkylthio” that are used in their conventional sense, and refer to alkyl groups linked to molecules via an oxygen atom, an amino group, a sulfur atom, respectively.
- alkoxy employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1 -propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers.
- heterocycloalkyl refers to a heteroalicyclic group containing one to four ring heteroatoms each selected from O, S and N.
- each heterocycloalkyl group has from 4 to 10 atoms in its ring system, with the proviso that the ring of said group does not contain two adjacent O or S atoms.
- the heterocycloalkyl group is fused with an aromatic ring.
- the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized.
- the heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure.
- a heterocycle may be aromatic or non-aromatic in nature.
- the heterocycle is a heteroaryl,
- An example of a 3-membered heterocycloalkyl group includes, and is not limited to, aziridine.
- 4-membered heterocycloalkyl groups include, and are not limited to, azetidine and a beta lactam.
- 5-membered heterocycloalkyl groups include, and are not limited to, pyrrolidine, oxazolidine and thiazolidinedione.
- 6-membered heterocycloalkyl groups include, and are not limited to, piperidine, morpholine and piperazine.
- Other non-limiting examples of heterocycloalkyl groups are:
- non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, pyrazolidine, imidazoline, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1 ,2,3,6-tetrahydropyridine, 1 ,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran,
- aromatic refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e. having (4n + 2) delocalized n (pi) electrons, where n is an integer.
- aryl employed alone or in combination with other terms, means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings), wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene.
- aryl groups include phenyl, anthracyl, and naphthyl.
- heteroaryl refers to a heterocycle having aromatic character.
- a polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include the following moieties: [00102]
- heteroaryl groups also include pyridyl, pyrazinyl, pyrimidinyl (particularly 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl (particularly 2-pyrrolyl), imidazolyl, thiazolyl, oxazolyl, pyrazolyl (particularly 3- and 5-pyrazolyl), isothiazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,3,4-triazolyl, tetrazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,4-thiadia
- polycyclic heterocycles and heteroaryls examples include indolyl (particularly 3-, 4-, 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (particularly 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (particularly 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1 ,8-naphthyridinyl, 1 ,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (particularly 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (particularly 3-, 4-, 5-, 6-, and 7-benzothien
- substituted means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
- substituted further refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted.
- the substituents are independently selected, and Substitution may be at any chemically accessible position. In one embodiment, the substituents vary in number between one and four. In another embodiment, the substituents vary in number between one and three. In yet another embodiment, the substituents vary in number between one and two. The substituents are independently selected, and substitution may be at any chemically accessible position.
- the substituents vary in number between one and four. In another embodiment, the substituents vary in number between one and three. In yet another embodiment, the substituents vary in number between one and two. In yet another embodiment, the substituents are independently selected from the group consisting of C 1-6 alkyl, -OH, C 1-6 alkoxy, halo, amino, acetamido and nitro. In yet another embodiment, the substituents are independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, halo, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic, with straight being preferred.
- the term "optionally substituted” means that the referenced group may be substituted or unsubstituted. In one embodiment, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In another embodiment, the referenced group is optionally substituted with one or more additional group(s) individually and independently selected from groups described herein.
- the substituents are independently selected from the group consisting of C 1-6 alkyl, -OH, C 1-6 alkoxy, halo, amino, acetamido, oxo and nitro. In yet another embodiment, the substituents are independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, halo, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic.
- an analog is meant to refer to a chemical compound or molecule made from a parent compound or molecule by one or more chemical reactions.
- an analog can be a structure having a structure similar to that of the small molecule therapeutic agents described herein or can be based on a scaffold of a small molecule therapeutic agents described herein, but differing from it in respect to certain components or structural makeup, which may have a similar or opposite action metabolical ly.
- An analog or derivative can also be a small molecule that differs in structure from the reference molecule, but retains the essential properties of the reference molecule.
- An analog or derivative may change its interaction with certain other molecules relative to the reference molecule.
- An analog or derivative molecule may also include a salt, an adduct, tautomer, isomer, or other variant of the reference molecule.
- the term “potency” refers to the dose needed to produce half the maximal response (EDso).
- the term “efficacy” refers to the maximal effect (Emax) achieved within an assay.
- Ranges throughout this invention, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
- the present invention relates to bifunctional compounds compositions containing such compounds, and their use in prevention and treatment of diseases and conditions including cancer.
- the bifunctional compounds contain one ligand that binds the target protein and another ligand that binds to a specific E3 ubiquitin ligase, which are linked via a linker molecule.
- the bifunctional compounds can simultaneously bind estrogen receptor alpha (ERa) (target protein) and a cereblon (CRBN) E3 ubiquitin ligase, which promotes ubiquitination of ER and leads to degradation of ER by the proteasome.
- ERa estrogen receptor alpha
- CRBN cereblon
- the present invention provides compounds having the structure of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof: ( )
- each occurrence of X 2 is independently selected from CH 2 and S.
- R 1 is selected from hydrogen, deuterium, halogen, or hydroxyl.
- R1 is selected from hydrogen, deuterium, F, Cl, Br, or I.
- R 2 is selected from hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy,
- R 3 is selected from hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy,
- each occurrence of R 4 , R 5 , and R 6 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- each occurrence of Z is selected from Li, Na, or K.
- each occurrence of m is independently an integer from 0 to 4.
- m is an integer 0.
- m is an integer 1.
- m is an integer 2.
- m is an integer 3.
- m is an integer 4.
- each occurrence of n is independently an integer from 0 to 4.
- n is an integer 0.
- n is an integer 1 .
- n is an integer 2.
- n is an integer 3.
- n is an integer 4.
- R 2 is selected from hydrogen, deuterium, F, Cl, Br, I,
- R 2 is hydrogen, F, Cl, Br, or I
- R 3 is selected from hydrogen, deuterium, F, Cl, Br, I, OH, OCH3,
- x is an integer from 0 to 2. In some embodiments, x is an integer 0 or 1. In one embodiment, x is an integer 0. In one embodiment, x is an integer 1. In one embodiment, x is an integer 2.
- y is an integer from 0 to 2. In some embodiments, y is an integer 1 or 2. In one embodiment, y is an integer 0. In one embodiment, y is an integer 1. In one embodiment, y is an integer 2.
- the compound having the structure of Formula (I) is a compound having the structure selected from I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the compound having the structure of Formula (II) is a compound having the structure of Formula (Ila) 3 or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the compound having the structure of Formula (I) is a compound having the structure selected from Formula (III), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the compound having the structure of Formula (III) is a compound having the structure of Formula (Illa) HO or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30 alkyl, branched or linear amino-C 8 -Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C 8 -C 30 alkyl, C5-C30 cycloalkyl, amino-C 8 -C 30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C 8 -C 30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C 8 -C 30 cycloalkyl, C5-C30 aryl-amino-C 8 -C 30 cycloalkyl, C5-C30 heteroaryl-C 8 -Cso cycloalkyl, or C 8 -Cso heteroaryl-a
- 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of O, N, and S.
- the E3 Ligand is selected from , 4
- the E3 Ligand i s Q is a compound having the structure of Formula (Ila ' ) Formula (Ila ). or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- Y 2 is selected from C(R4) or N.
- Y 3 is selected from C(R4) or N.
- R 4 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- R 5 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- R 6 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
- the E3 Ligand is one of the following structures
- the linker is an optionally substituted linking moiety.
- the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 5 to 30 carbon atoms in length, or any combination thereof.
- the linker is an optionally substituted linking moiety.
- the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 5 to 22 carbon atoms in length, or any combination thereof.
- the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 5 to 16 carbon atoms in length, or any combination thereof.
- the linking moiety comprises 1 to 8 of the carbon atoms that are optionally replaced with a heteroatom. In some embodiments, the linking moiety comprises 1 to 6 of the carbon atoms that are optionally replaced with a heteroatom. In some embodiments, the heteroatom is independently O, N, or S.
- the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30 alkyl, branched or linear amino-C 5 -Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-Cg-Cso alkyl, C5-C30 cycloalkyl, amino-C 8 -Cso cycloalkyl, hydroxy- C5-C30 cycloalky, thio-Cg-Cso cycloalkyl, -Y 4 -(CH2) a -(NH)b-W-(CH2) c -Y 5 -, or any combination thereof.
- the linker is an optionally substituted linking moiety selected from the group consisting of a branched or linear C5-C24 alkyl, branched or linear amino-C 8 -C24 alkyl, branched or linear C5-C24 alkoxy, branched or linear thio-C 8 -C24 alkyl, C5-C24 cycloalkyl, amino- C5-C24 cycloalkyl, hydroxy-C 8 -C24 cycloalky, thio-C 8 -C 2 4 cycloalkyl, -Y 4 -(CH 2 ) a -(NH)t ) -W-(CH 2 )c-Y 5 -, or any combination thereof.
- the linking moiety comprises a branched or linear C5-C22 alkyl, branched or linear amino-C 8 -C22 alkyl, branched or linear C5-C22 alkoxy, branched or linear thio-C 8 -C22 alkyl, C5-C22 cycloalkyl, amino-C5-C 22 cycloalkyl, hydroxy-C 8 -C ⁇ cycloalky, thjo-C 8 -C22 cycloalkyl, -Y 4 -(CH 2 )a-(NH)trW-(CH2)e-Y 5 -, or any combination thereof.
- the linking moiety comprises a branched or linear C5-C16 alkyl, branched or linear amino-C 8 -C 18 alkyl, branched or linear C5-C16 alkoxy, branched or linear thio-C 5 -Ci6 alkyl, C5-C16 Cycloalkyl, amino-Cg-Cw Cycloalkyl, hydroxy-Cg-Cie CyCloalky, thio-Cg-Cie cycloalkyl, -Y 4 - (CH2)a-(NH)j,-W-(CH 2 ) c -Y 5 -, or any combination thereof.
- the linker is -Y 4 -(CH 2 ) e -(NH)6-W-(CH 2 )c-Y 5 -.
- each occurrence of Y 4 and Y 5 is independently O, -NH-, 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S, or any combination thereof, or absent.
- Y 4 is absent or O.
- Y 5 is -NH- or 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S.
- said 5 to 9 membered heterocycloalkyl is piperidine or piperazine.
- each occurrence of a, b, and c is independently an integer of 0 to 7.
- each occurrence of a and c is independently an integer of 0 to 7.
- each occurrence of b is independently an integer of 0 or 1 .
- each occurrence of W is independently 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S.
- the linker is selected from:
- the compound of Formula (I) may encompass both the R and S isomers. In some embodiments, the compound of Formula (I) may be a mixture of trans- and - cis olefin.
- a compound, or pharmaceutically acceptable salt thereof chosen from the compounds listed in Table 1 :
- DC50 ER degradation
- composition which comprises a compound of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
- This specification also describes, in part, a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
- This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in reducing the level or activity of a target protein (e.g., an estrogen receptor).
- a target protein e.g., an estrogen receptor
- This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in inhibiting a target protein (e.g,, an estrogen receptor).
- a target protein e.g, an estrogen receptor
- This specification also describes, in part, a compound of Formula (1), or a pharmaceutically acceptable salt thereof, for use in therapy.
- This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
- This specification also describes, in part, a method for treating cancer in a warmblooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I), Or a pharmaceutically acceptable salt thereof.
- the invention provides for a pharmaceutical composition comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof.
- the pharmaceutical compound is for use in treatment of a proliferative disease, such as a cancer, for example, a breast cancer.
- a further embodiment may provide a method of treating breast cancer comprising administering to a subject in need of treatment or amelioration a compound according to any one of the preceding paragraphs.
- the breast cancer may be an ER-positive breast cancer.
- the subject may express a mutant ER-a protein or any variant of ER-a, such as ERa-36.
- An embodiment may provide proper and effective use of a compound as in the paragraphs above for treating and/or preventing breast cancer.
- the breast cancer is an ER-positive breast cancer.
- said subject expresses a mutant ER-a protein or a variant of ERa, such as ERa-36.
- a compound as presented above is used in the preparation of a medicament for treatment of breast cancer in a patient or subject, such as a human or animal.
- compositions of the present invention can be in any form known to those of skill in the art, and a suitable dosage form of the compound(s) can be administered by an appropriate route.
- the pharmaceutical compositions are in a form of a product for oral delivery, said product form being selected from a group consisting of a concentrate, dried powder, liquid, capsule, pellet, and pill.
- the pharmaceutical compositions of the invention are in the form of a product for parenteral administration including intravenous, intradermal, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal and subcutaneous administration.
- the compounds described herein may be administered as a single dose or a divided dose over a period of time.
- compositions disclosed herein may also further comprise carriers, binders, diluents, and excipients.
- the described carriers, diluents and excipients may include dried corn starch or lactose, the binder may include microcrystalline cellulose, gum tragacanth or gelatin, in addition, the excipients may also include a dispersing agent, a lubricant, a glidant, a sweetening agent or a flavoring agent.
- the present invention relates to new ER degrading composition
- a compound of Formula (I) and pharmaceutically acceptable salts and solvates thereof.
- said compound has a purity of about a 75%, ⁇ 80%, ⁇ 85%, ⁇ 90%, > 95%, > 96%, > 97%, or > 98%, and > 99%.
- a pharmaceutical composition comprising the new ER degrading composition, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new ER degrading compositions, either alone or in combination with at least one additional therapeutic agent, in the treatment of proliferative diseases including breast cancer at any stage of the disease diagnosis.
- the combination with an additional therapeutic agent may take the form of combining the new ER degrading compounds with any known therapeutic agent.
- the disclosed compounds can be used to slow the rate of primary tumor growth.
- the disclosed compounds can also be used to prevent, abate, minimize, control, and/or lessen tumor metastasis in humans and animals.
- the disclosed compounds when administered to a subject in need of treatment can be used to stop the spread of cancer cells.
- the compounds disclosed herein can be administered as part of a combination therapy with one or more drugs or other pharmaceutical agents.
- the decrease in metastasis and reduction in primary tumor growth afforded by the disclosed compounds allows for a more effective and efficient use of any pharmaceutical or drug therapy being used to treat the patient.
- control of metastasis by the disclosed compound affords the subject a greater ability to concentrate the disease in one location.
- cancers that can be treated by the disclosed methods and compositions: Acute Lymphoblastic; Acute Myeloid Leukemia; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Appendix Cancer; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bone Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors; Cerebellar Astrocytoma; Cerebral Astrocytotna/Malignant Glioma; Craniopharyngioma; Ependymoblastoma; Ependymoma; Medulloblastom
- Leukemia Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer;
- the methods for treating a clinical indication by the ER degrading compounds disclosed herein may be effectuated by administering a therapeutically effective amount of the ER degrading compounds to a patient in need thereof, this therapeutically effective amount may comprise administration of the prodrug to the patient at about 1 mg/kg/day, 2 mg/kg/day, 3 mg/kg/day, 4 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day and 20 mg/kg/day.
- amounts ranging from about 0.001 mg/kg/day to about 0.01 mg/kg/day, or about 0.01 mg/kg/day to about 0.1 mg/kg/day, or about 0.1 mg/kg/day to about 1 mg/kg/day, or about 1 mg/kg/day to 10 mg/kg/day, or about 10 mg/kg/day to about 100 mg/kg/day are also contemplated.
- a further object of the invention is a kit, comprising a composition containing at least one ER degrading compound for treatment and prevention of cancer and cancer related morbidities.
- the composition of the kit may comprise at least one carrier, at least one binder, at least one diluent, at least one excipient, at least one other therapeutic agent, or mixtures thereof.
- the kit may be designed, developed, distributed, or sold as a unit for performing the methods of the present invention and to deliver the drugs to the targeted cells for the treatment and prevention of cancer and related diseases.
- the kits may also include instructions to customers for proper usage of the kit to treat patients exhibiting the symptoms of the desired disease, e.g., cancer or breast cancer.
- One aspect of the present invention is the compounds disclosed herein as well as the intermediates as used for their synthesis, and the synthetic scheme for the preparation of the disclosed final compounds and the intermediates resulted before the final compound is generated.
- the invention is not intended to be limited to the details specified, since a person of ordinary skill in the relevant art will understand that various omissions, modifications, substitutions, and changes in the forms and details of the invention illustrated and in its operation may be made without departing in any way from the spirit of the present invention. No feature of the invention is critical or essential unless it is specifically stated as being “critical” or “essential”.
- Another object of the invention is to provide a composition, for example a pharmaceutical composition, comprising at least one ER degrader compound in an amount effective for the indication of proliferative diseases such as cancer, including but not limited to endocrine related cancer.
- the cancer is an ER-positive tumor, such as a tumor of the breast, endometrium, uterus, or ovary.
- the tumor is an ER-positive tumor of the breast.
- the breast tumor is determined to be ER-positive by an immunohistochemical method described by Hammond et al. [8].
- the object of such treatment is to degrade estrogen receptor and/or inhibit estrogen-induced proliferation of a cell.
- said object is to inhibit estrogen-induced proliferation of a cell by a mechanism selected from SERM, SERD, and PROTAC.
- treating means administering to a subject a pharmaceutical composition to ameliorate, reduce or lessen the symptoms of a disease.
- “treating” or “treat” describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes the administration of a compound disclosed herein, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
- the term “treat” may also include treatment of a cell in vitro or an animal model.
- subject or “subjects” refers to any animal, such as mammals including rodents (e.g., mice or rats), dogs, primates, lemurs or humans.
- Treating cancer may result in a reduction in size of a tumor.
- a reduction in size of a tumor may also be referred to as “tumor regression.”
- tumor size is reduced by about 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater than about 75% or greater.
- Size of a tumor may be measured by any reproducible means of measurement. The size of a tumor may be measured as a diameter of the tumor.
- Treating cancer may result in a reduction in tumor volume.
- tumor volume is reduced by about 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by about 75% or greater.
- Tumor volume may be measured by any reproducible means of measurement.
- Treating cancer may result in a decrease in number of tumors.
- tumor number is reduced by about 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater than about 75%.
- Number of tumors may be measured by any reproducible means of measurement.
- the number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification.
- the specified magnification is 2 ⁇ , 3 ⁇ , 4 ⁇ . 5 ⁇ , 10 ⁇ , or 50x.
- Treating cancer may result in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site.
- the number of metastatic lesions is reduced by about 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater than about 75%.
- the number of metastatic lesions may be measured by any reproducible means of measurement.
- the number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification.
- the specified magnification is 2 ⁇ , 3 ⁇ , 4 ⁇ . 5 ⁇ , 10 ⁇ , or 50x.
- Treating cancer may result in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone.
- the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- Treating cancer may result in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects.
- the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- Treating cancer may result in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
- the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound disclosed herein, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
- the mortality rate is decreased by more than about 2%; more preferably, by more than about 5%; more preferably, by more than about 10%; and most preferably, by more than about 25%.
- a decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means.
- a decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound.
- a decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.
- Treating cancer may result in a decrease in tumor growth rate.
- tumor growth rate is reduced by at least about 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%.
- Tumor growth rate may be measured by any reproducible means of measurement. Tumor growth rate may be measured according to a change in tumor diameter per unit time.
- Treating cancer may result in a decrease in tumor regrowth, for example, following attempts to remove it surgically.
- tumor regrowth is less than about 5%; more preferably, tumor regrowth is less than about 10%; more preferably, less than about 20%; more preferably, less than about 30%; more preferably, less than about 40%; more preferably, less than about 50%; even more preferably, less than about 50%; and most preferably, less than about 75%.
- Tumor regrowth may be measured by any reproducible means of measurement. Tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. A decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.
- Treating or preventing a cell proliferative disorder may result in a reduction in the rate of cellular proliferation.
- the rate of cellular proliferation is reduced by at least about 5%; more preferably, by at least about 10%; more preferably, by at least about 20%; more preferably, by at least about 30%; more preferably, by at least about 40%; more preferably, by at least about 50%; even more preferably, by at least about 50%; and most preferably, by at least about 75%.
- the rate of cellular proliferation may be measured by any reproducible means of measurement.
- the rate of cellular proliferation is measured, for example, by measuring the number of dividing cells in a tissue sample per unit time.
- Treating or preventing a cell proliferative disorder may result in a reduction in the proportion of proliferating cells.
- the proportion of proliferating cells is reduced by at least about 5%; more preferably, by at least about 10%; more preferably, by at least about 20%; more preferably, by at least about 30%; more preferably, by at least about 40%; more preferably, by at least about 50%; even more preferably, by at least about 50%; and most preferably, by at least about 75%.
- the proportion of proliferating cells may be measured by any reproducible means of measurement.
- the proportion of proliferating cells is measured, for example, by quantifying the number of dividing cells relative to the number of nondividing cells in a tissue sample.
- the proportion of proliferating cells may be equivalent to the mitotic index.
- Treating or preventing a cell proliferative disorder may result in a decrease in size of an area or zone of cellular proliferation.
- size of an area or zone of cellular proliferation is reduced by at least about 5% relative to its size prior to treatment; more preferably, reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%.
- Size of an area or zone of cellular proliferation may be measured by any reproducible means of measurement.
- the size of an area or zone of cellular proliferation may be measured as a diameter or width of an area or zone of cellular proliferation.
- Treating or preventing a cell proliferative disorder may result in a decrease in the number or proportion of cells having an abnormal appearance or morphology.
- the number of cells having an abnormal morphology is reduced by at least about 5% relative to its size prior to treatment; more preferably, reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%.
- An abnormal cellular appearance or morphology may be measured by any reproducible means of measurement.
- An abnormal cellular morphology may be measured by microscopy, e.g., using an inverted tissue culture microscope.
- An abnormal cellular morphology may take the form of nuclear pleiomorphism.
- the present invention relates, in part, to a method of inhibiting a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
- the target protein is an estrogen receptor.
- Example 1 Bifunctional Compounds that Perform as Modulators of Estrogen
- Estrogens play central roles in the development and maintenance of normal sexual and reproductive function. In addition, both ER ⁇ and ER ⁇ were found to have distinct biological effects in the immune, skeletal, cardiovascular, and central nervous systems [1].
- Estrogen receptors are mainly expressed in ovarian, uterus, liver cells, and are found overexpressed in certain tumor cells, such as breast cancer, ovarian cancer and prostate cancer. The most potent and abundant estrogen produced in human body is 17p-estradiol. Anti-estrogens, designed to block ERa by retreating estrogens from the active site, are widely and effectively used clinically for breast cancer treatment [2].
- SERM e.g., tamoxifen, raloxifene, toremifene
- aromatase inhibitors Als, including anastrozole, exemestane, letrozole
- SERD fullvestrant
- the conventional anti-estrogens such as SERMs and SERDs, cannot fully yield the full pharmacological efficacy in the treatment of breast cancer.
- the SERDs can downregulate the estrogen receptor protein level and block transcriptional activity, the existing drugs are also prone to resistance. Therefore, alternative drugs and new approaches are needed for delivering the drugs to target cells and degrade specific receptors, so as to increase the efficiency of the drugs and lower the side effects.
- Proteolysis targeting chimeric (PROTAC) technology has emerged as powerful tool for targeted degradation of endogenous proteins [7].
- PROTAC a bifunctional compound attached by a linker molecule, which contain a target protein binding moiety and E3 ubiquitin ligase binding moiety, can simultaneously bind the target protein and E3 ligase and promote ubiquitination of the target protein and degradation of the same by proteasome.
- linker molecule which contain a target protein binding moiety and E3 ubiquitin ligase binding moiety
- Many publications provide the usage of PROTO molecules as modulators of targeted proteins via ubiquitination and subsequent degradation by cell proteasome. The present example exploits this powerful tool to specifically degrade estrogen receptor by developing bifunctional compounds consisting ER binding moiety and CRBN E3 ligase binding moiety linked by various chemical linkers for the treatment of ER+ breast cancer.
- PROTACs proteolysis targeting chimeric molecules
- the present bifunctional compounds simultaneously bind ERa and a specific E3 ubiquitin ligase, which promotes ubiquitination of ER and leads to degradation of ER by the proteasome. While small molecules can easily bind enzymes or receptors in tight and well- defined pockets, protein-protein interactions are difficult to target by small molecules. E3 ubiquitin ligases confer substrates specifically for ubiquitination, making it an attractive therapeutic strategy for protein degradation by proteasome.
- the present invention relates to bifunctional compounds that perform as modulators of estrogen receptor (target protein), which are degraded or inhibited as a result of ubiquitination and subsequent degradation of the ubiquitinated ER by the proteasome.
- target protein target protein
- the present invention provides the methods for making these compounds and their usage in treating or ameliorating disease conditions/states associated with aggregation or accumulation of estrogen receptor.
- the invention also relates to pharmaceutical compositions comprising these ER degrading bifunctional compounds, and methods for using the same for treatment of estrogen receptor mediated pathological developments, including cancers.
- the compounds described here can provide effective endocrine therapy for breast cancers, especially those that are associated with overexpression or aggregation of estrogen receptor (estrogen receptor positive or “ER+“ breast cancers), including its mutant form, as the first line adjuvant treatment regimen, or as the second-line therapy for treating or ameliorating patients with disease progression owing to drug resistance after prior endocrine therapy such as selective estrogen receptor modulators (SERMs), aromatase inhibitors (Als), SERDs, or combinations of such endocrine therapies with other anticancer agents.
- SERMs selective estrogen receptor modulators
- Als aromatase inhibitors
- SERDs SERDs
- the present disclosed compounds herein can be used for the treatment of ER+ breast cancer, including the advanced drug-resistant ER+ breast cancer.
- Example 2 General Synthesis
- the chemical entities described herein can be synthesized according to one or more illustrative schemes herein and/or techniques well known in the art. Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from about -10 °C. to about 200 °C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -10 °C. to about 200 °C over a period that can be, for example, about 1 to about 24 hours; reactions left to run overnight in some embodiments can average a period of about 16 hours.
- Isolation and purification of the chemical entities and intermediates described herein can be implemented, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
- any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
- suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
- protecting groups for sensitive or reactive groups may be employed where necessary, in accordance with general principles of chemistry.
- Protecting groups are manipulated according to standard methods of organic synthesis [9]. These groups may be removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
- disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, or can be readily prepared by those skilled in the art using commonly employed synthetic methodology.
- Step 1 Preparation of 3-(5-fluoro-1,3-dioxo-2,3-dihydro-1 H-inden-2-yl) piperidine-2, 6-dione (C1c)
- Step 2 Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6- dihydropyridine-1 (2H)-carboxylate (C2d)
- Step 3 Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidine-1- car boxy late (C2e)
- Step 4 Preparation of 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2, 6-dione (C2)
- Step 1 Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1- carboxylate (C3a)
- the reaction mixture of KI in PPA (1 g SM in 5 g PPA) was heated at 100 °C for 3 h with vigorous stir under N 2 . After cooling down, the mixture was poured to ice-water slowly followed by extracted with EA. The combined EA layers were washed with water, sat. NaCI solution, dried over sodium sulfate. The crude K2 was obtained by concentrating the desired solution and used for next step without further purification.
- Step 1 Preparation of intermediate K3a and K4a
- Step 1 Preparation of intermediate K5
- the mixture of key intermediate CORE, halogenated hydrocarbons (2.0 eq.) and DIPEA (2.5 eq.) in MeCN was stirred at r.t. under N2 overnight.
- Step 4 Preparation of 3-(4-(benzyloxy)phenoxy)-2-(4-chlorophenyl)-6- methoxybenzo[b]thiophene 1 -oxide (5d)
- Step 5 Preparation of 3-(4-(benzyloxy)phenoxy)-2-(4-chlorophenyl)-6- methoxybenzo[b]thiophene (5e)
- This compound was prepared by the procedure identical to the preparation of intermediate K2e in Method B with 5d (0.52 g, 1.06 mmol) as SM (5e: 0.42 g, 83.8 %).
- LC-MS (ESI+) [M+H] + 457.1 .
- Step 7 Preparation of 4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3-yl)oxy)phenyl trifluoromethanesulfonate (5g)
- Step 8 Preparation of tert-butyl 4-(4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazine-1-carboxylate (5h)
- Step 9 Preparation of 1-(4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazine (5i)
- Step 10 Preparation of 1-(3-chloropropyl)-4-(4-((2-(4-fluorophenyl)-6-methoxybenzo[b]thiophen- 3-yl)oxy)phenyl)piperazine (5j)
- Step 11 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6- methoxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3- dione (5k)
- Step 12 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6- hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3- dione (5m)
- Step 13 Preparation of 3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-diOxoiSOindolin-5- yl)piperazin-1-yl)propyl)piperazin-1-yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl trifluoromethanesulfonate (5n)
- Step 1 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1- yl)propyl)piperazin-1-yl)isoindoline-1, 3-dione (5o)
- Step 14 Preparation of (3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5- yl)piperazin-1-yl)propyl)piperazin-1-yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid (5)
- Step 1 Preparation of 4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl acetate (10b)
- Step 3 Preparation of 4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl trifluoromethanesulfonate (10d)
- Step 4 Preparation of tert-butyl 4-(4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenyl)piperazine-1-carboxylate (10e)
- Step 5 Preparation of (2-(4-fluorophenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(piperazln-1- yl)phenyl)methanone (1 Of)
- Step 77 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6- methoxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (10h)
- Step 8 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1, 3-dione (10)
- Example 8 Preparation of Compound 67
- the following compound, denoted Compound 67 was synthesized:
- Step 2 Preparation of 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene 1 -oxide (67c) This compound was prepared by the procedure identical to the preparation of intermediate K2c in Method B with 67b (5.00 g, 14.4 mmol) as SM (67c: 4.70 g, 90.0 %).
- LC-MS (ESI+) [M+HJ* 365.0.
- Step 3 Preparation of 3-(4-(benzyloxy)phenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[b] thiophene-1 -oxide (67d)
- Step 4 Preparation of 3-(4-(benzyloxy)phenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[b] thiophene (67e)
- Step 6 Preparation of tert-butyl 4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidine-1 -carboxylate (67g)
- Step 7 Preparation ooff 4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidine (67h)
- Step 8 Preparation of 1-(3-chloropropyl)-4-((4-((6-methoxy-2-(4- methoxyphenyl)benzo[b]thiophen-3-yl)oxy)phenoxy)methyl)pi peridine (67i)
- Step 9 Preparation of 3-(5-(4-(3-(4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (67g)
- Step 10 Preparation of 3-(5-(4-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (67)
- Step 2 Preparation of (2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophen-3-yl)(4- hydroxyphenyl)methanone (106c)
- Step 3 Preparation of 4-(2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl trifluoromethanesulfonate (106d)
- Step 4 Preparation of tert-butyl 4-(4-(2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenyl)piperazine-1 -carboxylate (10e)
- Step 6 Preparation of (4-(4-(3-chloropropyl)piperazin-1-yl)phenyl)(2-(4-methoxyphenyl)-6- methoxybenzo[b]thiophen-3-yl)methanone (106g)
- Step 77 Preparation ooff 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-methoxyphenyl)-6- methoxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (106h)
- Step 8 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-hydroxyphenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (106)
- This compound was prepared by the procedure identical to the preparation of intermediate 1 m with 106h (0.10 g, 0.48 mmol) as SM (106: 0.06 g, 64.0 %).
- LC-MS (ESI+) [M+H] + 798.3.
- Step 1 Preparation of 4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl acetate (119b)
- Step 2 Preparation of (2-(4-chlorophenyl)-6-methoxybenzo[b ⁇ thiophen-3-yl)(4- hydroxyphenyl)methanone (106c)
- Step 4 Preparation of tert-butyl 4-(2-(4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazine-1 -carboxylate (119e)
- Step 5 Preparation of (2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(2-(piperazin-1- yl)ethoxy)phenyl)methanone (119f)
- Step 6 Preparation of (2-(4-chloraphenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(2-(4-(3- chloropropyl)piperazin-1-yl)ethoxy)phenyl)methanone (119g)
- Step 7 Preparation of 3-(5-(1-(3-(4-(2-(4-(2-(4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (119h)
- Step 8 Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-hydroxyphenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (119i)
- Step 7 Preparation of 3-(5-(1-(3-(4-(2-(4-(6-hydroxy-2-(4-(4,4,5,5-tetramethyi-1 ,3,2- dioxaborolan-2-yl)phenyl)benzo[b]thiophene-3-carbonyl)phenoxy)ethyl)piperazin-1- yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2 l 6-dione (119j)
- Step 3 3-(5-(4-(4-(4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazine-1-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione (compound 161)
- Example 12 Synthesis of compound 170 & compound 173
- the following compounds, denoted Compounds 170 were synthesized:
- Step 1 tert-butyl 4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carboxylate
- Step 3 3-(5-(4-(4-((4-(4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazin-1 -y l)methyl) piperidi ne-1 -carbonyl)piperazi n-1 -y I ) -1 -oxoisoindol in-2- yl)piperidine-2, 6-dione (compound 170)
- Step 11 1-(4-(4-((4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1 -yl) methyl) pi perid in-1-yl)pheny l)dihydropy rim idine-2, 4(1 H,3H)-dione
- Step 3 4-(4-((4-(4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoicacid
- Example 15 Degradation of ER in MCF-7 Breast Cancer Cells by Exemplary Compounds of Formula (I)
- MCF-7 cells were plated in 24-well plates at a density of 10 5 cells/well. Media containing various drug concentrations were added on the day following plating (day 0) and allowed to incubate for 24 hours for Western blot. Media with the tested compound was changed every other day. Cells were lysed, snapped frozen in liquid nitrogen, and stored at -80 °C until assay for ERa. Media were removed and dishes were washed with 1 x DPBS. Lysates were made by adding 150 pL of complete lysis solution and scraping cells into a 1.5 mL microcentrifuge tube. Lysates were placed on a rotisserie at 4 °C for 30 min and then spun at 4 °C at 12000 ref for 10 min.
- Figures 1A.2A, 3A, 4A, 5A, 6A, 7A, 8A, 9, 10, 11 A, 12 show the ER degradation efficacy of compounds 8, 10, 12, 74, 94, 103, 106, 107, 115, 131, 160, 167, 170, 173 in MCF-7 cells at various concentrations.
- Degradation of ER was expressed as an DC50 value and was determined for exemplary compounds in Table 1 by calculation of the concentration of compound that was required to give a 50% reduction of ER expression level.
- Maximal degradation of ER was expressed as a Dmax value by measuring the highest percentage of ER reduction achieved by exemplary compound in the treatment concentration range. DC50 value and Dmax value for each compound are listed in Table 1.
- the T47d-kb-Luc cells are stably transfected with an artificial gene from the firefly that is only induced in the cells if estrogens bind and activate the ER to induce the gene product (Luciferase) that is then measured with a quantitative enzyme assay that produces light. Antagonist activities were measured by the compound’s ability to inhibit the activity of estradiol, the natural estrogen. Data were then normalized relative to the activity of the estradiol control and determinations were performed for five concentrations of the samples in quadruplicate in at least three separate experiments. IC50 values were obtained from dose-response curves for exemplary compounds that are listed in Table 1.
- Figures 1 B, 2B, 3B, 4B, 5B, 6B, 7B, 8B, 11 B, and 13-17 illustrate the antiestrogenic activity of compounds 8, 10, 74, 94, 106, 107, 115, 131, 103, 167, 170, 173, 185, and 186.
- the anti-proliferative activities of the exemplary compounds were assessed by a cell viability assay in MCF-7 breast cancer cells.
- MCF-7 cells were plated in six-well plates at a density of 50,000 each well in 5% FBS DMEM medium. The cells were then treated with exemplary compounds or fulvestrant separately at 6 different doses ranging from 10" 10 M to 10" 5 M for 5 days, while equal volumes of DMSO were used as vehicle controls. Viable cell numbers were counted with a Z Series Coulter Counter instrument (Beckman-Coulter) following manufacturer’s instructions. The ratio of drug treated viable cell numbers to vehicle treated viable cell numbers was defined as survival ratio where the control has the survival ratio of 100%. ICM values were obtained from dose-response curves for exemplary compounds that are listed in Table 1.
- Example 18 The Anti-Proliferative Activities of the Exemplary Compounds were Assessed by a Cell Viability Assay in CAMA-1 and MCF-7 Breast Cancer Cells
- CAMA-1 or MCF-7 cells were plated in six-well plates at a density of 50,000 each well in 5% FBS DMEM medium. The cells were then treated with exemplary compounds Separately at 6 different doses ranging from 10" 1 ° M to 10 -5 M for 5 days, while equal volumes of DMSO were used as vehicle controls. Viable cell numbers were counted with a Z Series Coulter Counter instrument (Beckman-Coulter) following manufacturer’s instructions. The ratio of drug treated viable cell numbers to vehicle treated viable cell numbers was defined as survival ratio where the control has the survival ratio of 100%. ICsa values were obtained from dose-response curves for exemplary compounds that are listed in Table 1. Figures 18-21 illustrate the anti-proliferative activities of compounds 167, 170, 173, 186 in CAMA-1 or MCF-7 breast cancer cells.
- Example 19 Pharmacokinetic Properties of Exemplary Compounds.185 and 186 were Assessed in Female Sprague Dawlev Rats
- PG propylene glycol
- PG propylene glycol
- solutol 40%HP-b-CD in DI water (20:5:75 v:v) at a single dose of 10 mg/kg.
- blood samples were collected from the tail vein of the rats at various time points into 1.5 ml microcentrifuge tubes containing 0.1 ml of 10 % EDTA anticoagulant. Plasma was then separated from cell pellets by centrifugation in a refrigerated centrifuge at 4 °C and transferred to a separate tube. Plasma samples were frozen at -80 °C until analysis.
- Plasma samples were extracted with chloroform/methanol (2:1) using traditional Folch method for lipid extraction. Methanol (1 mL) and chloroform (2 mL) were added to each plasma sample followed by addition of 5 ng trans- Tamoxifen-1302, 15N to each sample as the internal standard. The mixtures were stored at -20 °C overnight. Next the samples were sonicated for 5 min and centrifuged with a Thermo Scientific Heraeus Megafuge16 Centrifuge. The top layer was transferred to another test tube. The bottom layer was washed with 1 mL chloroform/methanol (2:1 ), centrifuged, and the solvent was transferred and combined with previous washings.
- a binary mobile phase (A: water with 0.05% formic acid, B: acetonitrile with 0.05% formic acid) was used to achieve the gradient of initial 30% B for 1 min and then to 80% B at 8 min, to 100% B at 9 mln, and returned to 30% B for 4 min.
- the flow rate was controlled at 0.6 mL/min.
- the settings of HESI source were as follows: spray voltage (3200 volt); vaporizer temperature (365 °C); sheath gas pressure (45 psi); auxiliary gas pressure (10 psi); capillary temperature (330 °C). Nitrogen was used as the sheath gas and axillary gas. Argon was used as the collision gas.
- Figures 22 and 23 show the pharmacokinetic profile of exemplary compound 185 and 186, respectively.
Abstract
The present Invention relates to bifunctional compounds that serve as degraders and/or inhibitors of a target protein of interest (e.g. estrogen receptor). In the present invention, the bifunctional compounds, which contain a target protein (e.g., estrogen receptor) binding moiety and a E3 ubiquitin ligase (CRBN) binding moiety, are directed to bind to both estrogen receptor and CRBN, such that the ER is placed in dose proximity to the E3 ligase to mediate ubiquitylation of the target protein followed by degradation of the target protein by the proteasome. The present invention provides methods for synthesizing the herein disclosed bifunctional compounds, and their pharmacological activities associated with degradation or inhibition of the target protein. Further, the present invention discloses the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ERT breast cancer.
Description
TITLE OF THE INVENTION
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ESTROGEN
RECEPTORS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Serial No. 63/334,759, filed April 26, 2022, the disclosure of which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] Estrogen receptor is a member of the nuclear hormone receptor superfamily of transcription factors, and has a great pharmaceutical interest as a target for the treatment of breast cancer, osteoporosis and other endocrine female disorders. Binding of the natural ligand, 17-beta-estradiol, to the ER causes dimerization of the ER, which in turn binds to the estrogen response elements (ERE) in the promoters of the target gene or can interact with other transcription factor complexes like Fos/Jun (AP-1 -responsive elements), and influence transcription of genes. The ERa regulates a large number of genes in many different target tissues and plays important roles in the development and progression of breast cancer. Thus, modulation of ER through binding of natural or synthetic ER ligands can have great impacts on the physiology and pathophysiology of the organism. Towards this goal several selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs) have been developed, as antiestrogens. In this approach, these antiestrogens that bind to and compete for ER present in the estrogen responsive tissue antagonize ER activation by estrogen withdrawal from the binding site. Even though traditional antiestrogens, such as tamoxifen, vie efficiently for ER binding, their effectiveness is often hampered by partial agonism or acquired resistance to drugs, which results in partial blockade of estrogen-mediated activity. Hence there is an urgent need for other approaches to antagonize the ER.
[0003] Thus, there is a need in the art for compositions and methods for modulating specific target proteins, e.g., estrogen receptor (ER), which are degraded or inhibited as a result of ubiquitination and subsequent degradation of the ubiquitinated targeted protein by the proteasome. The present invention addresses this unmet need in the art.
SUMMARY OF THE INVENTION
[0004] The present invention relates to novel bifunctional compounds and compositions useful for the degradation of a target protein by recruiting the target protein to an E3 ubiquitin ligase for degradation by the endogenous cellular ubiquitin proteasome system (UPS). In particular, the present invention furnishes ; bifunctional compounds, otherwise known as proteolysis targeting chimeric (PROTAC) compounds, which facilitates targeted ubiquitination of
estrogen receptor (target protein), and then undergo degradation and/or exhibit inhibition of the target protein by the bifunctional compounds disclosed herein. In addition, the present invention provides the methods of making such compounds and compositions; methods of using such compounds and compositions; pharmaceutical compositions comprising such compounds and compositions; and methods of using such pharmaceutical compositions, for the treatment or amelioration of a disease condition, such as cancer, especially breast cancer.
[0005] In an additional aspect, the present invention provides a method of ubiquitinating followed by degrading a target protein by bifunctional compounds attached by a chemical linker; therapeutic compositions comprising an effective amount of a compound disclosed herein or salt/solvate form thereof, and its delivery using a pharmaceutically acceptable carrier. In yet another aspect, the therapeutic compositions of a compound or multiple compounds that degrade and/or inhibit the target protein in a patient or subject, such as a human or animal, can be used for treating or ameliorating disease conditions/states, e.g., breast cancer, through modulation of wild-type ER or mutant ER or other variants of ER.
[0006] In one aspect, the present invention provides a compound having the structure of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof: rmula (I).
[0007] In some embodiments, each occurrence of X1 and X2 is independently selected from O, S, C(R4)(R5), or C=O. In some embodiments, each occurrence of X1 is independently selected from O or C=O. In some embodiments, each occurrence of X2 is independently selected from CH2 and S.
[0008] In some embodiments, R1 is selected from hydrogen, deuterium, halogen, or hydroxyl.
In some embodiments, R1 is selected from hydrogen, deuterium, F, Cl, Br, or I.
[0009] In some embodiments, R2 and R3 are each independently selected from hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy,
” "O . In some embodiments, each occurrence of R4, R5, and RG is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl. In some embodiments, each occurrence of Z is selected from Li, Na, or K In some embodiments, each occurrence of m and n is independently an integer from 0 to 4.
[0010] In some embodiments, R2 is selected from hydrogen, deuterium, F, Cl, Br, I, OH,
some embodiments, R3 is selected from hydrogen, deuterium, F, Cl, Br, I, OH, OCH3,
[0011] In some embodiments, x and y are each independently an integer from 0 to 2. In some embodiments, x is an integer 0 or 1 . In some embodiments, y is an integer 1 or 2.
[0012] In some embodiments, the compound having the structure of Formula (I) is a compound having the structure selected from
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof; or
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof. In some embodiments, the compound having the structure of Formula (II) is
a compound having the structure of Formula (Ila)
R3
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof. In some embodiments, the compound having the structure of Formula (III) is a compound having the structure of Formula (Illa)
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[0013] In some embodiments, the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30 alkyl, branched or linear amino-C8-Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C8-Cso alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C8-Cso cycloalkyl, or any combination thereof. In some embodiments, the linker is an optionally substituted linking moiety selected from the group consisting of a branched or linear C5-C24 alkyl, branched or linear amino-C5-C24 alkyl, branched or linear C5-C24 alkoxy, branched or linear thio-C8-C24 alkyl, C5-C24 cycloalkyl, amino-C8-C24 cycloalkyl, hydroxy-C8-C24 cycloalky, thio-C5-C24 cycloalkyl, or any combination thereof. In some embodiments, 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from O, N, and S.
y
[0015] In some embodiments, the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30 alkyl, branched or linear amino-C8-C30 alkyl, branched or linear C5-C3Q alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C8-C30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C8-C30 cycloalkyl, C5-C30 aryl-amino-C8-C30 cycloalkyl, C5-C30 heteroaryl-C8-Cgo cycloalkyl, or C5-C30 heteroaryl-amino-C8-C30 cycloalkyl. In some embodiments, 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of O, N, and S.
C(R4)(R5) or C=O. In some embodiments, Y2 and Y3 are each independently selected from C(R4) or N. In some embodiments, R4, R5, and R6 are each independently selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
[0017] In some embodiments, the E3 Ligand is selected from
[0018] In one aspect, the present invention relates, in part, to a composition comprising at least one compound of the present invention. In various embodiments, the composition is a pharmaceutical composition and/or a pharmaceutical formulation. In one embodiment, the composition comprises at least one compound of the present invention and a pharmaceutically acceptable carrier. In some embodiments, the composition is suitable for enteral administration, oral administration, and/or parenteral administration.
[0019] In one aspect, the present invention relates, in part, to a method of preparing at least one compound of the present invention or composition or pharmaceutical composition or
pharmaceutical formulation thereof.
[0020] In one aspect, the present invention relates, in part, to a method of treating a disease or disorder in a subject in need thereof, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof to the subject. In some embodiments, the disease or disorder is selected from a breast cancer, all stages of breast cancer, ER-positive breast cancer, invasive breast cancer, or any combination thereof. Thus, in one aspect, the present invention relates, in part, to a method for treating breast cancer in a subject in need thereof, the method comprising administering an effective amount of a compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof to the subject. In one embodiment, the breast cancer is an ER-positive breast cancer and/or invasive breast cancer. In one embodiment, the subject expresses a mutant ER-a protein.
[0021] In one aspect, the present invention relates, in part, to a method of reducing the level or activity of a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
[0022] In another aspect, the present invention relates, in part, to a method of inhibiting a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof.
[0023] In one embodiment, the target protein is an estrogen receptor.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] For a further understanding of the nature, objects, and advantages of the present disclosure, reference should be had to the following detailed description, read in conjunction with the following drawings, wherein like reference numerals denote like elements.
[0025] The following detailed description of preferred embodiments of the invention will be better understood when read in conjunction with the appended drawings. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.
[0026] Figure 1 shows A) dose-dependent ERa degradation by exemplary compounds 8, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 8, of the present invention in T47D breast cancer cells.
[0027] Figure 2 shows A) dose-dependent ERa degradation by exemplary compounds 10, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 10 of the present invention in T47D breast cancer cells.
[0028] Figure 3 shows A) dose-dependent ERa degradation by exemplary compounds 74, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 74 of the present
invention in T47D breast cancer cells.
[0029] Figure 4 shows A) the dose-dependent ERa degradation by exemplary compound 94, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 94 of the present invention in T47D breast cancer cells.
[0030] Figure 5 shows A) the dose-dependent ERa degradation by exemplary compound 106, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 106 of the present invention in T47D breast cancer cells.
[0031] Figure 6 shows A) the dose-dependent ERa degradation by exemplary compound 107, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 107 of the present invention in T47D breast cancer cells.
[0032] Figure 7 shows A) the dose-dependent ERa degradation by exemplary compound 115, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 115 of the present invention in T47D breast cancer cells.
[0033] Figure 8 shows A) the dose-dependent ERa degradation by exemplary compound 131 , B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 131 of the present invention in T47D breast cancer cells.
[0034] Figure 9 shows the dose-dependent ERa degradation by exemplary compound 10 in comparison with fulvestrant in MCF-7 breast cancer cells.
[0035] Figure 10 shows the dose-dependent ERa degradation by exemplary compound 12, compound 160, and Compound 106 of the present invention in MCF-7 breast cancer cells.
[0036] Figure 11 shows A) the dose-dependent ERa degradation by exemplary compound 103, B) dose-dependent inhibition of ER transcriptional activity by exemplary compound 103 of the present invention in T47D breast cancer cells.
[0037] Figure 12 shows the dose-dependent ERa degradation by exemplary compounds 167, compound 173, and compound 180 of the present invention in MCF-7 breast cancer cells.
[0038] Figure 13 shows the antiestrogenic effects of exemplary compound 167 on T47D-kb- luc cells.
[0039] Figure 14 shows the antiestrogenic effects of exemplary compound 170 on T47D-kb- luc cells.
[0040] Figure 15 shows the antiestrogenic effects of exemplary compound 173 on T47D-kb- luc cells.
[0041] Figure 16 shows the antiestrogenic effects of exemplary compound 185 on T47D-kb- luc cells.
[0042] Figure 17 shows the antiestrogenic effects of exemplary compound 186 on T47D-kb- luc cells.
[0043] Figure 18 shows the effects of exemplary compound 167 on cell proliferation of CAMA- 1 breast cancer cells.
[0044] Figure 19 shows the effects of exemplary compound 170 on cell proliferation of CAMA- 1 breast cancer cells.
[0045] Figure 20 shows the effects of exemplary compound 173 on cell proliferation of CAMA-
1 breast cancer cells.
[0046] Figure 21 shows the effects of exemplary compound 186 on cell proliferation of MCF- 7 breast cancer cells.
[0047] Figure 22 shows the single dose pharmacokinetic profile of compound 185 in Sprague Dawley rat.
[0048] Figure 23 shows the single dose pharmacokinetic profile of compound 186 in Sprague Dawley rat.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0049] The present invention relates to compounds that bind competitively and/or non- competitively to the estrogen receptor alpha (ERa), and the E3 ubiquitin ligase, cereblon (CRBN) to effect ubiquitination and subsequent degradation of the ERa protein, thereby blocking the estrogen signaling pathways and inhibiting the growth of estrogen receptor (ER) dependent cells. The invention also relates to pharmaceutical compositions comprising these ER degrading compounds, and methods for using the same for treatment of diseases and conditions mediated by the estrogen receptor, including breast cancer.
[0050] Based on the ideas of the invention described above, the disclosed bifunctional compounds can be applied for targeted degradation of ER, and be used to treat or prevent ER+ breast cancer. The following detailed description is furnished to assist those skilled in the art in joining the present invention.
[0051] Before the subject disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments of the disclosure described below, as variations of the particular embodiments may be made by those of ordinary skill in the art and still maintain the spirit and scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present disclosure will be established by the appended claims.
[0052] In this specification and the appended claims, the singular forms “a," "an," and “the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs.
[0053] In this specification and the claims reported herein, the phrase “and/or," as used is construed to mean “either or both" of the elements, i.e., either the elements can be conjunctively present in some cases or the elements can be disjunctively present in other cases.
[0054] “About" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
[0055] The terms "patient," “subject," or "individual” are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject or individual is a human.
[0056] A “disease" is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate.
[0057] In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.
[0058] As used herein, the term “cancer” refers to any of various types of malignant neoplasms, most of which invade surrounding tissues, may metastasize to several sites and are likely to recur after attempted removal and to cause death of the patient unless adequately treated. As used herein, neoplasia comprises cancer. Representative cancers include, for example, squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias, including non-acute and acute leukemias, such as acute myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia (APL), acute T-cell lymphoblastic leukemia, T-lineage acute lymphoblastic leukemia (T-ALL), adult T-cell leukemia, basophilic leukemia, eosinophilic leukemia, granulocytic leukemia, hairy cell leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, neutrophilic leukemia and stem cell leukemia; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin s disease, Wilms' tumor and teratocarcinomas, among others, which may be treated by one or more compounds of the present
invention.
[0059] A disease or disorder is “alleviated” if the severity of a sign or symptom of the disease or disorder, the frequency with which such a sign or symptom is experienced by a patient, or both, is reduced.
[0060] As used herein, the term “minimize1' or “reduce", or derivatives thereof, include a complete or partial degradation of a target protein (ER) and/or inhibition of a specified biological effect and/or reduction of ER expression at the transcript or protein level, (which is apparent from the context in which the terms "minimize" or “reduce" are used).
[0061] The term “inhibit," as used herein, means to suppress or block an activity or function by at least about ten percent relative to a control value. Preferably, the activity is suppressed or blocked by 50% compared to a control value, more preferably by 75%, and even more preferably by 95% or more.
[0062] As used herein, the term "treatment” or "treating” is defined as the application or administration of a therapeutic agent, i.e., a compound of the invention (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell from a patient (e.g., for diagnosis or ex vivo applications), who has a disease or disorder contemplated herein, a sign or symptom of a disease or disorder contemplated herein or the potential to develop a disease or disorder contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a disease or disorder contemplated herein, the signs or symptoms of a disease or disorder contemplated herein or the potential to develop a disease or disorder contemplated herein. Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. To "treat” a disease as the term is used herein, means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.
[0063] “Parenteral" administration of a composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), or intrasternal injection, or infusion techniques.
[0064] The compounds according to the disclosure are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as chromatography on a suitable support material. Furthermore, reverse phase preparative HPLC of compounds of the present invention which possess a sufficiently basic or acidic functionality, may result in the formation of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological
assays. Additionally, the drying process during the isolation of compounds of the present invention may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognize which solvates or inclusion complexes are acceptable to be used in subsequent biological assays. It is to be understood that the specific form (e.g., salt, free base, solvate, inclusion complex) of a compound of the present invention as isolated as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.
[0065] One aspect of the invention is salts of the compounds according to the invention including all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
[0066] Examples of salts include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, meglumine, ammonium, salts optionally derived from NH3 or organic amines having from 1 to 16 C-atoms such as, e.g„ ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, ethylendiamine, N-methylpiperindine, arginine, lysine, and guanidinium salts.
[0067] The salts of the disclosed compounds include pharmaceutically acceptable water- insoluble and, particularly, water-soluble salts.
[0068] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a earner or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing an undesirable biological effect or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0069] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the compounds disclosed herein wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydra ba mic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl
sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicyclic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluene sulfonic, and the commonly occurring amine acids, e.g., glycine, alanine, phenylalanine, arginine, etc.
[0070] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1 -carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, and the like. The present invention also encompasses salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In the salt form, it is understood that the ratio of the compound to the cation or anion of the salt may be 1:1, or any ratio other than 1:1 , e.g., 3:1 , 2:1, 1:2, or 1:3.
[0071] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt. [0072] Salts of the compounds of Formula (I) according to the invention can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethyl ketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added. The acid or base can be employed in salt preparation, depending on whether a mono- or polybasic acid or base is concerned and depending on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained by filtering, reprecipitating, precipitating with a non-solvent for the salt or by evaporating the solvent. Salts obtained can be converted into the free compounds which, in turn, can be converted into salts. In this manner, pharmaceutically unacceptable salts, which can be obtained, for example, as process products in the manufacturing on an industrial scale, can be converted into pharmaceutically acceptable salts by processes known to the person skilled in the art.
[0073] According to the person skilled in the art the compounds of Formula (I) according to this invention as well as their salts may contain, e.g., when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of Formula (I) according to this invention as well as all solvates and in particular all hydrates of the salts of the compounds of Formula (I) according to this invention.
[0074] “Solvate" means solvent addition forms that contain either stoichiometric or non- stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
[0075] The compounds according to the invention and their salts can exist in the form of tautomers which are included in the embodiments of the invention.
[0076] The term “tautomer” refers to one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH conditions. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism.
[0077] Where the present specification depicts a compound prone to tautomerization, but only depicts one of the tautomers, it is understood that all tautomers are included as part of the meaning of the chemical depicted. It is to be understood that the compounds disclosed herein may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be included, and the naming of the compounds does not exclude any tautomer form.
[0078] Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism arises as a result of the aldehyde group ( — CHO) in a sugar chain molecule reacting with one of the hydroxy groups ( — OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
[0079] Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), imine-enamine and enamine-enamine.
[0080] The compounds of the invention may, depending on their structure, exist in different stereoisomeric forms. These forms include configurational isomers or optically conformational isomers (enantiomers and/or diastereoisomers including those of atropisomers). The present invention therefore includes enantiomers, diastereoisomers as well as mixtures thereof. From those mixtures of enantiomers and/or disastereoisomers pure stereoisomeric forms can be isolated with methods known in the art, preferably methods of chromatography, especially high performance liquid chromatography (HPLC) using achiral or chiral phase. The invention further
includes all mixtures of the stereoisomers mentioned above independent of the ratio, including the racemates.
[0081] The compounds of the invention may, depending on their structure, exist in various stable isotopic forms. These forms include those in which one or more hydrogen atoms have been replaced with deuterium atoms, those in which one or more nitrogen atoms have been replaced with 15N atoms, or those in which one or more atoms of carbon, fluorine, chlorine, bromine, sulfur, or oxygen have been replaced by the stable isotope of the respective, original atoms.
[0082] Some of the compounds and salts according to the invention may exist in different crystalline forms (polymorphs) which are within the scope of the invention.
[0083] It is a further object of the invention to provide ER degrading compounds, methods of synthesizing the ER degrading bifunctional compounds, methods of manufacturing the ER degrading compounds, and methods of using the ER degrading compounds.
[0084] As used herein, the term “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration. The term “pharmacological composition," “therapeutic composition,” "therapeutic formulation” or "pharmaceutically acceptable formulation" can mean, but is in no way limited to, a composition or formulation that allows for the effective distribution of an agent provided by the invention, which is in a form suitable for administration to the physical location most suitable for their desired activity, e.g., systemic administration.
[0085] Non-limiting examples of agents suitable for formulation with the, e.g., compounds provided by the instant invention include: cinnamoyl, PEG, phospholipids or lipophilic moieties, phosphorothioates, P-glycoprotein inhibitors (such as Pluronic P85) which can enhance entry of drugs into various tissues, for example the CNS (Jolliet-Riant and Tillement, 1999, Fundam. Clin. Pharmacol., 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after implantation (Emerich, D F et al, 1999, Cell Transplant, 8, 47-58) Alkermes, Inc. Cambridge, Mass.; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry, 23, 941-949, 1999).
[0086] A “therapeutic" treatment is a treatment administered to a subject who exhibits signs or symptoms of pathology disease or disorder, for the purpose of diminishing or eliminating those signs or symptoms.
[0087] As used herein, the terms "effective amount," “pharmaceutically effective amount" and “therapeutically effective amount" refer to a sufficient amount of an agent to provide the desired
biological or physiologic result. That result may be reduction and/or alleviation of a sign, a symptom, or a cause of a disease or disorder, or any other desired alteration of a biological system. An appropriate effective amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
[0088] As used herein, the term “pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butterand suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier" may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
[0089] As used herein, the term “halo" or "halogen" alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0090] As used herein, the term "alkyl," by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e. Ci-s means one to six carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples include, but are not limited to, groups such as methyl, ethyl,
n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. The term “alkyl,” unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as "heteroalkyl”, “haloalkyl" and “homoalkyl”.
[0091] As used herein, the term "substituted alkyl” means alkyl, as defined above, substituted by one, two or three substituents selected from the group consisting of halogen, -OH, alkoxy, - NH2, -N(CH3)2, -C(=O)OH, trifluoromethyl, -C=N, -C(=O)O(Ci-C4)alkyi, -C(=O)NH2, -SO2NH2, - C(-NH)NH2, and -NO2, preferably containing one or two substituents selected from halogen, -OH, alkoxy, -NH2, trifluoromethyl, -NtCHsfe, and -C(=O)OH, more preferably selected from halogen, alkoxy and -OH. Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2-carboxycyclopentyl and 3-chloropropyl.
[0092] As used herein, the term “cycloalkyl” refers to a mono cyclic or polycyclic non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. In one embodiment, the cycloalkyl group is saturated or partially unsaturated. In another embodiment, the cycloalkyl group is fused with an aromatic ring. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
[0093] Monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Dicyclic cycloalkyls include, but are not limited to, tetrahydronaphthyl, indanyl, and tetrahydropentalene. Polycyclic cycloalkyls include adamantine and norbomane. The term cycloalkyl includes "unsaturated nonaromatic carbocyclyl" or “nonaromatic unsaturated carbocyclyl" groups, both of which refer to a nonaromatic carbocycle as defined herein, which contains at least one carbon double bond or one carbon triple bond.
[0094] As used herein, the term “heteroalkyl" by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quatemized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the
fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include: -O-CH2-CH2-CH3, -CH2-CH2-CH2-OH, -CH2-CH2-NH-CH3, -CH2-S-CH2-CH3, and -CH2CH2-S(=O)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3, or -CH2-CH2-S-S-CH3. As used herein, the terms “heteroalkyl” refers to “alkoxy," “alkylamino" and “alkylthio” that are used in their conventional sense, and refer to alkyl groups linked to molecules via an oxygen atom, an amino group, a sulfur atom, respectively.
[0095] As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1 -propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers.
[0096] As used herein, the term “heterocycloalkyl” or “heterocyclyl” refers to a heteroalicyclic group containing one to four ring heteroatoms each selected from O, S and N. In one embodiment, each heterocycloalkyl group has from 4 to 10 atoms in its ring system, with the proviso that the ring of said group does not contain two adjacent O or S atoms. In another embodiment, the heterocycloalkyl group is fused with an aromatic ring. In one embodiment, the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or non-aromatic in nature. In one embodiment, the heterocycle is a heteroaryl,
[0097] An example of a 3-membered heterocycloalkyl group includes, and is not limited to, aziridine. Examples of 4-membered heterocycloalkyl groups include, and are not limited to, azetidine and a beta lactam. Examples of 5-membered heterocycloalkyl groups include, and are not limited to, pyrrolidine, oxazolidine and thiazolidinedione. Examples of 6-membered heterocycloalkyl groups include, and are not limited to, piperidine, morpholine and piperazine. Other non-limiting examples of heterocycloalkyl groups are:
[0098] Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, pyrazolidine, imidazoline, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1 ,2,3,6-tetrahydropyridine, 1 ,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran,
2.3-dihydropyran, tetrahydropyran, 1 ,4-dioxane, 1 ,3-dioxane, homopiperazine, homopiperidine,
1 .3-dioxepane, 4,7-dihydro-1 ,3-dioxepin, and hexamethyleneoxide.
[0099] As used herein, the term “aromatic" refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e. having (4n + 2) delocalized n (pi) electrons, where n is an integer.
[00100] As used herein, the term “aryl,” employed alone or in combination with other terms, means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings), wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples of aryl groups include phenyl, anthracyl, and naphthyl.
[00101] As used herein, the term “heteroaryl” or ‘'heteroaromatic'’ refers to a heterocycle having aromatic character. A polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include the following moieties:
[00102] Examples of heteroaryl groups also include pyridyl, pyrazinyl, pyrimidinyl (particularly 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl (particularly 2-pyrrolyl), imidazolyl, thiazolyl, oxazolyl, pyrazolyl (particularly 3- and 5-pyrazolyl), isothiazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,3,4-triazolyl, tetrazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
[00103] Examples of polycyclic heterocycles and heteroaryls include indolyl (particularly 3-, 4-, 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (particularly 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (particularly 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1 ,8-naphthyridinyl, 1 ,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (particularly 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (particularly 3-, 4-, 5-, 6-, and 7-benzothienyl), benzoxazolyl, benzothiazolyl (particularly 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl (particularly 2-benzimldazolyl), benzotriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl.
[00104] The aforementioned listing of heterocyclyl and heteroaryl moieties is intended to be representative and not limiting.
[00105] As used herein, the term “substituted" means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group. The term “substituted” further refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and Substitution may be at any chemically accessible position. In one embodiment, the substituents vary in number between one and four. In another embodiment, the substituents vary in number between one and three. In yet another embodiment, the substituents vary in number between one and two. The substituents are independently selected, and substitution may be at any chemically accessible position. In one embodiment, the substituents vary in number between one and four. In another embodiment, the substituents vary in number between one and three. In yet another embodiment, the substituents vary in number between one and two. In yet another embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, -OH, C1-6 alkoxy, halo, amino, acetamido and nitro. In yet another embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic, with straight being preferred.
[00106] As used herein, the term "optionally substituted" means that the referenced group may be substituted or unsubstituted. In one embodiment, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In another embodiment, the referenced group is optionally substituted with one or more additional group(s) individually and independently selected from groups described herein.
[00107] In one embodiment, the substituents are independently selected from the group consisting of oxo, halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, alkyl (including straight chain, branched and/or unsaturated alkyl), substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, fluoro alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, fluoroalkoxy, -S-alkyl, S(=O)2alkyl, -C(=O)NH[substituted or unsubstituted alkyl, or substituted or unsubstituted phenyl], -C(=O)N[H or alkyl]2, -OC(=O)N [substituted or unsubstituted alkyl]2, -NHC(=O)NH[substituted or unsubstituted alkyl, or substituted or unsubstituted phenyl], -NHC(=O)alkyl, -N[substituted or unsubstituted alkyl]C(=O)[substituted or unsubstituted alkyl], -NHC(=O)[substituted or unsubstituted alkyl], -C(OH)[substituted or unsubstituted alkyl]2, and -C(NH2)[substituted or unsubstituted alkyl]2. In another embodiment, by way of example, an optional substituent is selected from oxo, fluorine, chlorine, bromine, iodine, - CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -OCH3, - OCH2CH3, -OCH(CH3)2, -OCF3, - OCH2CF3, -S(=O)2-CH3, -C(=O)NH2, -C(=O)-NHCH3, - NHC(=O)NHCH3, -C(=O)CH3, -ON(O)2, and -C(=O)OH. In yet one embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, -OH, C1-6 alkoxy, halo, amino, acetamido, oxo and nitro. In yet another embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic. [00108] As used herein, the term "analog," “analogue," or "derivative" is meant to refer to a chemical compound or molecule made from a parent compound or molecule by one or more chemical reactions. As such, an analog can be a structure having a structure similar to that of the small molecule therapeutic agents described herein or can be based on a scaffold of a small molecule therapeutic agents described herein, but differing from it in respect to certain components or structural makeup, which may have a similar or opposite action metabolical ly. An analog or derivative can also be a small molecule that differs in structure from the reference molecule, but retains the essential properties of the reference molecule. An analog or derivative may change its interaction with certain other molecules relative to the reference molecule. An analog or derivative molecule may also include a salt, an adduct, tautomer, isomer, or other variant of the reference molecule.
[00109] As used herein, the term "potency" refers to the dose needed to produce half the maximal response (EDso).
[00110] As used herein, the term “efficacy" refers to the maximal effect (Emax) achieved within an assay.
[00111] Ranges: throughout this invention, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of
the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
Description
[00112] The present invention relates to bifunctional compounds compositions containing such compounds, and their use in prevention and treatment of diseases and conditions including cancer. The bifunctional compounds contain one ligand that binds the target protein and another ligand that binds to a specific E3 ubiquitin ligase, which are linked via a linker molecule. In the present invention the bifunctional compounds can simultaneously bind estrogen receptor alpha (ERa) (target protein) and a cereblon (CRBN) E3 ubiquitin ligase, which promotes ubiquitination of ER and leads to degradation of ER by the proteasome.
Compounds
[00113] In one aspect, the present invention provides compounds having the structure of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof:
( )
[00114] In some embodiments, each occurrence of X1 is independently selected from O, S, C(R4)(R5), or C=O. For example, in some embodiments, each occurrence of X1 is independently selected from O or C=O.
[00115] In some embodiments, each occurrence of X2 is independently selected from O, S, C(R4)(R5), or C=O. For example, in some embodiments, each occurrence of X2 is independently selected from CH2 and S.
[00116] In some embodiments, R1 is selected from hydrogen, deuterium, halogen, or hydroxyl. For example, in some embodiments, R1 is selected from hydrogen, deuterium, F, Cl, Br, or I.
[00117] In some embodiments, R2 is selected from hydrogen, deuterium, halogen, hydroxyl,
alkyl, alkoxy,
[00118] In some embodiments, R3 is selected from hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy,
[00119] In some embodiments, each occurrence of R4, R5, and R6 is independently selected from hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
[00120] In some embodiments, each occurrence of Z is selected from Li, Na, or K.
[00121] In some embodiments, each occurrence of m is independently an integer from 0 to 4. For example, in one embodiment, m is an integer 0. In one embodiment, m is an integer 1. In one embodiment, m is an integer 2. In one embodiment, m is an integer 3. In one embodiment, m is an integer 4.
[00122] In some embodiments, each occurrence of n is independently an integer from 0 to 4. For example, in one embodiment, n is an integer 0. In one embodiment, n is an integer 1 . In one embodiment, n is an integer 2. In one embodiment, n is an integer 3. In one embodiment, n is an integer 4.
[00123] Thus, in some embodiments, R2 is selected from hydrogen, deuterium, F, Cl, Br, I,
H
In some embodiments, R2 is hydrogen, F, Cl, Br, or I
[00125] In some embodiments, x is an integer from 0 to 2. In some embodiments, x is an integer 0 or 1. In one embodiment, x is an integer 0. In one embodiment, x is an integer 1. In one embodiment, x is an integer 2.
[00126] In some embodiments, y is an integer from 0 to 2. In some embodiments, y is an integer 1 or 2. In one embodiment, y is an integer 0. In one embodiment, y is an integer 1. In one embodiment, y is an integer 2.
[00127] For example, in one embodiment, x is an integer 1 and y is an integer 1. Thus, in one embodiment, the compound having the structure of Formula (I) is a compound having the structure
selected from I),
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00128] For example, in one embodiment, X2 is S. Thus, in one embodiment, the compound having the structure of Formula (II) is a compound having the structure of Formula (Ila) 3
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00129] In one embodiment, x is an integer 0 and y is an integer 2. Thus, in one embodiment, the compound having the structure of Formula (I) is a compound having the structure selected from
Formula (III), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00130] For example, in one embodiment, the compound having the structure of Formula (III) is a compound having the structure of Formula (Illa)
HO
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00131] In some embodiments, the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30 alkyl, branched or linear amino-C8-Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy- C5-C30 cycloalky, thio-C8-C30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C8-C30 cycloalkyl, C5-C30 aryl-amino-C8-C30 cycloalkyl, C5-C30 heteroaryl-C8-Cso cycloalkyl, or C8-Cso heteroaryl-amino-C8-C30 cycloalkyl .
[00132] In some embodiments, 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of O, N, and S.
For example, in one embodiment, the E3 Ligand i
s Q . Thus, in one embodiment, in one embodiment, the compound having the structure of Formula (Ila) is a compound having the structure of Formula (Ila')
Formula (Ila ).
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00134] In some embodiments, Y1 is selected from C(R4)(R5) or C=O.
[00135] In some embodiments, Y2 is selected from C(R4) or N.
[00136] In some embodiments, Y3 is selected from C(R4) or N.
[00137] In some embodiments, R4 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
[00138] In some embodiments, R5 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
[00139] In some embodiments, R6 is selected from hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl.
[00140] In some embodiments, the E3 Ligand is one of the following structures;
[00141] In some embodiments, the linker is an optionally substituted linking moiety. In some embodiments, the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 5 to 30 carbon atoms in length, or any combination thereof. In some embodiments, the linker is an optionally substituted linking moiety. In some embodiments, the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated chain of 5 to 22 carbon atoms in length, or any combination thereof. In some embodiments, the linker comprises a branched or unbranched, cyclized or uncyclized, saturated or unsaturated
chain of 5 to 16 carbon atoms in length, or any combination thereof.
[00142] In some embodiments, the linking moiety comprises 1 to 8 of the carbon atoms that are optionally replaced with a heteroatom. In some embodiments, the linking moiety comprises 1 to 6 of the carbon atoms that are optionally replaced with a heteroatom. In some embodiments, the heteroatom is independently O, N, or S.
[00143] In some embodiments, the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30 alkyl, branched or linear amino-C5-Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-Cg-Cso alkyl, C5-C30 cycloalkyl, amino-C8-Cso cycloalkyl, hydroxy- C5-C30 cycloalky, thio-Cg-Cso cycloalkyl, -Y4-(CH2)a-(NH)b-W-(CH2)c-Y5-, or any combination thereof. In some embodiments, the linker is an optionally substituted linking moiety selected from the group consisting of a branched or linear C5-C24 alkyl, branched or linear amino-C8-C24 alkyl, branched or linear C5-C24 alkoxy, branched or linear thio-C8-C24 alkyl, C5-C24 cycloalkyl, amino- C5-C24 cycloalkyl, hydroxy-C8-C24 cycloalky, thio-C8-C24 cycloalkyl, -Y4-(CH2)a-(NH)t)-W-(CH2)c-Y5-, or any combination thereof. In some embodiments, the linking moiety comprises a branched or linear C5-C22 alkyl, branched or linear amino-C8-C22 alkyl, branched or linear C5-C22 alkoxy, branched or linear thio-C8-C22 alkyl, C5-C22 cycloalkyl, amino-C5-C22 cycloalkyl, hydroxy-C8-C^ cycloalky, thjo-C8-C22 cycloalkyl, -Y4-(CH2)a-(NH)trW-(CH2)e-Y5-, or any combination thereof. In some embodiments, the linking moiety comprises a branched or linear C5-C16 alkyl, branched or linear amino-C8-C18 alkyl, branched or linear C5-C16 alkoxy, branched or linear thio-C5-Ci6 alkyl, C5-C16 Cycloalkyl, amino-Cg-Cw Cycloalkyl, hydroxy-Cg-Cie CyCloalky, thio-Cg-Cie cycloalkyl, -Y4- (CH2)a-(NH)j,-W-(CH2)c-Y5-, or any combination thereof.
[00144] In some embodiments, the linker is -Y4-(CH2)e-(NH)6-W-(CH2)c-Y5-.
[00145] In some embodiments, each occurrence of Y4 and Y5 is independently O, -NH-, 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S, or any combination thereof, or absent.
[00146] In some embodiments, Y4 is absent or O.
[00147] In some embodiments, Y5 is -NH- or 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S. For example, in some embodiments, said 5 to 9 membered heterocycloalkyl is piperidine or piperazine.
[00148] In some embodiments, each occurrence of a, b, and c is independently an integer of 0 to 7.
[00149] In some embodiments, each occurrence of a and c is independently an integer of 0 to 7.
[00150] In some embodiments, each occurrence of b is independently an integer of 0 or 1 .
[00151] In some embodiments, each occurrence of W is independently 5 to 9 membered heterocycloalkyl having one or two heteroatoms selected from N, O, and S.
y
[00153] In some embodiments, the compound of Formula (I) may encompass both the R and S isomers. In some embodiments, the compound of Formula (I) may be a mixture of trans- and - cis olefin.
[00154] In some embodiments, provided herein is a compound, or pharmaceutically acceptable salt thereof, chosen from the compounds listed in Table 1 :
£ o
TABLE 1. Exemplary Compounds of the Invention
ER antagonism (T47D ERE luciferase): □ o o
A : IC50 < 10 nM; B: IC50 =10-50 nM; C - IC50 >5O nM
SB. z
MCF-7 proliferation with 0.1 nM 17-beta estradiol: 0 A: IC50 < 20 nM; B: IC50=2O-5O nM; C: IC50 >5O nM KD O O) C KDD
ER degradation (DC50): A < 10 nM; B:10-50 nM; C: >50 nM
ER degradation (Dmax): A - >90%; B >75%; C > 50%; D <50% O O O
□ o o
SB. z p KD O G)
O O O
O O § o
Pharmaceutical Compositions
[00155] This specification also describes, in part, a composition which comprises a compound of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
[00156] This specification also describes, in part, a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[00157] This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in reducing the level or activity of a target protein (e.g., an estrogen receptor).
[00158] This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in inhibiting a target protein (e.g,, an estrogen receptor).
[00159] This specification also describes, in part, a compound of Formula (1), or a pharmaceutically acceptable salt thereof, for use in therapy.
[00160] This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
[00161] This specification also describes, in part, a method for treating cancer in a warmblooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I), Or a pharmaceutically acceptable salt thereof.
[00162] In one embodiment, the invention provides for a pharmaceutical composition comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the pharmaceutical compound is for use in treatment of a proliferative disease, such as a cancer, for example, a breast cancer. A further embodiment may provide a method of treating breast cancer comprising administering to a subject in need of treatment or amelioration a compound according to any one of the preceding paragraphs. The breast cancer may be an ER-positive breast cancer. The subject may express a mutant ER-a protein or any variant of ER-a, such as ERa-36. An embodiment may provide proper and effective use of a compound as in the paragraphs above for treating and/or preventing breast cancer. In some embodiments, the breast cancer is an ER-positive breast cancer. In some embodiments said subject expresses a mutant ER-a protein or a variant of ERa, such as ERa-36. In some embodiments a compound as presented above is used in the preparation of a medicament for treatment of breast cancer in a patient or subject, such as a human or animal.
[00163] The pharmaceutical compositions of the present invention can be in any form known to those of skill in the art, and a suitable dosage form of the compound(s) can be administered by an appropriate route. For instance, in some embodiments the pharmaceutical compositions are in
a form of a product for oral delivery, said product form being selected from a group consisting of a concentrate, dried powder, liquid, capsule, pellet, and pill. In other embodiments, the pharmaceutical compositions of the invention are in the form of a product for parenteral administration including intravenous, intradermal, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal and subcutaneous administration. The compounds described herein may be administered as a single dose or a divided dose over a period of time. The pharmaceutical compositions disclosed herein may also further comprise carriers, binders, diluents, and excipients. The described carriers, diluents and excipients may include dried corn starch or lactose, the binder may include microcrystalline cellulose, gum tragacanth or gelatin, in addition, the excipients may also include a dispersing agent, a lubricant, a glidant, a sweetening agent or a flavoring agent.
[00164] Also, in other aspects, the present invention relates to new ER degrading composition comprising one or more compounds selected from the group consisting of a compound of Formula (I) and pharmaceutically acceptable salts and solvates thereof. In an embodiment, said compound has a purity of about a 75%, ≥ 80%, ≥ 85%, ≥ 90%, > 95%, > 96%, > 97%, or > 98%, and > 99%. In an embodiment, a pharmaceutical composition is provided comprising the new ER degrading composition, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new ER degrading compositions, either alone or in combination with at least one additional therapeutic agent, in the treatment of proliferative diseases including breast cancer at any stage of the disease diagnosis. The combination with an additional therapeutic agent may take the form of combining the new ER degrading compounds with any known therapeutic agent.
[00165] The disclosed compounds can be used to slow the rate of primary tumor growth. The disclosed compounds can also be used to prevent, abate, minimize, control, and/or lessen tumor metastasis in humans and animals. The disclosed compounds when administered to a subject in need of treatment can be used to stop the spread of cancer cells. As such, the compounds disclosed herein can be administered as part of a combination therapy with one or more drugs or other pharmaceutical agents. When used as part of the combination therapy, the decrease in metastasis and reduction in primary tumor growth afforded by the disclosed compounds allows for a more effective and efficient use of any pharmaceutical or drug therapy being used to treat the patient. In addition, control of metastasis by the disclosed compound affords the subject a greater ability to concentrate the disease in one location.
[00166] The following are non-limiting examples of cancers that can be treated by the disclosed methods and compositions: Acute Lymphoblastic; Acute Myeloid Leukemia; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Appendix Cancer; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bone Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem
Glioma, Childhood; Brain Tumor, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors; Cerebellar Astrocytoma; Cerebral Astrocytotna/Malignant Glioma; Craniopharyngioma; Ependymoblastoma; Ependymoma; Medulloblastoma; Medulloepithelioma; Pineal Parenchymal Tumors of intermediate Differentiation; Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma; Visual Pathway and Hypothalamic Glioma; Brain and Spinal Cord Tumors; Breast Cancer; Bronchial Tumors; Burkitt Lymphoma; Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Central Nervous System Atypical Teratoid/Rhabdoid Tumor; Central Nervous System Embryonal Tumors; Central Nervous System Lymphoma; Cerebellar Astrocytoma Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Chordoma, Childhood; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Colon Cancer; Colorectal Cancer; Craniopharyngioma; Cutaneous T-Cell Lymphoma; Esophageal Cancer; Ewing Family of Tumors; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin Lymphoma; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma; intraocular Melanoma; Islet Cell Tumors; Kidney (Renal Cell) Cancer; Langerhans Cell Histiocytosis; Laryngeal Cancer; Leukemia, Acute Lymphoblastic; Leukemia, Acute Myeloid; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoma, AIDS-Related; Lymphoma, Burkitt; Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin; Lymphoma, NonHodgkin; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocvtoma of Bone and Osteosarcoma; Medulloblastoma; Melanoma; Melanoma, intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, (Childhood); Multiple Myeloma/Plasma Cell Neoplasm; Mycosis; Fungoides; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid
Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer;
Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung Cancer; Oral Cancer; Oral Cavity Cancer; Oropharyngeal Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Islet Cell Tumors; Papillomatosis;
Parathyroid Cancer; Penile Cancer; Pharyngeal Cancer; Pheochromocytoma; Pineal Parenchymal Tumors of Intermediate Differentiation; Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors; Pituitary Tumor; Plasma Celt Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Primary Central Nervous System Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15; Retinoblastoma; Rhabdomyosarcoma; Salivary Gland Cancer; Sarcoma, Ewing Family of Tumors; Sarcoma, Kaposi; Sarcoma, Soft Tissue; Sarcoma, Uterine; Sezary Syndrome; Skin Cancer (Nonmelanoma); Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma, Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Supratentorial Primitive Neuroectodermal Tumors; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Throat Cancer; Thymoma and Thymic Carcinoma; Thyroid Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; and Wilms Tumor.
Methods of Treatment
[00167] The methods for treating a clinical indication by the ER degrading compounds disclosed herein, may be effectuated by administering a therapeutically effective amount of the ER degrading compounds to a patient in need thereof, this therapeutically effective amount may comprise administration of the prodrug to the patient at about 1 mg/kg/day, 2 mg/kg/day, 3 mg/kg/day, 4 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day and 20 mg/kg/day. Alternatively, amounts ranging from about 0.001 mg/kg/day to about 0.01 mg/kg/day, or about 0.01 mg/kg/day to about 0.1 mg/kg/day, or about 0.1 mg/kg/day to about 1 mg/kg/day, or about 1 mg/kg/day to 10 mg/kg/day, or about 10 mg/kg/day to about 100 mg/kg/day are also contemplated.
[00168] A further object of the invention is a kit, comprising a composition containing at least one ER degrading compound for treatment and prevention of cancer and cancer related morbidities. The composition of the kit may comprise at least one carrier, at least one binder, at least one diluent, at least one excipient, at least one other therapeutic agent, or mixtures thereof. The kit may be designed, developed, distributed, or sold as a unit for performing the methods of the present invention and to deliver the drugs to the targeted cells for the treatment and prevention of cancer and related diseases. The kits may also include instructions to customers for proper usage of the kit to treat patients exhibiting the symptoms of the desired disease, e.g., cancer or breast cancer.
[00169] One aspect of the present invention is the compounds disclosed herein as well as the intermediates as used for their synthesis, and the synthetic scheme for the preparation of the
disclosed final compounds and the intermediates resulted before the final compound is generated. [00170] While certain features of this invention shown and described below are pointed out in the annexed claims, the invention is not intended to be limited to the details specified, since a person of ordinary skill in the relevant art will understand that various omissions, modifications, substitutions, and changes in the forms and details of the invention illustrated and in its operation may be made without departing in any way from the spirit of the present invention. No feature of the invention is critical or essential unless it is specifically stated as being “critical" or “essential". [00171] These and other features, aspects, and advantages of embodiments of the present invention will become more evident with regard to the following descriptions, claims, and accompanying drawings explained below.
[00172] Another object of the invention is to provide a composition, for example a pharmaceutical composition, comprising at least one ER degrader compound in an amount effective for the indication of proliferative diseases such as cancer, including but not limited to endocrine related cancer. In an embodiment, the cancer is an ER-positive tumor, such as a tumor of the breast, endometrium, uterus, or ovary. In an embodiment, the tumor is an ER-positive tumor of the breast. In an embodiment, the breast tumor is determined to be ER-positive by an immunohistochemical method described by Hammond et al. [8].
[00173] In an embodiment, the object of such treatment is to degrade estrogen receptor and/or inhibit estrogen-induced proliferation of a cell. In a further embodiment, said object is to inhibit estrogen-induced proliferation of a cell by a mechanism selected from SERM, SERD, and PROTAC.
[00174] As used herein, “treating" means administering to a subject a pharmaceutical composition to ameliorate, reduce or lessen the symptoms of a disease. As used herein, “treating" or “treat" describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes the administration of a compound disclosed herein, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder. The term “treat" may also include treatment of a cell in vitro or an animal model. As used herein, “subject” or “subjects” refers to any animal, such as mammals including rodents (e.g., mice or rats), dogs, primates, lemurs or humans.
[00175] Treating cancer may result in a reduction in size of a tumor. A reduction in size of a tumor may also be referred to as “tumor regression." Preferably, after treatment, tumor size is reduced by about 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater
than about 75% or greater. Size of a tumor may be measured by any reproducible means of measurement. The size of a tumor may be measured as a diameter of the tumor.
[00176] Treating cancer may result in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by about 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by about 75% or greater. Tumor volume may be measured by any reproducible means of measurement.
[00177] Treating cancer may result in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by about 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater than about 75%. Number of tumors may be measured by any reproducible means of measurement. The number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2×, 3×, 4×. 5×, 10×, or 50x.
[00178] Treating cancer may result in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by about 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by about 10% or greater; more preferably, reduced by about 20% or greater; more preferably, reduced by about 30% or greater; more preferably, reduced by about 40% or greater; even more preferably, reduced by about 50% or greater; and most preferably, reduced by greater than about 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. The number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2×, 3×, 4×. 5×, 10×, or 50x.
[00179] Treating cancer may result in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. Preferably, the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a
first round of treatment with an active compound.
[00180] Treating cancer may result in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
[00181] Treating cancer may result in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound disclosed herein, or a pharmaceutically acceptable salt thereof. Preferably, the average survival time is increased by more than about 30 days; more preferably, by more than about 60 days; more preferably, by more than about 90 days; and most preferably, by more than about 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
[00182] Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. Treating cancer may result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound disclosed herein, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. Preferably, the mortality rate is decreased by more than about 2%; more preferably, by more than about 5%; more preferably, by more than about 10%; and most preferably, by more than about 25%. A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means. A decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.
[00183] Treating cancer may result in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least about 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%. Tumor growth rate may be measured by any reproducible means of measurement. Tumor growth rate may be measured according to a change in tumor diameter per unit time.
[00184] Treating cancer may result in a decrease in tumor regrowth, for example, following attempts to remove it surgically. Preferably, after treatment, tumor regrowth is less than about 5%; more preferably, tumor regrowth is less than about 10%; more preferably, less than about 20%; more preferably, less than about 30%; more preferably, less than about 40%; more preferably, less than about 50%; even more preferably, less than about 50%; and most preferably, less than about 75%. Tumor regrowth may be measured by any reproducible means of measurement. Tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. A decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.
[00185] Treating or preventing a cell proliferative disorder may result in a reduction in the rate of cellular proliferation. Preferably, after treatment, the rate of cellular proliferation is reduced by at least about 5%; more preferably, by at least about 10%; more preferably, by at least about 20%; more preferably, by at least about 30%; more preferably, by at least about 40%; more preferably, by at least about 50%; even more preferably, by at least about 50%; and most preferably, by at least about 75%. The rate of cellular proliferation may be measured by any reproducible means of measurement. The rate of cellular proliferation is measured, for example, by measuring the number of dividing cells in a tissue sample per unit time.
[00186] Treating or preventing a cell proliferative disorder may result in a reduction in the proportion of proliferating cells. Preferably, after treatment, the proportion of proliferating cells is reduced by at least about 5%; more preferably, by at least about 10%; more preferably, by at least about 20%; more preferably, by at least about 30%; more preferably, by at least about 40%; more preferably, by at least about 50%; even more preferably, by at least about 50%; and most preferably, by at least about 75%. The proportion of proliferating cells may be measured by any reproducible means of measurement. Preferably, the proportion of proliferating cells is measured, for example, by quantifying the number of dividing cells relative to the number of nondividing cells in a tissue sample. The proportion of proliferating cells may be equivalent to the mitotic index.
[00187] Treating or preventing a cell proliferative disorder may result in a decrease in size of an area or zone of cellular proliferation. Preferably, after treatment, size of an area or zone of cellular proliferation is reduced by at least about 5% relative to its size prior to treatment; more
preferably, reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%. Size of an area or zone of cellular proliferation may be measured by any reproducible means of measurement. The size of an area or zone of cellular proliferation may be measured as a diameter or width of an area or zone of cellular proliferation.
[00188] Treating or preventing a cell proliferative disorder may result in a decrease in the number or proportion of cells having an abnormal appearance or morphology. Preferably, after treatment, the number of cells having an abnormal morphology is reduced by at least about 5% relative to its size prior to treatment; more preferably, reduced by at least about 10%; more preferably, reduced by at least about 20%; more preferably, reduced by at least about 30%; more preferably, reduced by at least about 40%; more preferably, reduced by at least about 50%; even more preferably, reduced by at least about 50%; and most preferably, reduced by at least about 75%. An abnormal cellular appearance or morphology may be measured by any reproducible means of measurement. An abnormal cellular morphology may be measured by microscopy, e.g., using an inverted tissue culture microscope. An abnormal cellular morphology may take the form of nuclear pleiomorphism.
[00189] In another aspect, the present invention relates, in part, to a method of inhibiting a target protein, the method comprising administering at least one compound of the present invention or composition or pharmaceutical composition or pharmaceutical formulation thereof. [00190] In one embodiment, the target protein is an estrogen receptor.
EXAMPLES
[00191] Hereby are provided non-limiting examples of embodiments of compounds disclosed herein. The examples and preparations provided below further illustrate and exemplify the compounds as disclosed herein and methods of preparing such compounds. It is to be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples and preparations. Unless stated otherwise, starting materials were commercially available. All solvents and commercial reagents were of laboratory grade and were used as received.
[00192] Example 1 : Bifunctional Compounds that Perform as Modulators of Estrogen
Receptor
[00193] Cellular signaling of estrogens is mediated through two estrogen receptor (ER) subtypes, ERa and ERβ . and they belong to the nuclear receptor family of transcription factors.
Estrogens play central roles in the development and maintenance of normal sexual and reproductive function. In addition, both ERα and ERβ were found to have distinct biological effects in the immune, skeletal, cardiovascular, and central nervous systems [1]. Estrogen receptors are mainly expressed in ovarian, uterus, liver cells, and are found overexpressed in certain tumor cells, such as breast cancer, ovarian cancer and prostate cancer. The most potent and abundant estrogen produced in human body is 17p-estradiol. Anti-estrogens, designed to block ERa by retreating estrogens from the active site, are widely and effectively used clinically for breast cancer treatment [2].
[00194] Breast cancer remains the most common cancer in women worldwide, with over 1.7 million new cases diagnosed in 2012, and it is the second most common cancer overall. This represents about 12% of all new cancer cases and 25% of all cancers in women. Nearly 80% of breast cancer cases are estrogen receptor positive (ER+) [3, 4] and for most of these patients, endocrine therapy is an appropriate option in both the adjuvant and advanced setting. This therapy is used to prevent or block the hormones from stimulating the growth of cancer cells. Current endocrine therapy for ER+ breast cancer comprises three regimen options that can be used in varied sequences for optimal outcome: SERM (e.g., tamoxifen, raloxifene, toremifene), aromatase inhibitors (Als, including anastrozole, exemestane, letrozole), and SERD (fulvestrant) [2], [00195] Tamoxifen is a first-line agent for pre-menopausal patients and for women requiring secondary chemoprevention after a DCIS diagnosis. In postmenopausal women Als are generally preferred to tamoxifen because of more favorable time to progression and less severe side effects [5, 6]. Although these synthetic anti-estrogens are the mainline therapy for treating ER+ breast cancers, these drugs cause unwanted adverse effects in non-targeted tissues, and the cancers become resistant to endocrine therapy. After a prolonged treatment, most patients with advanced metastatic breast cancer eventually develop resistance to tamoxifen or Al treatment while retaining the expression of ERa in the recurrent and/or progressive disease. This clinical information provides a viable therapeutic rationale for using effective ER-targeting antagonists that are not cross-resistant to previous endocrine agents.
[00196] The conventional anti-estrogens, such as SERMs and SERDs, cannot fully yield the full pharmacological efficacy in the treatment of breast cancer. Though the SERDs can downregulate the estrogen receptor protein level and block transcriptional activity, the existing drugs are also prone to resistance. Therefore, alternative drugs and new approaches are needed for delivering the drugs to target cells and degrade specific receptors, so as to increase the efficiency of the drugs and lower the side effects. Proteolysis targeting chimeric (PROTAC) technology has emerged as powerful tool for targeted degradation of endogenous proteins [7]. PROTAC, a bifunctional compound attached by a linker molecule, which contain a target protein binding moiety and E3 ubiquitin ligase binding moiety, can simultaneously bind the target protein and E3 ligase and promote ubiquitination of the target protein and degradation of the same by
proteasome. Many publications provide the usage of PROTO molecules as modulators of targeted proteins via ubiquitination and subsequent degradation by cell proteasome. The present example exploits this powerful tool to specifically degrade estrogen receptor by developing bifunctional compounds consisting ER binding moiety and CRBN E3 ligase binding moiety linked by various chemical linkers for the treatment of ER+ breast cancer.
[00197] SERDs reduce the ERa protein level as well as block ER transcription activity. Another method that exploits/utilizes proteasome has offered researchers a tool to manipulate levels of a specific protein and test its function or develop treatment for diseases. In order to exploit the proteasome’s role as a drug and manipulate protein levels, proteolysis targeting chimeric molecules (PROTACs) have been developed. PROTACs molecules contain a ligand that recognizes the target protein linked via a linker molecule to a ligand that binds to a specific E3 ubiquitin ligase. The present bifunctional compounds (or PROTACs) simultaneously bind ERa and a specific E3 ubiquitin ligase, which promotes ubiquitination of ER and leads to degradation of ER by the proteasome. While small molecules can easily bind enzymes or receptors in tight and well- defined pockets, protein-protein interactions are difficult to target by small molecules. E3 ubiquitin ligases confer substrates specifically for ubiquitination, making it an attractive therapeutic strategy for protein degradation by proteasome.
[00198] The present invention relates to bifunctional compounds that perform as modulators of estrogen receptor (target protein), which are degraded or inhibited as a result of ubiquitination and subsequent degradation of the ubiquitinated ER by the proteasome. The present invention provides the methods for making these compounds and their usage in treating or ameliorating disease conditions/states associated with aggregation or accumulation of estrogen receptor. The invention also relates to pharmaceutical compositions comprising these ER degrading bifunctional compounds, and methods for using the same for treatment of estrogen receptor mediated pathological developments, including cancers.
[00199] The compounds described here can provide effective endocrine therapy for breast cancers, especially those that are associated with overexpression or aggregation of estrogen receptor (estrogen receptor positive or “ER+“ breast cancers), including its mutant form, as the first line adjuvant treatment regimen, or as the second-line therapy for treating or ameliorating patients with disease progression owing to drug resistance after prior endocrine therapy such as selective estrogen receptor modulators (SERMs), aromatase inhibitors (Als), SERDs, or combinations of such endocrine therapies with other anticancer agents. Thus, the present disclosed compounds herein can be used for the treatment of ER+ breast cancer, including the advanced drug-resistant ER+ breast cancer.
[00200] Example 2: General Synthesis
[00201] The chemical entities described herein can be synthesized according to one or more illustrative schemes herein and/or techniques well known in the art. Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from about -10 °C. to about 200 °C. Further, except as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -10 °C. to about 200 °C over a period that can be, for example, about 1 to about 24 hours; reactions left to run overnight in some embodiments can average a period of about 16 hours. Isolation and purification of the chemical entities and intermediates described herein can be implemented, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. See, e.g., Carey et al. Advanced Organic Chemistry, 3rd Ed., 1990 New York: Plenum Press; Mundy et al., Name Reaction and Reagents in Organic Synthesis, 2nd Ed., 2005 Hoboken, N.J.: J. Wiley & Sons. Specific illustrations of suitable separation and isolation procedures are given by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can also be used.
[00202] In all of the methods, it is well understood that protecting groups for sensitive or reactive groups may be employed where necessary, in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis [9]. These groups may be removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
[00203] In some embodiments, disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, or can be readily prepared by those skilled in the art using commonly employed synthetic methodology.
[00204] The discussion below is offered to illustrate certain of the diverse methods available for use in making the disclosed compounds and is not intended to limit the scope of reactions or reaction sequences that can be used in preparing the compounds provided herein. The skilled artisan will understand that standard atom valencies apply to all compounds disclosed herein in genus or named compound for unless otherwise specified.
[00205] Example 3: Preparation of 3-(1,3-dioxo-5-(piperazin-1-vl)-2.3-dihydro-1 H-inden-
Step 1: Preparation of 3-(5-fluoro-1,3-dioxo-2,3-dihydro-1 H-inden-2-yl) piperidine-2, 6-dione (C1c)
The mixture of 5-fluoroisobenzofuran-1 , 3-dione (C1a, 5.00 g, 30.1 mmol), 3-aminopiperidine-2,6- dione (C1b, 4.24 g, 33.0 mmol) and sodium acetate (3.70 g, 45.2 mmol) in glacial acetic acid was stirred at 90 °C (oil bath) overnight. The reaction mixture was carefully poured to ice-water with
stir, followed by being stood at r.t for 3h. The suspension was filtered. The cake was washed with water, dried in the oven, followed by being purified with flash column (SiO2, MeOH in DCM = 0- 7.0 %) to give C1c as an off-white solid (7.45 g, 90.0 % yield). LC-MS (ESI+) [M+H]+ = 277.2. 1H NMR (300 MHz, DMSO-d6) 5 11.20 (s, 1H), 8.00 (dd, J = 8.0, 4.1 Hz, 1H), 7.85 (dd, J = 7.5, 2.0 Hz, 1H), 7.80 (m, 1H), 5.17 (dd, J = 13.0, 5.4 Hz, 1H), 2.90 (m, 1H), 2.60 (m, 2H), 2.10 (m, 1H). Step 2: Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-2,3-dihydro-1H-inden-5- yl)piperazine-1 -carboxylate (C1d)
The mixture of C1c (5.00 g, 18.2 mmol), tert-butyl piperazine-1 -carboxylate (4.06 g, 21 .8 mmol) and DiPEA in NMP was stirred at 110 °C (oil bath) under N2 for 3 h. The reaction mixture was poured to water with stirred, extracted with ethyl acetate (30 ml * 4). The combined organic layers were washed with water (30 ml x 4), sat. NaCI sol. (30 ml x 2), dried with anhydrous sodium sulfate. The crude product was purified with flash column (SiOa, MeOH in DCM = 0-10 %) to give C1d as a yellow solid (7.45 g, 90.0 % yield). LC-MS (ESI+) [M+H]+ = 442.2. 1H NMR (300 MHz, DMSO-d6) 5 8.23 (s, 1H), 7.71 (d, J =8.0 Hz, 1H), 7.28 (d, J =2.5 Hz, 1 H), 7.06 (dd, J = 8.0 Hz, 2.5 Hz 1H), 4.95 (dd, = 12.0 Hz, 5.0 Hz, 1H), 3.60 (mt 4H), 3.40 (m, 4H), 2.90 (b, 1 H), 2.75 (b, 1H), 2.15 (b, 1H), 2.00 (s, 1H), 1 .49 (s, 9H).
Strep 3: Preparation of 3-(1 ,3-dioxo-5-(piperazin-1-yl)-2,3-dihydro-1H-inden-2-yl)piperidine-2,6- dione (C1)
To the solution of C1d (5.0 g, 11.3 mmol) in DCM was added TFA (2.5 ml, 32.7 mmol) dropwise at 0 °C. Upon the addition, the reaction mixture was stirred at r.t. for 1.5 h, followed by being evaporated. The resulting residue was dissolved in toluene (15 ml), then being evaporated. The crude product of C1 trifluoroacetate was obtained as a yellow solid (3.96g, 80 %, Trifluoroacetate). LC-MS (ESI+)[M+H]+ = 342.2.
[00206] Example 4: Preparation of 3-f1-oxo-54DiDeridin-4-vl)isoindolin-2-vl)DiDeridine-
Step 1* Preparation of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2 ,6-dione (C2b)
To the solution of commercially available methyl 4-bromo-2-(bromomethyl)-benzoate in DMF (C2a, 5.00g, 16.3 mmol) in DMF was added 3-aminopiperidine-2,6-dione (C1b, 2.30 g, 17.9 mmol) and potassium carbonate (6.73 g, 48.7 mmol). The resulting mixture was stirred at 70 °C (oil bath) for 16 h. The mixture was cooled to r.t. and poured to water (200 ml) with stir. The suspension was filtered. The cake was washed with water, dried in oven, used in next step without further purification (3.10g, 87.8 % yield). LC-MS (ESI+) [M+H]+ = 323.0 (50 %), 325.0 (50 %). 1H NMR (300 MHz, DMSO-d6) 6 10.99 (s, 1 H), 7.90 (m, 1 H), 7.72 (dd, J = 8.0, 1.5 Hz, 1 H),7.67 (d, J = 8.0 Hz, 1H), 5.10 (dd, J = 13.0, 5.0 Hz, 1H), 4.50 (d, J = 17.5 Hz, 1H), 4.28 (d, J = 17.5 Hz, 1H), 3.00 (m, 1H), 2.60 (m, 1H), 2.30 (m, 1H), 2.01 (m, 1H).
Step 2: Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,6- dihydropyridine-1 (2H)-carboxylate (C2d)
The mixture of C2b (1.50 g, 4.67 mmol), potassium phosphate (1.20g, 5.56 mmol) in DMF (15 ml) was degassed for 2 min prior to the addition of 3,6-dihydro-2H-pyridine-l-fer/-butoxycarbonyl-4- boron acid pinacol ester (C2c, 1.83g, 5.98 mmol) and Pd(dppf)CI2 (0.19 g, 0.23 mmol). The reaction mixture was degassed for 2 min and stirred at 90 °C for 16 h. Then the suspension was filtered. The cake was washed with chloroform and methanol. The combined filtrates were evaporated and redissolved in EA (50 ml), followed by being washed with water (15 ml * 3), sat. NaCI solution (15 ml x 2), dried over sodium sulfate. The crude product was purified with flash column (SiO2, MeOH in CHCI3 = 0-15 %) to give the C2d as a brown semi-solid (0.80 g, 40.6 %). LC-MS (ESI+)[M+H]+ = 426.1.
Step 3: Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidine-1- car boxy late (C2e)
The suspension of C2d (0.50 g, 1.17 mmol) and Pd-C (5%, 0.10 g) in MeOH (20 ml) was degassed for 2 min, then stirred under H2 at 50 degree overnight, followed by being filtered. The cake was washed with MeOH and THF. The combined filtrates were concentrated to give the crude C2e as an off-white solid (0.50 g, -100 %). LC-MS (ESI+) [M+H]+ - 428.2.
Step 4: Preparation of 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2, 6-dione (C2)
To the suspension of C2e (0.50 g, 1.17 mmol) in DCM (10 ml) was added TFA (2 ml) dropwise with stir. The reaction mixture was stirred at r.t. for 1 h, followed by being concentrated. The residue was dissolved in toluene (10 ml). The solvent was removed to obtain the crude C2 trifluoroacetate as yellow solid (0.41 g, 82.0 %, Trifluoroacetate). LC-MS (ESI+)[M+H]+ = 328.2.
[00207] Example 5: Preparation of 3-(1-oxo-5-(piperazin-1-vl)isoindolin-2-vl)piperidine-
Step 1; Preparation of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1- carboxylate (C3a)
The suspension of C2b (0.50 g, 1.55 mmol), tert-butyl piperazine- 1 -carboxylate (0.82 g, 1.86 mmol) and CS2CO3 (1.00 g, 3.09 mmol) in 1 ,4-dioxane (10 ml) was degassed for 2 min, followed by adding RuPhos (0.15 g, 0.31 mmol), RuPhos Pd G2 (0.24 g, 0.31 mmol). The reaction mixture was stirred under N2 at 100 °C for 16 h, followed by being filtered. The cake was washed with
MeOH. The combined filtrates were concentrated and separate by flash column (SiO2, MeOH in CHCl3 = 0-15 %) to give the C3a as brown solid (0.38 g, 57.6 %). LC-MS (ESI+) [M+H]+ = 429.2. Step 2: Preparation of 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2, 6-dione (C3)
To the solution of C3a (0.38 g, 0.89 mmol) in DCM (10 ml) was added TFA (2 ml) dropwise with stir. The reaction mixture was stirred at r.t. for 1 h, followed by being concentrated. The residue was dissolved in toluene (10 ml). The solvent was removed to obtain the crude C3 trifluoroacetate as yellow solid (0.23 g, 80.0 %, Trifluoroacetate). LC-MS (ESI+) [M+H]+ = 329.2.
Slep1: Preparation of 1-(4-substitutedphenyl)-2-((3-substitedphenyl)thio)ethan-1-one (K1)
To the suspension of 3-substituted benzenethiol and KOH (2.0 eq.) in EtOH/H2O (3/1, v/v) was added solution of 4-substituted-2-bromo-1-phenylethan-1-one (1.1 eq) in EtOH dropwise at 0 °C. Upon the addition, the reaction mixture was stirred at r.t. overnight. The organic solvent was removed under pressure, the residue mixture was extracted with EA. The combine organic layers were washed with sat. NaCI solution, dried with sodium sulfate. The crude K1 was obtained by concentrating the desired solution and used for next step without further purification.
Step2: Preparation of substituted 2-phenylbenzo[b]thiophene (K2)
The reaction mixture of KI in PPA (1 g SM in 5 g PPA) was heated at 100 °C for 3 h with vigorous stir under N2. After cooling down, the mixture was poured to ice-water slowly followed by extracted with EA. The combined EA layers were washed with water, sat. NaCI solution, dried over sodium sulfate. The crude K2 was obtained by concentrating the desired solution and used for next step without further purification.
Step 1: Preparation of intermediate K2a
To the suspension of K2 in DCM was added AICIs (2.0 eq.) carefully at 0 °C under N2. After being stirred for 15 min, 4-(chlorocarbonyl)phenyl acetate (1.0 eq) was added at 0 °C. The reaction mixture was stirred under N2 overnight. The mixture was diluted with DCM and washed with water,
sat. NaCI solution, dried over sodium sulfate. The crude K2a was purified with flash column (SiO2, EA in HE = 0-30 %), and recrystallized in EA/HE to give an off-white solid.
Step 2: Preparation of key intermediate K3
To the solution of K2a in MeOH/H2O (4/1, v/v) was added KOH (2.0 eq.) slowly. The reaction mixture was stirred at r.t. for 3 h followed by neutralized with HCI solution (2M). After the organic solvent was removed, the residue was extracted with EA. The combined EA layers were washed with sat. NaCI solution, dried over sodium sulfate. The crude K3 was purified with flash column (SiO2, EA in HE = 0-30 %) to give an off-white to yellow solid.
Step 1: Preparation of intermediate K2b
To a suspension of K2 in THF was added NBS (1.1 eq.) at 0 °C. After warmed up to r.t, the reaction mixture was stirred under N2 for 2.0 h. After the solvent was removed, the residue mixture was dissolved in EA followed by washed with HCI solution (2M), sat. NaCI solution, dried over sodium sulfate. The crude K2b was obtained as a yellow solid and used for next step without further purification.
Step 2: Preparation of intermediate K2c
To a suspension of K2b in DCM was added TFA dropwise at 0 °C. After being stirred for 15 min, H2O2 (1.1 eq.) was added dropwise. The reaction mixture was stirred at 0 °C for 90 min, stirred r.t for other 90 min. The reaction mixture was diluted with water followed by being extracted with DCM. The combined DCM layers were washed with sat. NaCI solution, dried over sodium sulfate. The crude K2c was purified with flash column (SiO2, EA in HE = 0-50 %) as a yellow solid.
Step 3: Preparation of intermediate K2d
The mixture of K2c, 4-(benzyloxy) phenol (1.1 eq.) and CS2CO3 (1 .5 eq.) in DMF was stirred at 80 °C (oil bath) under N2 for 12 h. After being poured to water, the suspension was extracted with CHCb. The combined CHCI3 layers were washed with HCI solution (2M), sat. NaCI solution, dried with sodium sulfate. The crude K2d was obtained by separation with flash column (SIO2, EA in
HE = 0-50 %) and recrystallization in 10 % EA in HE as a yellow needle crystal.
Step 4: Preparation of intermediate K2e
To a solution of K2d in anhydrous THF was added UAIH4 (1.7 eq.) carefully at 0 °C under N2. After being stirred at 0 °C for 30 min, the reaction was stirred at r.t for other 30 min. The solvent was removed. The residue was dissolved with CHCh followed by being washed with HCI solution (2M), sat. NaCI solution, dried with sodium sulfate. The crude K2e was purified with flash column (SiO2, EA in HE = 0-15 %) as an off-white solid.
Step 5: Preparation of key intermediate K4
The mixture of K2d and Pd-C (10 %) in MeOH and EtOH under Hz at 35 °C overnight. The reaction mixture was filtered, and the cake was washed with MeOH. The combined filtrates were concentrated to give the crude K4 as a white solid which was used for next step without further purification.
[00211] Method C: Preparation of key intermediate CORE I and CORE II
Bo;,
Step 1: Preparation of intermediate K3a and K4a
To the solution of K3 or K4 and pyridine (2.0 eq.) in DCM was added solution of Tf2O (1 .5 eq.) dropwise at -10 °C. Upon the addition, the reaction mixture was stirred at r.t. under N2 for 1.5 h followed by extracted DCM. The DCM layers washed with sat. NaCI solution, dried over sodium sulfate. The K3a or K4a were obtained through flash column (SiO2, EA in HE = 0-30 %) as a yellow solid.
Step 2: Preparation of intermediate K3b and K4b
The mixture of K3a or K4a, tert-butyl piperazine- 1 -carboxylate (1 .1 eq.) and Cs2COs (2.0 eq.) in 1 ,4-dioxane was degassed for 2 min prior to the addition of BINAP (0.1 eq.), Pd(OAc)2 (0.05 eq.). The reaction mixture was stirred under N2at 100 °C (oil bath) for 12 h.
The suspension was filtered, the cake was washed with MeOH. The combined filtrates were
separated with flash column (SiOa, EA in HE = 0-40 %) to give the K3b or K4b as yellow solid. Step 3: Preparation of key intermediate CORE I and CORE II
To the solution of K3b or K4b in DCM was added TFA dropwise at 0 °C. Upon the addition, the reaction mixture was stirred at r.t. for 1 h. The mixture was concentrated, the residue was dissolved in toluene (10 ml). The solvent was removed to obtain the crude CORE I or CORE II trifluoroacetate as brown solid.
[00212] Method D: Preparation of key intermediate CORE III and CORE IV
Step 1: Preparation of intermediate K3c and K4c
The mixture of K3 or K4, tert-butyl 4-(bromomethyl)piperidine-1-carboxylateand (2.5 eq.) and CS2CO3 (1.5 eq.) in DMF was stirred at 80 °C (oil bath) for under N2 for 8 h. The reaction mixture was poured to water slowly with stir. The suspension was extracted with EA. The combined EA layers were washed with HCI solution (2M), sat. NaCI solution, dried with sodium sulfate. The mixture was purified with flash column (SiO2, EA in HE = 0-20 %) to give K3c or K4c as an off- white solid.
Step 2: Preparation of key intermediate CORE III and CORE IV
To the solution of K3c or K4c in DCM was added TFA dropwise at 0 °C Upon the addition, the reaction mixture was stirred at r.t. for 1h. The mixture was concentrated, the residue was dissolved in toluene (10 ml). The solvent was removed to obtain the crude CORE III or CORE IV trifluoroacetate as brown solid.
Step 1: Preparation of intermediate K3d and K4d
The mixture of K3 or K4 and CS2CO3 in 1 ,2-dichloroethane was refluxed under N2 for 14 h. The mixture was separated with flash column (SiO2, CHCI3) to give K3d or K4d as colorless semi- solid.
Step 2: Preparation of intermediate K3e and K4e
The mixture of K3d or K4d, tert-butyl piperazine- 1 -carboxylate (1 .1 eq.) and CS2CO3 (2.0 eq.) in DMF was stirred at 80 degree (oil bath) under N2 for 16 h. The reaction mixture was poured to water, followed by extracting with CHCI3. The combined organic layers were washed with Sat. NaCI solution, dried over sodium sulfate. The mixture was separated with flash column (SiO2, EA in HE = 0- 95 %) to give the K3e or K4e as an off-white solid.
Step 3: Preparation of key intermediate CORE V and CORE VI
To the solution of K3e or K4e in DCM was added TFA dropwise at 0 °C. Upon the addition, the reaction mixture was stirred at r.t. for 1h. The mixture was concentrated, the residue was dissolved in toluene (10 ml). The solvent was removed to obtain the crude CORE V or CORE VI trifluoroacetate as brown solid.
Step 1: Preparation of intermediate K5
The mixture of key intermediate CORE, halogenated hydrocarbons (2.0 eq.) and DIPEA (2.5 eq.) in MeCN was stirred at r.t. under N2 overnight. The mixture was separated with flash column (S1O2, MeOH in ChCb = 0-20 %) to give the K5 as colorless to yellow semi-solid.
Step 2: Preparation of key intermediate K6
The mixture of K5, intermediate C (1*1 eq.), KI (2.0 eq.) and DIPEA (2.0 eq.) in NMP was stirred at 100 °C under N2 overnight. The mixture was separated with pre-LC (MeCN in Water = 10-100 %) to give the K6 as a yellow solid.
[00215] Example 6: Preparation of Compound 5
[00216] As an illustrative example of a compound of Formula (I), the following compound, denoted Compound 5, was synthesized:
Step 1: Preparation of 2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene (5a)
This compound was prepared by the procedure identical to the preparation of intermediate K2 with SM of 3-methoxy benzenethiol (5.00 g, 35.7 mmol) and 2-bromo-1-(4-chlorophenyl)ethan-1- one (9.00 g, 39.0 mmol) in the first step (5a: 6.70 g, 68.8 %, two steps). LC-MS (ESI+) [M+HJ* = 259.2.
Step 2: Preparation of 3-bromo-2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene (5b)
This compound was prepared by the procedure identical to the preparation of intermediate K2b in Method B with 5a (5.00 g, 18.2 mmol) as SM (5b: 6.00 g, 93.4 %). LC-MS (ESI+) [M+H]+ = 337.0. 1H NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 6.0 Hz, 1 H), 7.72 (dd, J = 6.0, 3.0 Hz, 2H), 7.32 (d, J = 3.0 Hz, 1 H), 7.12 (s, J = 6.0, 1 H), 7.05 (dd, J = 6.0, 3.0 Hz, 2H), 3.94 (s, 3H).
Step 3: Preparation of 3-bromo-2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene 1 -oxide (5c) This compound was prepared by the procedure identical to the preparation of intermediate K2c in Method B with 5b (3.00 g, 8.49 mmol) as SM (5c: 3.00 g, 95.5 %). LC-MS (ESI+) [M+H]+ = 353.0. 1H NMR (300 MHz, CDCb) 5 = 7.82 (d, J = 9.0 Hz, 2H), 7.59 (d, J = 9.0 Hz, 1 H), 7.53 (s, 1 H), 7.18 (s, J = 9.0, 1 H), 7.08 (d, J = 9.0 Hz, 2H), 3.97 (s, 3H).
Step 4: Preparation of 3-(4-(benzyloxy)phenoxy)-2-(4-chlorophenyl)-6- methoxybenzo[b]thiophene 1 -oxide (5d)
This compound was prepared by the procedure identical to the preparation of intermediate K2d in Method B with 5c (1.76 g, 4.76 mmol) as SM (5d: 1.92 g, 82.4 %). LC-MS (ESI+) [M+HJ+ = 473.1. 1H NMR (300 MHz, CDCI3) 5 = 7.79 (d, J = 9.0 Hz, 2H), 7.54 (d, J = 3.0 Hz, 1 H), 7.43-45 (m, 4H), 7.02-7.07 (m, 4H), 6.91-6.97 (m, 5H), 5.05 (s, 2H), 3.92 (s, 3H).
Step 5: Preparation of 3-(4-(benzyloxy)phenoxy)-2-(4-chlorophenyl)-6- methoxybenzo[b]thiophene (5e)
This compound was prepared by the procedure identical to the preparation of intermediate K2e in Method B with 5d (0.52 g, 1.06 mmol) as SM (5e: 0.42 g, 83.8 %). LC-MS (ESI+) [M+H]+ = 457.1 . 1H NMR (300 MHz, CDCI3) 5 = 7.73 (d, J = 9.0 Hz, 2H), 7.36-7.45 (m, 6H), 7.32 (d, J = 9.0 Hz, 2H), 6.90-6.94 (m, 6H), 5.03 (s, 2H), 3.92 (s, 3H)
Step 6: Preparation of 4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3-yl)oxy)phenol (5f) This compound was prepared by the procedure identical to the preparation of key intermediate K4 in Method B with 5e (1.36 g, 2.89 mmol) as SM (5f: 1.00 g, 90.4 %). LC-MS (ESI+) [M+H]+ = 367.2. 1H NMR (300 MHz, CDCI3) 6 =7.69 (d, J = 9.0 Hz, 2H), 7.27 (d , J = 9.0 Hz, 2H), 6.85-6.92 (m, 6H), 6.73 (d, J = 9.0 Hz, 2H), 3.88 (s, 3H).
Step 7: Preparation of 4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3-yl)oxy)phenyl trifluoromethanesulfonate (5g)
This compound was prepared by the procedure identical to the preparation of intermediate K4a in Method C with 5f (1.50 g, 3.92 mmol) as SM (5g: 1.80 g, 89.2 %). LC-MS (ESI+) [M+H]+ = 501.1. 1H NMR (300 MHz, CDCI3) 5 = 8.00 (s, 1 H), 7.68 (d, J = 7.0 Hz, 2H), 7.50 (d, J = 7.0 Hz, 2H), 7.40 (s, 1 H), 7.25 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.93 (s, 1 H), 3.88 (s, 3H).
Step 8: Preparation of tert-butyl 4-(4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazine-1-carboxylate (5h)
This compound was prepared by the procedure identical to the preparation of intermediate K4b in Method C with 5g (0.18 g, 0.35 mmol) as SM (5h: 0.16 g, 83.1 %). LC-MS (ESI+) [M+H]+ = 535.2. 1H NMR (300 MHz, CDCI3) 5 = 8.00 (S, 1H), 7.40 (S, 1H), 7.25 (d, J = 9.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.93 (s, 1 H), 6.68 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 3.88 (s, 3H), 3.30 (b, 8H), 1.35 (s,9H).
Step 9: Preparation of 1-(4-((2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazine (5i)
This compound was prepared by the procedure identical to the preparation of intermediate CORE II in Method C with 5h (0.16 g, 0.29 mmol) as SM (5i trifluoroacetate: 0.12 g, 75.9 %). LC-MS (ESI+)[M+H]+ = 435.2. 1H NMR (300 MHz, CDCI3) 5 = 8.03 (s, 1 H), 7.38 (s, 1 H), 7.23 (d, J = 9.0 Hz, 2H), 7.08 (d, J = 9.0 Hz, 2H), 6.90 (s, 1H), 6.65 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 4H), 2.98 (s, 4H), 0.98 (b,1 H).
Step 10: Preparation of 1-(3-chloropropyl)-4-(4-((2-(4-fluorophenyl)-6-methoxybenzo[b]thiophen- 3-yl)oxy)phenyl)piperazine (5j)
This compound was prepared by the procedure identical to the preparation of intermediate K5 in Method F with 5i (0.07 g, 0.16 mmol) as SM (5j: 0.07 g, 81 .1 %). LC-MS (ESI+) [M+ =H 5]+1 1.2. 1H NMR (300 MHz, CDCl3) 5 = 8.03 (s, 1 H), 7.40 (s, 1 H), 7.29 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 9.0 Hz, 2H), 6.93 (s, 1H), 6.60 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 2H), 3.48 (b, 8H), 2.90 (m, 4H).
Step 11: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-
methoxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3- dione (5k)
This compound was prepared by the procedure identical to the preparation of key intermediate K6 in Method F with 5i (0.05 g, 0.09 mmol) as SM (5k: 0.05 g, 65.7 %). LC-MS (ESI+) [M+Hf = 817.3. 1H NMR (300 MHz, CDCI3) 5 = 11 .0 (b, 1 H), 8.03 (s, 1 H), 7.60 (m, 3H), 7.40 (s, 1 H), 7.29 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 9.0 Hz, 2H), 6.93 (s, 1 H), 6.60 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 4.30 (m, 1H), 3.78 (s, 3H), 3.60 (s, 2H), 3.48 (m, 16H), 2.90 (m, 4H), 2.20 (m, 2H), 2.09 (m, 2H).
Step 12: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6- hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3- dione (5m)
To the suspension of 5k (0.05 g, 0.06 mmol) in DCM was added solution of BBra (1 M, 0.36 ml) dropwise under N2 at -15 °C. Upon the addition, the reaction mixture was stirred at 0 °C for 1 h, at r.t. for 1h. The mixture was quenched by adding 0.5 ml water at 0 °C, stirred for 30 min. The mixture was separated with pre-LC (MeCN in Water = 10-100 %) to give the 5m as yellow solid (0.02 g, 40.0 %). LC-MS (ESI+) [M+H =]+ 803.3. 1H NMR (300 MHz, CDCI3) 5 = 10.98 (b, 1 H),10.30 (b, 1H), 8.03 (s, 1H), 7.90 (s, 1H), 7.76 (d, J = 6.0 Hz, 1 H), 7.52 (d, J = 6.0 Hz, 1H), 7.40 (s, 1 H), 7.29 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 9.0 Hz, 2H), 6.93 (s, 1 H), 6.60 (d, J= 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 4.30 (m, 1H), 3.60 (s, 2H), 3.48 (m, 16H), 2.90 (m, 4H), 2.20 (m, 2H), 2.09 (m, 2H). Step 13: Preparation of 3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-diOxoiSOindolin-5- yl)piperazin-1-yl)propyl)piperazin-1-yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl trifluoromethanesulfonate (5n)
This compound was prepared by the procedure identical to the preparation of key intermediate K4a in Method C with 5m (0.05 g, 0.06 mmol) as SM (5n: 0.05 g, 86.5 %). LC-MS (ESI+) [M+H? = 935.2. 1H NMR (300 MHz, CDCI3) 5 = 10.98 (b, 1 H), 8.03 (s, 1H), 7.98 (s, 1 H), 7,72 (d, J = 6.0 Hz, 1 H), 7.38 (d, J = 6.0 Hz, 1 H), 7.35 (s, 1H), 7.29 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 9.0 Hz, 2H), 6.93 (s, 1 H), 6.60 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 4.30 (m, 1 H), 3.60 (s, 2H), 3.48 (m, 16H), 2.90 (m, 4H), 2.20 (m, 2H), 2.09 (m, 2H).
Step 1: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1- yl)propyl)piperazin-1-yl)isoindoline-1, 3-dione (5o)
The suspension of 5n (0.05 g, 0.05 mmol), B2Pin2 (0.025 g, 0.10 mmol), KOAc (0.01 g, 0.10 mmol) in 1 ,4-dioxane (5 ml) was degassed prior to the addition of Pd(OAc)z (2.2 mg, 0.01 mmol). The reaction mixture was stirred at 100 °C under N2 for 12 h. The suspension was filtered, and the cake was washed with MeOH. The combined filtrates were purified with pre-LC to give the designed 5o as off-white solid (0.03 g, 63.8 %). LC-MS (ESI+) [M+H]+ = 913.4.
Step 14: Preparation of (3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-
yl)piperazin-1-yl)propyl)piperazin-1-yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid (5)
The suspension of 5o (0.03 g, 0.03 mmol) in 1M MCI solution was stirred at r.t. overnight. The compound 5 was obtained by purifying with pre-LC as yellow solid (0.015g, 52.2 %). LC-MS (ESI+) [M+H]* = 831.3.
[00217] Example 7: Preparation of Compound 10
[00218] As an illustrative example of a compound of Formula (I), the following compound, denoted Compound 10, was synthesized:
Step 1: Preparation of 4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl acetate (10b)
This compound was prepared by the procedure identical to the preparation of intermediate K2a in Method A with 10a (5.00 g, 19.4 mmol) as SM (10b: 6.50 g, 80.0 %). Compound 10a was prepared by the synthesis route of K2 from 3-methoxybenzenethiol and 2-bromo-1-(4- fluorophenyl)ethan-1-one. LC-MS (ESI+) [M+H] =+ 421.1.
Step 2: Preparation of (2-(4-fluorophenyl)-6-methoxybenzo[b]thiophen-3-yl)(4- hydroxyphenyl)methanone (10c)
This compound was prepared by the procedure identical to the preparation of key intermediate K3 in Method A with 10b (3.00 g, 7.14 mmol) as SM (10c: 2.57 g, 95.0 %). LC-MS (ESI+) [M+H]+ = 379.1.
Step 3: Preparation of 4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl trifluoromethanesulfonate (10d)
This compound was prepared by the procedure identical to the preparation of intermediate K3a in Method C with 10c (2.00 g, 5.29 mmol) as SM (10d: 2.64 g, 98.0 %). LC-MS (ESI+) [M+H =]+ 511.0.
Step 4: Preparation of tert-butyl 4-(4-(2-(4-fluorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenyl)piperazine-1-carboxylate (10e)
This compound was prepared by the procedure identical to the preparation of intermediate K3b in Method C with 10d (2.00 g, 3.92 mmol) as SM (10e: 1.46 g, 68.0 %). LC-MS (ESI+) [M+H]+ =
547.2.
Step 5: Preparation of (2-(4-fluorophenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(piperazln-1- yl)phenyl)methanone (1 Of)
This compound was prepared by the procedure identical to the preparation of intermediate CORE I in Method C with 10e (1 .00 g, 1.83 mmol) as SM (1 Of trifluoroacetate: 0.83 g, 83.1 %). LC-MS (ESI+) [M+H]+ = 447.2.
Step 6; Preparation of (4-(4-(3-chloropropyl)piperazin-1-yl)phenyl)(2-(4-fluorophenyl)-6- methoxybenzo[b]thiophen-3-yl)methanone (10g)
This compound was prepared by the procedure identical to the preparation of intermediate K5 in Method F with 10f (0.50 g, 1.12 mmol) as SM (10g; 0.52 g, 89.0 %). LC-MS (ESI+) [M+HJ* =
523.2.
Step 77:: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6- methoxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (10h)
This compound was prepared by the procedure identical to the preparation of intermediate K6 in Method F with 10g (0.50 g, 1.10 mmol) as SM (10h: 0.49 g, 53.7 %). LC-MS (ESI+) [M+H]+ =
829.3.
Step 8: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1, 3-dione (10)
This compound was prepared by the procedure identical to the preparation of intermediate 1 m with 10h (0.40 g, 0.48 mmol) as SM (10: 0.17 g, 44.0 %). LC-MS (ESI+) [M+H]+ = 815.3.
[00219] Example 8: Preparation of Compound 67
[00220] As an illustrative example of a compound of Formula (I), the following compound, denoted Compound 67, was synthesized:
Step 1: Preparation of 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene (67b)
This compound was prepared by the procedure identical to the preparation of intermediate K2b in Method B with commercially available 67a (5.00 g, 18.5 mmol) as SM (67b: 5.94 g, 92.0 %). LC-MS (ESI+) [M+H]+ = 349.0.
Step 2: Preparation of 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene 1 -oxide (67c) This compound was prepared by the procedure identical to the preparation of intermediate K2c
in Method B with 67b (5.00 g, 14.4 mmol) as SM (67c: 4.70 g, 90.0 %). LC-MS (ESI+) [M+HJ* = 365.0.
Step 3: Preparation of 3-(4-(benzyloxy)phenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[b] thiophene-1 -oxide (67d)
This compound was prepared by the procedure identical to the preparation of intermediate K2d in Method B with 67c (4.00 g, 11.0 mmol) as SM (67d: 4.48 g, 84.0 %). LC-MS (ESI+) [M+H =]+
485.1.
Step 4: Preparation of 3-(4-(benzyloxy)phenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[b] thiophene (67e)
This compound was prepared by the procedure identical to the preparation of intermediate K2e in Method B with 67d (4.00 g, 8.26 mmol) as SM (67e: 3.63 g, 94.0 %). LC-MS (ESI+) [M+H =]+
469.1.
Step 5: Preparation of 4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)oxy)phenol (67f)
This compound was prepared by the procedure identical to the preparation of intermediate K4 in Method B with 67e (3.00 g, 6.41 mmol) as SM (67f: 2.37 g, 98.0 %). LC-MS (ESI+) [M+H]+ =
379.1.
Step 6: Preparation of tert-butyl 4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidine-1 -carboxylate (67g)
This compound was prepared by the procedure identical to the preparation of intermediate K4c in Method D with 67f (2.00 g, 5.29 mmol) as SM (67g: 2.40 g, 79.0 %). LC-MS (ESI+) [M+H =]+
576.2.
Step 7: Preparation ooff 4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidine (67h)
This compound was prepared by the procedure identical to the preparation of key intermediate CORE IV in Method D with 67g (2.00 g, 3.48 mmol) as SM (67h trifluoroacetate: 1.63 g, .0 %). LC-MS (ESI+) [M+H]+ = 476.2.
Step 8: Preparation of 1-(3-chloropropyl)-4-((4-((6-methoxy-2-(4- methoxyphenyl)benzo[b]thiophen-3-yl)oxy)phenoxy)methyl)pi peridine (67i)
This compound was prepared by the procedure identical to the preparation of intermediate K5 in Method F with 67h (1.00 g, 2.11 mmol) as SM (67i: 0.88 g, 76.0 %). LC-MS (ESI+) [M+H]+ =
552.2.
Step 9; Preparation of 3-(5-(4-(3-(4-((4-((6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (67g)
This compound was prepared by the procedure identical to the preparation of intermediate K6 in Method F with 67i (0.50 g, 0.91 mmol) as SM (67g: 0.35 g, 46.0 %). LC-MS (ESI+) [M+H]+ =
844.4.
Step 10; Preparation of 3-(5-(4-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (67)
This compound was prepared by the procedure identical to the preparation of intermediate 1 m with 67g (0.30 g, 0.35 mmol) as SM (67: 0.12 g, 42.0 %). LC-MS (ESI+) [M+H]+ = 816.3.
[00221] Example 9: Preparation of Compound 106
[00222] As an illustrative example of a compound of Formula (I), the following compound, denoted Compound 106 was synthesized:
Step 1: Preparation of 4-(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene-3-carbonyl)phenyl acetate (106b)
This compound was prepared by the procedure identical to the preparation of intermediate K2a in Method A with commercially available 67a (5.00 g, 18.5 mmol) as SM (106b: 7.11 g, 89.0 %). LC-MS (ESI+) [M+HJ* = 433.1.
Step 2: Preparation of (2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophen-3-yl)(4- hydroxyphenyl)methanone (106c)
This compound was prepared by the procedure identical to the preparation of key intermediate K3 in Method A with 106b (5.00 g, 11.6 mmol) as SM (106c: 4.10 g, 91.0 %). LC-MS (ESI+) [M+HJ* = 391.1.
Step 3: Preparation of 4-(2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl trifluoromethanesulfonate (106d)
This compound was prepared by the procedure identical to the preparation of intermediate K3a in Method C with 106c (4.00 g, 10.3 mmol) as SM (106d: 5.10 g, 95.0 %). LC-MS (ESI+) [M+HJ* = 523.0.
Step 4: Preparation of tert-butyl 4-(4-(2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenyl)piperazine-1 -carboxylate (10e)
This compound was prepared by the procedure identical to the preparation of intermediate K3b in Method C with 106d (5.00 g, 9.58 mmol) as SM (106e: 3.58 g, 66.8 %). LC-MS (ESI+) [M+HJ* = 559.2.
Step 5; Preparation of (2-(4-methoxyphenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(piperazin-1- yl)phenyl)methanone (106f)
This compound was prepared by the procedure identical to the preparation of intermediate CORE I in Method C with 106e (3.00 g, 5.38 mmol) as SM (106f trifluoroacetate: 2.56 g, 85.3 %). LC- MS (ESI+) [M+HJ* = 459.2.
Step 6: Preparation of (4-(4-(3-chloropropyl)piperazin-1-yl)phenyl)(2-(4-methoxyphenyl)-6- methoxybenzo[b]thiophen-3-yl)methanone (106g)
This compound was prepared by the procedure identical to the preparation of intermediate K5 in Method F with 106f (0.50 g, 1.10 mmol) as SM (106g: 0.44 g, 75.1 %). LC-MS (ESI+) [M+H =]+
535.2.
Step 77:: Preparation ooff 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-methoxyphenyl)-6- methoxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (106h)
This compound was prepared by the procedure identical to the preparation of intermediate K6 in Method F with 106g (0.30 g, 0.56 mmol) as SM (106h: 0.19 g, 42.8 %). LC-MS (ESI+) [M+HJ* =
826.3.
Step 8: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-hydroxyphenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (106)
This compound was prepared by the procedure identical to the preparation of intermediate 1 m with 106h (0.10 g, 0.48 mmol) as SM (106: 0.06 g, 64.0 %). LC-MS (ESI+) [M+H]+ = 798.3.
[00223] Example 10: Preparation of Compound 119
[00224] As an illustrative example of a compound of Formula (I), the following compound, denoted Compound 119 was synthesized:
Step 1: Preparation of 4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3-carbonyl)phenyl acetate (119b)
This compound was prepared by the procedure identical to the preparation of intermediate K2a in Method A with commercially available 119a (5.00 g, 18.2 mmol) as SM (106b: 6.28 g, 79.0 %). LC-MS (ESI+) [M+H]+ = 437.1.
Step 2: Preparation of (2-(4-chlorophenyl)-6-methoxybenzo[b}thiophen-3-yl)(4- hydroxyphenyl)methanone (106c)
This compound was prepared by the procedure identical to the preparation of key intermediate K3 in Method A with 119b (5.00 g, 11.4 mmol) as SM (119c: 4.52 g, 75.0 %). LC-MS (ESI+)
[M+H]+ = 395.0.
Step 3; Preparation of (4-(2-chloroethoxy)phenyl)(2-(4-chlorophenyl)-6- methoxybenzo[b]thiophen-3-yl)methanone (119d)
This compound was prepared by the procedure identical to the preparation of intermediate K3d in Method E with 119c (4.00 g, 7.59 mmol) as SM (119d: 1 .91 g, 55.0 %). LC-MS (ESI+) [M+H]+ = 457.0.
Step 4: Preparation of tert-butyl 4-(2-(4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazine-1 -carboxylate (119e)
This compound was prepared by the procedure identical to the preparation of intermediate K3e in Method E with 119d (1.50 g, 3.28 mmol) as SM (119e: 1 .99 g, 85.0 %). LC-MS (ESI+) [M+H]+ = 607.2.
Step 5: Preparation of (2-(4-chlorophenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(2-(piperazin-1- yl)ethoxy)phenyl)methanone (119f)
This compound was prepared by the procedure identical to the preparation of intermediate CORE V in Method E with 119e (1.50 g, 2.47 mmol) as SM (119f trifluoroacetate: 1.49 g, 95.0 %). LC- MS (ESI+) [M+H]+ = 507.1.
Step 6: Preparation of (2-(4-chloraphenyl)-6-methoxybenzo[b]thiophen-3-yl)(4-(2-(4-(3- chloropropyl)piperazin-1-yl)ethoxy)phenyl)methanone (119g)
This compound was prepared by the procedure identical to the preparation of intermediate K5 in Method F with 119f (1.00 g, 1.97 mmol) as SM (119g: 0.96 g, 83.1 %). LC-MS (ESI+) [M+H]+ =
583.2.
Step 7; Preparation of 3-(5-(1-(3-(4-(2-(4-(2-(4-chlorophenyl)-6-methoxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione (119h)
This compound was prepared by the procedure identical to the preparation of intermediate K6 in Method F with 119g (0.35 g, 0.60 mmol) as SM (119h: 0.27 g, 51.8 %). LC-MS (ESI+) [M+H]+ =
874.3.
Step 8: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-hydroxyphenyl)-6- hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline- 1 ,3-dione (119i)
This compound was prepared by the procedure identical to the preparation of intermediate 5m with 119h (0.20 g, 0.23 mmol) as SM (106: 0.14 g, 73.0 %). LC-MS (ESI+) [M+H]+ = 860.3
Step 7: Preparation of 3-(5-(1-(3-(4-(2-(4-(6-hydroxy-2-(4-(4,4,5,5-tetramethyi-1 ,3,2- dioxaborolan-2-yl)phenyl)benzo[b]thiophene-3-carbonyl)phenoxy)ethyl)piperazin-1- yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2l6-dione (119j)
This compound was prepared by the procedure identical to the preparation of 5o with 119i (0.14 g, 0.16 mmol) as SM (119j: 0.15 g, 76.8 %). LC-MS (ESI+) [M+H]+ = 952.4.
Step 8: Preparation of (4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5- yl)piperidin-1-yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2- yl)phenyl)boronic acid (119)
This compound was prepared by the procedure identical to the preparation of 5 with 119j (0.15 g, 0.16 mmol) as SM (119. 0.11 g, 81.6 %). LC-MS (ESI+) [M+H =]+ 870.4.
[00225] Example 11: Synthesis of compound 161 & compound 167
[00226] As illustrative examples of compounds of formula (I), the following compounds, denoted Compounds 161 were synthesized:
Scheme 1.
Step 1. (5R,6S)-6-phenyl-5-(4-(piperazin-1-yl)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
To a stirred suspension of tert- butyl 4-(4-((1 R,2S)-6-hydroxy-2-pheny1- 1 ,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazine-1-carboxylate (0.485 grams (g), 1 millimoles (mmol)) in 10 mL of methanol (MeOH) was added 2M hydrochloric acid (HCI) in methanol (MeOH) at room temperature. After stirring for 5 h, the solvent was removed in vacuo. 0.40 g of (5R,6S)-6-phenyl- 5-(4-(piperazin-1-yl)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol was obtained as white solid and used in the next step without further purification. LCMS [M+H] 385.
Step 2. 4-nitrophenyl 4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carboxylate
HO
To a stirred suspension of (5R, 6S)-6-phenyl-5-(4-(piperazin-1-yl)phenyl)-5, 6,7,8- tetrahydronaphthalen-2-ol (0.385 grams (g), 1 millimoles (mmol)) and triethylamine (0.40 g, 4 mmol) in 10 mL of dichloromethane (DCM) was added 4-nitrophenyl carbonochloridate (0.20 g, 1.0 mmol) in one portion at room temperature (rt). After stirring for 1 hour (h), the suspension became a clear yellow solution. The solvent was removed in vacuo. The residue was subjected to silica gel column chromatography to provide 0.49 g of 4-nitrophenyl 4-(4-((1 R,2S)-6-hydroxy-2- phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine-1 -carboxylate as yellow solid. LCMS [M+H] 550. 1H NMR (CDCI3, 300 MHz): 5 1H NMR: 5 1.79 (1H, d), 1.96 (1H, d), 2.60-2.89 (2H, m), 2.99-3.20 (5H, m), 3.53-3.69 (4H, m), 4.30 (1H, d), 6.60-6.74 (4H, m), 7.04 (1H, d), 7.12-7.39
(7H, m), 7.56 (2H, d), 8.16 (2H, d).
Step 3. 3-(5-(4-(4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazine-1-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione (compound 161)
A mixture of 4-nitrophenyl 4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carboxylate (110 milligrams (mg), 0.2 mmol), di isopropylethylamine (DIEA) (130 mg, 1 mmol) and 3-(1-oxo-5-(piperazin-1-yl)1soindolin-2-yl)piperidine-2, 6-dione (66 mg, 0.2 mmol) in 3 milliliters (ml) of n-methyl pyrrole (NMP) was stirred in a microwave (MW) reactor and heated to 120 °C for 0.5 h. After cooling to room temperature (rt), the mixture was subjected onto silica gel column chromatography to provide crude product. The crude product was further purified by prep-high pressure liquid chromatography (HPLC) by using C18 column eluted with 0.5% formic acid (FA) in water/MeCN. After lyophilization, 66 mg of 3-(5-(4-(4-(4-((1R,2S)-6-hydroxy- 2-phenyl-1 ,2,3, 4-tetrahydronaphthalen-1-yl)phenyl)piperazine-1 -carbonyl )pi perazin-1 -yl)-1- oxoisoindolin-2-yl)piperidine-2, 6-dione (compound 161) was obtained as white solid. LCMS [M+H] 739. 1H NMR (DMSO-d6, 300 MHz): 61.71-2.11 (4H, m), 2.23-2.41 (2H, m), 2.60-2.89 (2H, m), 2.98-3.31 (9H, m), 3.50-3.67 (8H, m), 4.26 (1H, d), 4.46-4.64 (3H, m), 6.60-6.74 (4H, m), 6.92- 7.11 (3H, m), 7.12-7.39 (7H, m), 7.79 (1 H, d), 11.08 (1H, s).
Following the above process, 3-(5-(4-((1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1, 2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1- oxoisoindolin-2-yl)piperidine-2, 6-dione (compound 167) LCMS [M+H] 836. 1H NMR (DMSO-d6, 300 MHz): 3 1.55-2.11 (12H, m), 2.23-2.48 (4H, m), 2.48-2.89 (10H, m), 2.94-3.31 (10H, m), 3.51- 3.75 (3H, m), 4.30 (1H, d), 4.46-4.64 (3H, m), 6.60-6.74 (4H, m), 6.92-7.11 (3H, m), 7.12-7.39 (7H, m), 7.79 (1H, d), 11.07 (1H, s) was synthesized as white solid by using corresponding amines.
[00227] Example 12: Synthesis of compound 170 & compound 173
[00228] As illustrative examples of compounds of formula (I), the following compounds, denoted Compounds 170 were synthesized:
Scheme 2.
Step 1. tert-butyl 4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carboxylate
To a stirred suspension of (5R,6S)-6-phenyl-5-(4-(piperazin-1-yl)phenyl)-5, 6,7,8- tetrahydronaphthalen-2-ol (0.385 g, 1 mmol) and triethylamine (0.40 g, 4 mmol) in 10 ml of DCM was added tert-butyl 4-formylpiperidine-1-carboxylate (0.25 g, 1.2 mmol) and sodium triacetoxyborohydride (0.42 g, 2 mmol) portionwise at rt. After stirring for 1 h, the solvent was removed in vacuo. The residue was subjected to silica gel column chromatography to provide
0.50 g of tert-butyl 4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carboxylate as white solid. LCMS [M+H] 582.
Step 2. (5R,6S)-6-phenyl-5-(4-(4-(piperidin-4-ylmethyl)piperazin-1 -yl)phenyl)-5, 6,7,8- tetrahydronaphthalen-2-ol
To a stirred suspension of tert-butyl 4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (0.29 grams (g), 0.5 millimoles (mmol)) in 5 mL of methanol (MeOH) was added 2M hydrochloric acid (MCI) in methanol (MeOH) at room temperature. After stirring for 16 h, the solvent was removed in vacuo. 0.30 g of (5R,6S)-6-phenyl-5-(4-(4-(piperidin-4-ylmethyl)piperazin-1-yl)phenyl)-5, 6,7,8- tetrahydronaphthalen-2-ol was obtained as white solid and used in the next step without further purification. LCMS [M+H] 482.
Step 3. 3-(5-(4-(4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1 - yl)phenyl)piperazin-1 -y l)methyl) piperidi ne-1 -carbonyl)piperazi n-1 -y I ) -1 -oxoisoindol in-2- yl)piperidine-2, 6-dione (compound 170)
A mixture of (5R,6S)-6-phenyl-5-(4-(4-(piperidin-4-ylmethyl)piperazin-1-yl)phenyl)-5, 6,7,8- tetrahydronaphthalen-2-ol (96 milligrams (mg), 0.2 mmol), diisopropylethylamine (DIEA) (130 mg, 1 mmol) and 4-nitrophenyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1- carboxylate (100 mg, 0.2 mmol) in 3 milliliters (mL) of n-methyl pyrrole (NMP) was stirred in a
microwave (MW) reactor and heated to 120 oC for 0.5 h. After cooling to room temperature (rt), the mixture was subjected onto silica gel column chromatography to provide crude product The crude product was further purified by prep-high pressure liquid chromatography (HPLC) by using C18 column eluted with 0.5% formic acid (FA) in water/MeCN. After lyophilization, 35 mg of 3-(5- (4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazln-1- yl)methyl )pi perid i ne- 1 -carbonyl)piperazi n- 1 -yl )- 1 -oxoisoindolin-2-yl )pi peridine-2, 6-dione (compound 170) was obtained as white solid. LCMS [M+H] 836. 1 H NMR (DMSO-d6, 300 MHz): 6 1H NMR: 6 1.50-2.11 (9H, m), 2.23-2.89 (10H, m), 3.00-3.41 (13H, m), 3.51-3.67 (4H, m), 4.30 (1H, d), 4.46-4.64 (3H, m), 6.60-6.74 (4H, m), 6.92-7.11 (3H, m), 7.12-7.39 (7H, m), 7.79 (1H, d), 11.08 (1H, s).
Following the above process, 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-N-(2-(4-(4- ((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1- yl)ethyl)piperazine-1-carboxamide (compound 173) LCMS [M+H] 782. 1 H NMR (DMSO-d6, 300 MHz): 6 1.71-2.11 (4H, m), 2.23-2.41 (2H, m), 2.50-2.89 (8H, m), 3.00-3.32 (9H, m), 3.35-3.46 (2H, m), 3.51-3.67 (4H, m), 4.30 <1 H, d), 4.46-4.64 (3H, m), 6.60-6.74 (4H, m), 6.92-7.11 (3H, m), 7.12-7.39 (7H, m), 7.79 (1H, d), 11.07 (1H, s) was synthesized as white solid by using corresponding starting materials.
[00229] Example 13: Synthesis of compound 185
[00230] As illustrative examples of compounds of formula (I), the following compounds, denoted Compounds 185 were synthesized;
compound 25
Scheme 3.
Step 11.. 1-(4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1 -yl) methyl) pi perid in-1-yl)pheny l)dihydropy rim idine-2, 4(1 H,3H)-dione
A mixture of (5R,6S)-6-phenyl-5-(4-(4-(piperidin-4-ylmethyl)piperazin-1-yl)phenyl)-5, 6,7,8-
tetrahydronaphthalen-2-ol (0.385 g, 1 mmol), 1-(4-bromophenyl)dihydropyrimidine-2,4(1 H,3H)- dione (0.54 g, 2 mmol), Ruphos-G3 ((2'-Amino-2-biphenylyl)(methanesulfonato-KO)palladium - dicyclohexyl(2’,6'-diisopropoxy-2-biphenylyl)phosphine (1 :1 )) (42 mg, 0.05 mmol), Ruphos (23 mg, 0.05 mmol) and CS2CO3 (3.25 g, 10 mmol) in 5 mL of 1 ,4-dioxane was stirred at reflux under Ar for 12 h. While cooled to room temperature, the solids were filtered through celite. The filtrate was evaporated in vacuo. The residue was subjected onto silica gel column chromatography to provide crude product. The crude product was further purified by prep-high pressure liquid chromatography (HPLC) by using C18 column eluted with 0.5% formic acid (FA) in water/MeCN. After lyophilization, 22 mg of 1-(4-(4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)dihydropyrimidine- 2,4(1 H,3H)-dione (compound 185) was obtained as white solid. LCMS [M+H] 670, 1 H NMR (DMSO-d6, 300 MHz): 5 1 .56-2.20 (7H, m), 2.34-2.89 (10H, m), 3.00-3.25 (9H, m), 3.54-3.77 (2H, m), 4.30 (1H, d), 6.60-6.84 (6H, m), 7.04 (1 H, d), 7.12-7.39 (7H, m), 7.51 (2H, d).
[00231] Example 14: Synthesis of compound 186
[00232] As illustrative examples of compounds of formula (I), the following compounds, denoted Compounds 186 were synthesized:
Scheme 4.
To a stirred solution of tert-butyl 4-(4-(hydroxymethyl)piperidin-1-yl)benzoate (0.68 g, 3 mmol) in 15 mL of dichloromethane was added Dess-Martin periodinane (2.0 g, 4.5 mmol) at room temperature. After stirring for 1 hour, partial of the solvent was evaporated in vacuo. The residue was subjected onto silica gel column chromatography to provide tert-butyl 4-(4-formylpiperidin-1- yl)benzoate as white solid. LCMS [M+H] 290.
Step 2. tert-butyl 4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoate
To a stirred suspension of (5R,6S)-6-phenyl-5-(4-(piperazin-1-yl)phenyl)-5,6,7,8- tetrahydronaphthalen-2-ol (104 mg, 0.268 mmol) and triethylamine (0.50 g, 1 mmol) in 5 mL of DCM was added tert-butyl 4-{4-formylpiperidin-1-yl)benzoate (0.12 g, 0.4mmol) followed by sodium triacetoxyborohydride (0.11 g, 0.54 mmol) in one portion at rt. After stirring for 1 h, the solvent was removed in vacuo. The residue was subjected to silica gel column chromatography to provide 0.17 g of tert-butyl 4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoate as white solid. LCMS [M+H] 658.
Step 3. 4-(4-((4-(4-((1 R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoicacid
To a stirred suspension of above obtained tert-butyl 4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl- 1 ,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-y1)benzoate (0.17 g, 0.26 mmol) in 5 mL of DCM was added 1 mL of trifluoroacetic acid (TFA) at rt. After stirring for 2 h, the solvent was removed in vacuo. 0.22 g of 4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoicacid nTFA salt was obtained as brown oil and used in the next step without further purification. bCMS [M+H] 602.
Step 4. N-(2,6-dioxopiperidin-3-yl)-4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1 ,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
HO
To a stirred solution of 4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzoic add nTFA salt (0.22 g), DIEA (1 mb), 3- aminopiperidine-2, 6-dione HCI salt in 5 mb of DMF was added HBTU (0.2 g, 0.5 mmol) at rt. After stirring for 2 additional hours, the mixture was diluted with 10 mb of water and extracted with ethyl acetate 3x10 mb. The combined organic layers were washed with brine, dried over Na2SO4, filtered, evaporated to dryness. The residue was subjected onto silica gel column chromatography with EA: MeOH as eluent. The crude product was further purified by prep-HPbC, C18 with 0.5% FA in water and MeCN as eluent. 122 mg of N-(2,6-dioxopiperidin-3-yl)-4-(4-((4-(4-((1R,2S)-6- hydroxy-2-phenyl-1 ,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-
yl)benzamide as white solid. LCMS [M+H] 712. 1H NMR: 5 1.57-2.12 (9H, m), 2.20-2.89 (10H, m), 3.00-3.20 (5H, m), 3.35-3.55 (4H, m), 4.30 (1H, d), 4.61 (1H, d), 6.60-6.74 (4H, m), 6.88-7.10 (3H, m), 7.12-7.39 (7H, m), 7.77 (2H, d).
[00233] Example 15: Degradation of ER in MCF-7 Breast Cancer Cells by Exemplary Compounds of Formula (I)
[00234] MCF-7 cells were plated in 24-well plates at a density of 105 cells/well. Media containing various drug concentrations were added on the day following plating (day 0) and allowed to incubate for 24 hours for Western blot. Media with the tested compound was changed every other day. Cells were lysed, snapped frozen in liquid nitrogen, and stored at -80 °C until assay for ERa. Media were removed and dishes were washed with 1 x DPBS. Lysates were made by adding 150 pL of complete lysis solution and scraping cells into a 1.5 mL microcentrifuge tube. Lysates were placed on a rotisserie at 4 °C for 30 min and then spun at 4 °C at 12000 ref for 10 min. Supernatants were assayed for protein content, snap-frozen, and stored a -80 °C if not run immediately. Then 50 pg of protein was subjected to Western blot protocol. Membranes were blocked and then incubated with 1:200 dilution of ERa antibody at 4 °C overnight followed by 1:10000 dilution of secondary antibody for 1 h at room temperature. They were then imaged on a LICOR infrared scanner.
[00235] Figures 1A.2A, 3A, 4A, 5A, 6A, 7A, 8A, 9, 10, 11 A, 12 show the ER degradation efficacy of compounds 8, 10, 12, 74, 94, 103, 106, 107, 115, 131, 160, 167, 170, 173 in MCF-7 cells at various concentrations. Degradation of ER was expressed as an DC50 value and was determined for exemplary compounds in Table 1 by calculation of the concentration of compound that was required to give a 50% reduction of ER expression level. Maximal degradation of ER was expressed as a Dmax value by measuring the highest percentage of ER reduction achieved by exemplary compound in the treatment concentration range. DC50 value and Dmax value for each compound are listed in Table 1.
[00236] Example 16
[00237] The antiestrogenic activity of the exemplary compounds was assessed in T47d-kb-Luc stably transfected human breast cancer cell.
[00238] The T47d-kb-Luc cells are stably transfected with an artificial gene from the firefly that is only induced in the cells if estrogens bind and activate the ER to induce the gene product (Luciferase) that is then measured with a quantitative enzyme assay that produces light. Antagonist activities were measured by the compound’s ability to inhibit the activity of estradiol, the natural estrogen. Data were then normalized relative to the activity of the estradiol control and determinations were performed for five concentrations of the samples in quadruplicate in at least three separate experiments. IC50 values were obtained from dose-response curves for exemplary
compounds that are listed in Table 1. Figures 1 B, 2B, 3B, 4B, 5B, 6B, 7B, 8B, 11 B, and 13-17 illustrate the antiestrogenic activity of compounds 8, 10, 74, 94, 106, 107, 115, 131, 103, 167, 170, 173, 185, and 186.
[00239] Example 17
[00240] The anti-proliferative activities of the exemplary compounds were assessed by a cell viability assay in MCF-7 breast cancer cells.
[00241] MCF-7 cells were plated in six-well plates at a density of 50,000 each well in 5% FBS DMEM medium. The cells were then treated with exemplary compounds or fulvestrant separately at 6 different doses ranging from 10"10 M to 10"5 M for 5 days, while equal volumes of DMSO were used as vehicle controls. Viable cell numbers were counted with a Z Series Coulter Counter instrument (Beckman-Coulter) following manufacturer’s instructions. The ratio of drug treated viable cell numbers to vehicle treated viable cell numbers was defined as survival ratio where the control has the survival ratio of 100%. ICM values were obtained from dose-response curves for exemplary compounds that are listed in Table 1.
[00242] Example 18: The Anti-Proliferative Activities of the Exemplary Compounds were Assessed by a Cell Viability Assay in CAMA-1 and MCF-7 Breast Cancer Cells
[00243] CAMA-1 or MCF-7 cells were plated in six-well plates at a density of 50,000 each well in 5% FBS DMEM medium. The cells were then treated with exemplary compounds Separately at 6 different doses ranging from 10"1° M to 10-5 M for 5 days, while equal volumes of DMSO were used as vehicle controls. Viable cell numbers were counted with a Z Series Coulter Counter instrument (Beckman-Coulter) following manufacturer’s instructions. The ratio of drug treated viable cell numbers to vehicle treated viable cell numbers was defined as survival ratio where the control has the survival ratio of 100%. ICsa values were obtained from dose-response curves for exemplary compounds that are listed in Table 1. Figures 18-21 illustrate the anti-proliferative activities of compounds 167, 170, 173, 186 in CAMA-1 or MCF-7 breast cancer cells.
[00244] Example 19; Pharmacokinetic Properties of Exemplary Compounds.185 and 186 were Assessed in Female Sprague Dawlev Rats
[00245] Sprague Dawley rats (n=3), weighing between 350 and 400 g (Charles River Laboratories, Portage, Ml) were given oral gavage containing compound 185 or compound 186 dissolved in propylene glycol (PG):solutol:40%HP-b-CD in DI water (20:5:75 v:v) at a single dose of 10 mg/kg. After drug administration, blood samples were collected from the tail vein of the rats at various time points into 1.5 ml microcentrifuge tubes containing 0.1 ml of 10 % EDTA anticoagulant. Plasma was then separated from cell pellets by centrifugation in a refrigerated centrifuge at 4 °C and transferred to a separate tube. Plasma samples were frozen at -80 °C until
analysis.
[00246] HPLC-MS/MS Analysis of Plasma Samples. Plasma samples were extracted with chloroform/methanol (2:1) using traditional Folch method for lipid extraction. Methanol (1 mL) and chloroform (2 mL) were added to each plasma sample followed by addition of 5 ng trans- Tamoxifen-1302, 15N to each sample as the internal standard. The mixtures were stored at -20 °C overnight. Next the samples were sonicated for 5 min and centrifuged with a Thermo Scientific Heraeus Megafuge16 Centrifuge. The top layer was transferred to another test tube. The bottom layer was washed with 1 mL chloroform/methanol (2:1 ), centrifuged, and the solvent was transferred and combined with previous washings. Eight tenth of a milliliter HPLC grade water was added to the extracts. After vortexing, the mixture was centrifuged. The bottom layer was dried out with nitrogen and re-suspended in 100 pL HPLC grade acetonitrile. An aliquot of 10 pL sample was injected onto a Hypersil Gold column (50*2.1 mm; particle size 1 .9 pm, Thermo Scientific) on a Dionex Ultimate 3000 UPLC system equipped with a TSQ Vantage triple quadrupole mass spectrometer for analysis. A binary mobile phase (A: water with 0.05% formic acid, B: acetonitrile with 0.05% formic acid) was used to achieve the gradient of initial 30% B for 1 min and then to 80% B at 8 min, to 100% B at 9 mln, and returned to 30% B for 4 min. The flow rate was controlled at 0.6 mL/min. The settings of HESI source were as follows: spray voltage (3200 volt); vaporizer temperature (365 °C); sheath gas pressure (45 psi); auxiliary gas pressure (10 psi); capillary temperature (330 °C). Nitrogen was used as the sheath gas and axillary gas. Argon was used as the collision gas.
[00247] Figures 22 and 23 show the pharmacokinetic profile of exemplary compound 185 and 186, respectively.
[00248] All references cited in this specification are herein incorporated by reference as though each reference was specifically and individually indicated to be incorporated by reference. The citation of any reference is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such reference by virtue of prior invention.
[00249] It will be understood that each of the elements described above, or multiple elements together may also find a useful application in other types of methods differing from the type described above, as well as in other types of diseases differing from the type described herein. Without further analysis, the foregoing will so fully reveal the gist of the present disclosure that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this disclosure set forth in the appended claims. The foregoing embodiments are presented by way of example only; the scope of the present disclosure is not intended to be limiting only by the following claims.
References:
1. Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling.
Trends Pharmacol Sci 2003; 24:479-485.
2. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012, 23(6): 1378-86.
3. Jasani B, Douglas-Jones A, Rhodes A, Wozniak S, Barrett-Lee PJ, Gee J, Nicholson R. Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections. Methods Mol Med. 2006;120:127-46.
4. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009 May 15;169(10):1251-9.
5. Nabholtz JM, Buzdar A, Pollak M etal. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
6. Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first- line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 39: 1684-1689.
7. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 2018; 36: 553-562.
8. Hammond et al., Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, Journal of Clinical Oncology, 2010; 28, 2784-2795.
9. T.W. Greene and P.G.M. Wuts (1999) Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons.
Claims
1. A compound having the structure of Formula (I), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof:
( ) wherein R1 is selected from the group consisting of hydrogen, deuterium, halogen, and hydroxyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, 4 deuterium, halogen, hydroxyl, alkyl, alkoxy, , and
each occurrence of X1 and X2 is independently selected from the group consisting of O, S, C(R4)(R5), and C=O; wherein each occurrence of R4, R5, and R6 is independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, and heteroaryl alkyl; each occurrence of Z is selected from the group consisting of Li, Na, and K; and each occurrence of m and n is independently an integer from 0 to 4; x and y are each independently an integer from 0 to 2; the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30 alkyl, branched or linear amino-C8-C30 alkyl, branched or linear C8-C30 alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy-C8-C30 cycloalky, thio-C8-C30 cycloalkyl, or any combination thereof; wherein 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from O, N, and S; and the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30
alkyl, branched or linear amino-C8-C30 alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy-C8-C30 cycloalky, thio-C8-C30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C8-C30 cycloalkyl, C5-C30 aryl-amino-C8-C30 cycloalkyl, C5-C30 heteroaryl-C8-C30 cycloalkyl, or C5-C30 heteroaryl-amino-C8-C30 cycloalkyl; wherein 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of 0, N, and S.
2. The compound of claim 1 , wherein R1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, and I.
5. The compound of claim 1, wherein each occurrence ofX1 is independently selected from the group consisting of O and C=O.
6. The compound of claim 1 , wherein each occurrence of X2 is independently selected from the group consisting of CH2 and S.
The compound of claim 1 , wherein x is an integer 0 or 1 .
8. The compound of claim 1 , wherein y is an integer 1 or 2.
9. The compound of claim 1 , wherein the compound having the structure of Formula
(I) is a compound having the structure selected from the group consisting of
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof; and
or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof; wherein R1 is selected from the group consisting of hydrogen, deuterium, halogen, and hydroxyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, alkyl, alkoxy,
(R,^OSBd. each occurrence of X1 and X2 is independently selected from the group consisting of O, S, C(R4)(R5), and C=O; wherein each occurrence of R4, R5, and R6 is independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, and heteroaryl alkyl; each occurrence of Z is independently selected from the group consisting of Li, Na, and K; and each occurrence of m and n is independently an integer from 0 to 4; the linker is an optionally substituted linking moiety comprising a branched or linear C5-C30
alkyl, branched or linear amino-C8-Cso alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-Cso cycloalkyl, hydroxy-C8-C30 cycloalky, thio-C8-C30 cycloalkyl, or any combination thereof; wherein 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from O, N, and S; and the E3 ligand is an optionally substituted E3 ligand comprising a branched or linear C5-C30 alkyl, branched or linear amino-C8-C30 alkyl, branched or linear C5-C30 alkoxy, branched or linear thio-C8-C30 alkyl, C5-C30 cycloalkyl, amino-C8-C30 cycloalkyl, hydroxy-C8-C30 cycloalky, thio-C8-C30 cycloalkyl, C5-C30 aryl, C5-C30 heteroaryl, C5-C30 aryl-C8-C30 cycloalkyl, C5-C30 aryl-amino-C8-Cso cycloalkyl, C5-C30 heteroaryl-C8-C30 cycloalkyl, or C5-C30 heteroaryl-amino-C8-C30 cycloalkyl; wherein 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of O, N, and S.
10. The compound of claim 9, wherein the compound having the structure of Formula
Formula (Ila), or a tautomer, stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or derivative thereof.
11. The compound of claim 9, wherein the compound having the structure of Formula
12. The compound of claim 1 , wherein the linker is an optionally substituted linking moiety selected from the group consisting of a branched or linear C5-C24 alkyl, branched or linear amino-C8-C24 alkyl, branched or linear C5-C24 alkoxy, branched or linear thio-C5-C24 alkyl, C5-C24 cycloalkyl, amino-C8-C24 cycloalkyl, hydroxy-Cs CZ cycloalky, thio-Cs-C24 cycloalkyl, and any combination thereof; wherein 1 to 8 of the carbon atoms are optionally replaced with a heteroatom independently selected from the group consisting of O, N, and S.
14. The compound of claim 1 , wherein the E3 Ligand is selected from the group 5 5 consisting of wher
ein Y is selected from the group consisting of C(R )(R ) and C=O;
Y2 and Y3 are each independently selected from the group consisting of C(R4) and N; and R4, R5, and R6 are each independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, aryl alkyl, heteroaryl, and heteroaryl alkyl.
15. The compound of claim 14, wherein the E3 Ligand is selected from the group consisting of:
16. The compound of claim 1, wherein the compound represented by Formula (I) is selected from the group consisting of:
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin- 1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin- 1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin-
1 -yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin- 1-yl)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin-1- yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin-1- yl)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]th iophene-3- carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
3-(5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
3-(5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperidin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindoli n-5-yl)piperazin-1 - yl)propyl)piperidin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin- 1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin- 1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(1-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenyl)piperidin-4-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(1-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenyl)piperidin-4-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
3-(5-(4-(3-(1-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)piperidin-4- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
3-(5-(4-(3-(1-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperidin-4- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
(4-(3-(4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)propyl)piperazin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)propyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[bJthiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)propyl)piperazin-
1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)propyl)piperazin- 1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenyl)piperazin-1-yl)propyl)piperidin-1-yl)isoindoline-1 ,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]th iophene-3- carbonyl)phenyl)piperazin-1-yl)propyl)pi peridin- 1 -yl)isoindoline-1, 3-dione,
3-(5-(4-(3-(4-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1- yl)propyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
3-(5-(4-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1- yl)propyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethyl)piperazin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1 - yl)ethyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl )- 1 -oxoisoi ndolin-5-yl)piperazin- 1 -yl )ethyl )piperazin-1 - yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisolndolin-5-yl)piperazin-1-yl)ethyl)piperazin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-
1-yl)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1- yl)phenoxy)-2-(4-fluorophenyl )benzo[b]th iophen-6-y l)boron ic acid ,
(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1- yl)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethyl)piperidin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethyl)piperidin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1- yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)ethyl)piperazin-1-yl)phenoxy)-6-hydroxybenzo[b]thlophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)ethyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperazin-1- yl)phenoxy)-6-hyd roxybenzo[b]thiophen-2-yl)p henyl )boron ic acid ,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperazin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperidin-
1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperidin-
1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-{2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperidin-1- yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperidin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolln-5-yl)piperazin-1- yl)methyl)piperidin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)methyl)piperidin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1 -yl)methyl)piperidin-1- yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)methyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)phenoxy)-6-hyd roxybenzo[b]thiophen-2-yl )p henyl )boron ic acid ,
(4-(3-(4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1- yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperidln-4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1l3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperidin-4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoiin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1 -yl)propyl)piperazin-1-yl)isoindoline-1, 3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1, 3-dione,
3-(5-(4-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(4-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1, 3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-(6-hydroxy-2-(4-hydroxypheny|)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
3-(5-(4-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b)thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(4-(3-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-6-hydroxybenzo[b}thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)pheny|)boronicacid,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(2-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(2-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
3-(5-(4-(3-(4-(2-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(4-(3-(4-(2-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl>-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin-
1-yl)ethoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperazin-
1-yl)ethoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(2-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindollne-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(2-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
3-(5-(4-(3-(4-(2-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(4-(3-(4-(2-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[bJthiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b)thiophene-3- carbonyl)phenyl)piperazin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
3-(5-(4-(3-(4-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)oxy)phenyl)piperazin-1- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione,
3-(5-(4-(3-(4-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3-carbonyl)phenyl)piperazin-
1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperidin-4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1- yl)propyl)piperidin-4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione,
3-(5-(4-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-
dione,
3-(5-(4-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-({1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-
4-yl )methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-({1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-4- yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronic acid,
(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)propyl)piperidin-4- yl)methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thlophen-6-yl)boronic acid,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-{(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1 , 3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperazin-1-yl)isoindoline-1 ,3-dione,
3-(5-(4-(3-(4-((4-((6-hydroxy-2-(4-hydroxy phenyl) benzo[b] thiophen-3-yl)oxy)phenoxy) methyl)piperidin-1-yl)propyl) piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
3-(5-(4-(3-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thiophene-3-carbonyl)phenoxy) methyl)piperidin-1-yl)propyl) piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1 ,3-dione,
3-(5-(1-(3-(4-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]tiiiophene-3-carbonyl)phenyl)piperazin-
1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1 ,3-dione,
3-(5-(1-(3-(4-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3-carbonyl)phenyl)piperazin-1- yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2, 6-dione,
(4-(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic add,
(4-(3-(4-(4-(3-(4-(2-{2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperazin- 1-yl)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronic acid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)propyl)piperazin- 1-yl)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoiso1ndolin-5-yl)piperidin-1-yl)propyl)piperazin-1- yl)benzoyI)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(2-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(2-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(3-(4-(2-(4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(1-(3-(4-(2-(4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-(2-(4-(3-(4-{2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperazin-1-yl)ethoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperazin-
1-yl)ethoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-(2-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperazin-
1-yl)ethoxy)phenoxy)-2-(4-fluorophenyl)benzo[blthiophen-6-yl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(2-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-(2-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(3-(4-(2-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)ethyl)piperazin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(1-(3-(4-(2-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)ethyl)piperazin-1-yl)prQpyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(2-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(2-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(2-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbony)phenoxy) methy)piperidin-l-yl)ethy)piperidin-4-yl)l-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(1-(2-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(4-(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)ethyl)piperidin-4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacidr
(4-(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)ethyl)piperidin-4-yl)methoxy)phenoxy)-6-hydroxybenzo[b)thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-((1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)ethyl)piperidin-4- yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid.
2-(2,6-dioxopiperidin-3-yl)-5-(1-(2-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(2-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(2-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
3-(5-(1-(2-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(3-(4-((4-(2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2l6- dione,
3-(5-(1-(3-(4-((4-((2-(4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperidin-4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1- yl)propyl)piperidin-4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-
4-yl)methoxy)benzoyl)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(4-(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-
4-yl)methoxy)phenoxy)-6-hydroxybenzo[b]thiophen-2-yl)phenyl)boronicacid,
(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1l3-dioxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-
4-yl)methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-
4-yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-((1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-4- yl)methoxy)benzoyl)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
(3-(4-({1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)propyl)piperidin-4- yl)methoxy)phenoxy)-2-(4-fluorophenyl)benzo[b]thiophen-6-yl)boronicacid,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)iscindoline-1,3-dione,
2-(2,6-dioxopiperidin-3-yl)-5-(1-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)isoindoline-1,3-dione,
3-(5-(1-(3-(4-((4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3- carbonyl)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)-1-oxolsoindolin-2-yl)plperidine-2,6- dione,
3-(5-(1-(3-(4-((4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3- yl)oxy)phenoxy)methyl)piperidin-1-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione;
3-(5-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine- 1-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-
1-yl)phenyl)piperazine-1-carbonyl)piperazin-1-yl)benzamide;
1-(4-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1l2,3l4-tetrahydronaphthalen-1-yl)phenyl)piperazine-
1-carbonyl)piperazin-1-yl)phenyl)dihydropyrimidine-2r4(1H,3H)-dione;
3-(5-(4-(1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)piperazin-1-yl)benzamide;
1-(4-(4-(1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
3-(5-(4-((1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1- yl)benzamide;
1-(4-(4-((1-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazine-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
3-(5-(4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dlone;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-((4-(4-((1R.2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperazin-1- yl)benzamide;
1-(4-(4-(4-((4-(4-((1Rl2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-N-(2-(4-(4-((1Rl2S)-6-hydroxy-2-phenyl-
1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)ethyl)piperazine-1-carboxamide;
4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)phenyl)-N-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)ethyl)piperazine-1-carboxamide;
4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-N-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-
1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)ethyl)piperazine-1-carboxamide;
3-(5-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperazine-1-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenoxy)ethyl)piperazine-1-carbonyl)piperazin-1-yl)benzamide;
1-(4-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenoxy)ethyl)piperazine-1-carbonyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)- dione;
3-(5-(1-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenoxy)ethyl)piperidine-1-carbonyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(1-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenoxy)ethyl)piperidine-1-carbonyl)piperidin-4-yl)benzamide;
1-(4-(1-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-
yl)phenoxy)ethyl)piperidine-1-carbonyl)piperidin-4-yl)phenyl)dihydropyrimidine-2,4(1H,3H)- dione;
4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-N-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2t3,4- tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazine-1-carboxamide;
4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)phenyl)-N-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazine-1-carboxamide;
4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-N-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-
1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazine-1-carboxamide;
1-(4-(4-((4-(4-((1R,2S}-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-
1-yl)methyl)piperidin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide;
3-(5-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine- 1-carbonyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen- 1-yl)phenyl)piperazine-1-carbonyl)piperidin-1-yl)benzamide;
3-((4-(4-(4-(4-((1R,2S}-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine- 1-carbonyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione;
1-(4-(4-(4-(4-((1R,2S}-6-hydroxy-2-phenyl-1,2r3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine-
1-carbonyl)piperidin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
1-(4-(4-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)-2-oxoethyl)piperidin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
1-(4-(4-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenyl)piperazin-1-yl)ethyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
3-(5-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazine- 1-carbonyl)-[1,4'-bipiperidin]-T-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((4-(4-((1R,2S)-6-hydraxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)-[1,4,-bipiperidin]-1'-yl)benzamide;
3-((4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin- 1-yl)methyl)-[1,4'-bipiperidin]-T-yl)phenyl)amino)piperidine-2,6-dione;
3-(5-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-
1-yl)methyl)-[1,4'-bipiperidin]-1'-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(1-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)piperazin-1-yl)benzamide;
1-(4-(4-(1-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
3-(5-(4-((1-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((1-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperazin-1- yl)benzamide;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((1-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)piperazin-1- yl)benzamide;
3-((4-(4-((1-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6- dione;
1-(4-(4-((1-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
1-(4-(4-((1-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
3-(5-(4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperidin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperidin-1- yl)benzamide;
1-(4-(4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)piperidin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
1-(4-(4-((4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)methyl)piperidin-1-yl)phenyl)dihydropyrimidine- 2,4(1H,3H)-dione;
1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-N-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-
1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)ethyl)piperidine-4-carboxamide;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenyl)piperazin-1-yl)butanoyl)piperazin-1-yl)benzamide;
1-(4-(4-(4-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperazin-1-yl)butanoyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
3-(5-(4-(1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenoxy)ethyl)piperidine-4-carbonyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(5-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperazine-1-carbonyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2;6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenoxy)ethyl)piperidine-4-Garbonyl)piperazin-1-yl)benzamide;
N-(2,6-dioxopiperidin-3-yl)-4-(4-((1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)benzamide;
1-(4-(4-(1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)- dione;
3-(5-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidine-1-carbonyl)pjperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-1-yl)phenoxy)ethyl)piperidine-1-carbonyl)piperidin-1-yl)benzamide;
1-(4-(4-(1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)- dione;
1-(4-(4-((1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)d)hydropyrimidine-2,4(1H,3H)- dione;
3-((4-(4-((1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione;
3-(5-(4-((1-(2-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)piperidine-2,6-dione;
3-(5-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-
4-yl)propanoyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
1-(4-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-
4-yl)propanoyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-l-yl)phenyl)piperazin-1-yl)ethyl)piperazin-1-yl)benzamide;
3-((4-(4-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenyl)piperazin-1-yl)ethyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione;
3-(5-(4-(2-(4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-l- yl)phenyl)piperazin-1-yl)ethyl)piperazin-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1- yl)piperidine-2,6-dione;
N-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4- tetrahydronaphthalen-l-yl)phenyl)piperidin-4-yl)propanoyl)piperazin-1-yl)benzamide;
3-((4-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1- yl)phenyl)piperidin-4-yl)propyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione;
3-(5-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-
4-yl)propyl)piperazin-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6- dione;
1-(4-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin- 4-yl)propyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
1-(4-(4-(3-(1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-
4-yl)propanoyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione;
3-((4-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1]2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin- 1-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione;
3-(5-(4-((4-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperazin- 1-yl)methyl)piperidin-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6- dione; andanycombinationthereof.
17. A composition comprising at least one compound of any one of claims 1-16.
18. A pharmaceutical composition comprising at least one compound of any one of claims 1-16 and a pharmaceutically acceptable carrier.
19. A pharmaceutical formulation comprising at least one compound of any one of claims 1-16 and a pharmaceutically acceptable carrier.
20. The pharmaceutical composition of claim 18 and/or the pharmaceutical formulation of claim 19, wherein the pharmaceutical composition is suitable for enteral administration and/or the pharmaceutical formulation is suitable for enteral administration.
21. The pharmaceutical composition of claim 18 and/or the pharmaceutical formulation of claim 19, wherein the pharmaceutical composition is suitable for oral administration and/or the pharmaceutical formulation is suitable for oral administration.
22. The pharmaceutical composition of claim 18 and/or the pharmaceutical formulation of claim 19, wherein the pharmaceutical composition is suitable for parenteral administration and/or the pharmaceutical formulation is suitable for parenteral administration.
23. A method of preparing at least one compound of any one of claims 1-16 or composition of claim 17 or pharmaceutical composition of any one of claims 18 or 20-22 or pharmaceutical formulation of any one of claims 19-22.
24. A method for treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one compound of any one of claims 1-16 or composition of claim 17 or pharmaceutical composition of any one of claims 18 or 20-22 or pharmaceutical formulation of any one of claims 19-22.
25. The method of claim 24, wherein the disease or disorder is selected from the group consisting of a breast cancer, all stages of breast cancer, ER-positive breast cancer, invasive breast cancer, and any combination thereof.
26. A method for treating breast cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one compound of any one of claims 1-16 or composition of claim 17 or pharmaceutical composition of any one of claims 18 or 20-22 or pharmaceutical formulation of any one of claims 19-22.
27. The method of claim 25 or 26, wherein the breast cancer is an ER-positive breast cancer, including invasive breast cancer.
28. The method of claim 24 or 26, where the subject expresses a mutant ER-o protein.
29. A method of reducing the level or activity of a target protein, the method comprising administering at least one compound of any one of claims 1-16 or composition of ciaim 17 or pharmaceutical composition of any one of claims 18 or 20-22 or pharmaceutical formulation of any one of claims 19-22.
30. A method of inhibiting a target protein, the method comprising administering at least one compound of any one of claims 1-16 or composition of claim 17 or pharmaceutical composition of any one of claims 18 or 20-22 or pharmaceutical formulation of any one of claims 19-22.
31. The method of claim 29 or 30, wherein the target protein is an estrogen receptor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263334759P | 2022-04-26 | 2022-04-26 | |
US63/334,759 | 2022-04-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2023212599A2 true WO2023212599A2 (en) | 2023-11-02 |
WO2023212599A3 WO2023212599A3 (en) | 2023-12-07 |
WO2023212599A9 WO2023212599A9 (en) | 2024-03-21 |
Family
ID=88519832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/066243 WO2023212599A2 (en) | 2022-04-26 | 2023-04-26 | Compounds and methods for targeted degradation of estrogen receptors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023212599A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3577109A4 (en) * | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
CN117050002A (en) * | 2018-11-21 | 2023-11-14 | 冰洲石生物科技公司 | Novel compounds having estrogen receptor alpha degrading activity and uses thereof |
TW202102497A (en) * | 2019-03-29 | 2021-01-16 | 瑞典商阿斯特捷利康公司 | Compounds and their use in treating cancer |
US20220348595A1 (en) * | 2021-04-09 | 2022-11-03 | Endotarget Inc. | Compounds and methods for the targeted degradation of estrogen receptors |
-
2023
- 2023-04-26 WO PCT/US2023/066243 patent/WO2023212599A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023212599A9 (en) | 2024-03-21 |
WO2023212599A3 (en) | 2023-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021129824A1 (en) | New-type k-ras g12c inhibitor | |
WO2021190467A1 (en) | Spiro ring-containing quinazoline compound | |
JP7320263B2 (en) | EZH2 inhibitors and uses thereof | |
AU2009290365B2 (en) | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | |
WO2011106650A2 (en) | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease | |
US20170275291A1 (en) | Indazole compounds as fgfr kinase inhibitor, preparation and use thereof | |
CN115175679A (en) | Methods of treating estrogen receptor-related disorders | |
KR20210107046A (en) | Macrocyclic compounds and their use in the treatment of diseases | |
Li et al. | Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents | |
JP2021500334A (en) | Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods for synthesizing them. | |
US20230137175A1 (en) | Compounds and methods for the targeted degradation of bruton's tyrosine kinase | |
Zhai et al. | Design, synthesis and biological evaluation of novel 4-phenoxy-6, 7-disubstituted quinolines possessing (thio) semicarbazones as c-Met kinase inhibitors | |
WO2016140971A1 (en) | Novel rad51 inhibitors and uses thereof | |
BR112020000564A2 (en) | new heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and / or 2 (hdac1-2) | |
Liu et al. | Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma | |
WO2019056120A1 (en) | Pentafluorophenyl sulfonamide compounds, compositions and uses thereof | |
WO2020253762A1 (en) | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | |
US20220348595A1 (en) | Compounds and methods for the targeted degradation of estrogen receptors | |
WO2020173417A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
JP5186566B2 (en) | Dithiolopyrrolone compounds, their preparation and use | |
WO2023280182A1 (en) | Compound serving as kat6 inhibitor | |
US20230295118A1 (en) | Compounds and methods for the targeted degradation of cyclin dependent kinases | |
CN107428762A (en) | Phthalazinone derivatives, preparation method and the usage | |
WO2023212599A2 (en) | Compounds and methods for targeted degradation of estrogen receptors | |
WO2022171088A1 (en) | Pyrazolo[3,4-d]pyrimidin-3-one derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23797513 Country of ref document: EP Kind code of ref document: A2 |